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1CHAPTER I
INTRODUCTION
Regulation of Proliferation and Differentiation
During embryonic development, proliferation must be carefully balanced with
differentiation in order to produce a mature, functional organ. Inappropriate initiation or
termination of either of these processes can have dire consequences on the organism, resulting in
congenital malformations and tumorigenesis. Since every tissue has unique functions and needs,
each controls proliferation and differentiation differently. The developmental mechanisms that
determine the balance of these two processes are not well characterized but of utmost importance
in understanding embryogenesis and tumorigenesis.
The diversity of regulatory systems can be witnessed by examining three systems: the
small intestine, skeletal muscle, and cardiac muscle. The small intestine is subjected to harsh and
varied environmental conditions due to the enzymes required to digest a plethora of nutritional
components. For this reason, the enterocyte population retains and utilizes its proliferative ability
throughout the life of an organism (Ross et al., 1995). Continuously, epithelial cells from a stem
cell population at the base of intestinal crypts undergo cell division and migrate towards the tips
of the villi to replace older enterocytes that have been shed. Even though proliferation of
enterocytes never ceases, it still is regulated for the health of the organism. Dysregulation leads
to uncontrolled growth and tumor formation (Cotran et al., 1999). The situation in skeletal
muscle is different in important respects (Naya and Olson, 1999; Buckingham, 2001). During
development, mesodermal precursor cells in the somites are actively proliferating while
transcription factors, such as Pax3, MyoD, and Myf5, combinatorially regulate myoblast
commitment. These myoblasts continue dividing as they travel to the regions of the body where
skeletal muscle will eventually form. After reaching an appropriate population size, the
transcription factor myogenin is somehow activated and signals initiation of differentiation.
However, for differentiation to occur in skeletal myoblasts, they must first undergo cell cycle
arrest by a mechanism that is not well understood but is postulated to involve retinoblastoma
(Rb) protein (Yee et al., 1998). After this arrest, myocytes fuse to form myotubes and eventually
mature skeletal muscle. Similar to the intestine, however, skeletal muscle retains a stem cell
2population, called satellite cells, that can be recruited to proliferate in order to replace damaged
muscle.
In cardiac muscle, on the other hand, there is no proliferation in the terminally
differentiated tissue. As in skeletal muscle, there is a pathway of transcription factors (Nkx2.5,
MEF2C, and others) that regulates the activation of genes involved in differentiation (Sucov,
1998; Pasumarthi and Field, 2002). However, cardiomyocytes, unlike their skeletal counterparts,
are unique in that they continue to proliferate in the embryonic heart at the same time as they
begin to undergo differentiation. The reasons for the ability of these cardiomyocytes to
proliferate and differentiate simultaneously are not well understood, although Rb once again may
be involved (McGill and Brooks, 1995). During the first postnatal week of development in
mouse, these cardiomyocytes receive a signal to permanently exit the cell cycle and undergo
terminal differentiation (Soonpaa et al., 1996; Soonpaa and Field, 1998). The exact triggers of
this cell cycle arrest and terminal differentiation remain unclear. Nonetheless, the result is that
cardiomyocytes are incapable of proliferation after this process is complete, although this has
become a source of great controversy recently (Mathur and Martin, 2004), and there does not
seem to be a clear stem cell population, as in skeletal muscle (Soonpaa and Field, 1998). For this
reason, myocardial infarctions are a leading cause of death in humans (Center for Disease
Control and Prevention, Atlanta, GA). Understanding the mechanisms of control of terminal
differentiation in the heart and other tissues is thus of great scientific and clinical value.
The LEK Family of Proteins
Studies in our laboratory identified LEK1, a murine member of the LEK family of
proteins (Goodwin et al., 1999). The name of the family comes from the approximately 40%
leucine, glutamic acid, and lysine (LEK) amino acid composition of the proteins. The known
proteins comprising this family are LEK1 (mouse), CMF1 (chicken), and Mitosin/CENP-F
(human). These LEK family members are large proteins (approximately 300 kDa in size) that
have conserved sequences (Figure 1) with Mitosin/CENP-F being 75% homologous at the amino
acid level to LEK1. In addition, they share a similar domain structure (Liao et al., 1995; Zhu et
al., 1995a; Zhu et al., 1995b; Goodwin et al., 1999). The N-terminus is comprised of a cluster of
leucine zippers. The central region is predicted to fold into a coiled coil arrangement and
contains a spectrin repeat along with additional leucine zippers. The identified domains in the C-
3terminus include a nuclear localization signal (NLS), a helix-loop-helix (HLH) dimerization
domain, an atypical Retinoblastoma (Rb) binding site, and numerous leucine zippers. Despite
this homology, individual members of the LEK family display, as discussed below, unique
expression patterns and activities.
Mitosin/CENP-F was initially identified in a screen for proteins that interact with Rb
(Liao et al., 1995; Zhu et al., 1995b). Two separate laboratories used a different name for
essentially the same protein, and it is referred to here by both: Mitosin/CENP-F. It exhibits a cell
cycle-specific expression pattern without any known tissue specificity (Liao et al., 1995; Zhu et
al., 1995b). The protein first begins to be expressed throughout the entire nucleus during late S
phase of the cell cycle. Its distribution then changes, presumably due to alterations in
phosphorylation status, during M phase when it becomes localized to the outer plate of the
chromosomal kinetochore. The regions required for kinetochore binding have been identified
(Zhu, 1999), and they are present to some degree, albeit incompletely, in all LEK family
members. As mitosis proceeds, Mitosin/CENP-F is also detected on the spindle apparatus and,
later, at the cellular midbody (Liao et al., 1995; Zhu et al., 1995b). The protein is also found
transiently at the nuclear envelope in late G2 phase. Following completion of mitosis, the protein
is rapidly degraded. In terms of function, Mitosin/CENP-F, predominantly through its
kinetochore interaction, is believed to play a role in mitotic checkpoint control, as dominant
negative N-terminal truncations of the protein result in inhibition of proliferation due to a G2/M
arrest (Zhu et al., 1995b). Not surprisingly, increased expression of Mitosin/CENP-F has been
detected in various human cancers (de la Guardia et al., 2001; Esguerra et al., 2004).
More recently, it has been suggested that farnesylation of Mitosin/CENP-F at a C-
terminal CAAX motif may be required for several of its functions (Hussein and Taylor, 2002).
Protein farnesylation is a post-translational modification that consists of the addition of a 15-
carbon isoprenoid lipid molecule to the sulfur atom in a C-terminal cysteine (Sinensky, 2000).
This reaction is catalyzed by the enzyme farnesyltransferase. Interestingly, presence of the
CAAX motif is required for a dominant negative Mitosin/CENP-F protein to delay G2/M
progression (Hussein and Taylor, 2002). Additionally, mutation of this farnesylation motif
significantly decreases the ability of Mitosin/CENP-F to localize to the nuclear envelope and
kinetochore during mitosis. Degradation of the protein after mitosis also is dependent on the
CAAX motif. Notably, this farnesylation motif is conserved among the known LEK family
N-terminus 
• No known function
• Numerous leucine zippers
• Predicted coiled-coil structure
• Spectrin repeat
C-terminus
• Functional NLS 
• Atypical Rb binding site
• Numerous leucine zippers
• HLH dimerization domain
Structure of the LEK Family of Proteins
*
*
Proposed cleavage site of LEK1
Spec1 863
Figure 1. Structure of LEK family proteins. Members of the family include LEK1 (mouse), Mitosin/CENP-F (human), and CMF1
(chicken). The proteins share a similar domain structure.
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5members but has only been studied with respect to Mitosin/CENP-F. Since farnesylation is
emerging as an important post-translational modification of several proteins involved in
regulation of proliferation, such as the proto-oncogene Ras and Mitosin/CENP-F,
farnesyltransferase inhibitors are being looked at as a new potential drug class in the treatment of
cancer (Russo et al., 2004).
As is common for the LEK family, the chicken member, CMF1, differs substantially
from Mitosin/CENP-F in terms of its expression and function. CMF1 was first identified in a
chicken expression library screen searching for proteins reactive to an antiserum against the
basic helix-loop-helix (bHLH) domain of MyoD, an important muscle transcription factor (Wei
et al., 1996). Surprisingly, the CMF1 protein itself does not display strong homology to any
known member of the bHLH family of myogenic factors. As with all LEK family members,
CMF1 has an atypical Rb binding site, and the protein has been shown to bind Rb both in vitro
and in vivo (Redkar et al., 2002). The expression of CMF1 is regulated during embryonic
development, and the protein is specifically expressed in skeletal and cardiac myocytes (Wei et
al., 1996; Dees et al., 2000). Expression is highest during early embryonic stages and
significantly decreases after embryonic day 7 (Pabon-Pena et al., 2000). It cannot be detected in
adult animals, suggestive of a role during development. Even though CMF1 contains a NLS that
has been determined to be functional when attached to a reporter protein, CMF1 itself is
observed predominantly in the cytoplasm of myocytes in vitro and in vivo (Dees et al., 2000;
Pabon-Pena et al., 2000). However, very early myoblasts in primary culture do have transient
expression of a nuclear form of CMF1 (Dees et al., 2000), and one group has reported detecting
nuclear CMF1 in the embryo (Redkar et al., 2002). Since expression of CMF1 precedes
expression of muscle-specific proteins such as sarcomeric myosin heavy chain (sMHC), it was
postulated that CMF1 might play a role in muscle differentiation. Indeed, inhibition of CMF1
expression in cultured myoblasts and mesodermal cells using antisense technology results in a
substantial decrease in sMHC expression, suggesting that CMF1 is important for myocyte
differentiation (Wei et al., 1996; Dees et al., 2000). Notably, every cell expressing sMHC also
expressed CMF1. Thus, CMF1 is currently believed to play a critical role in the differentiation of
skeletal and cardiac myocytes during embryogenesis.
LEK1, the murine member of the LEK family, differs from both Mitosin/CENP-F and
CMF1 and is the primary focus of the experiments presented in this document. The LEK1 cDNA
6was partially cloned via reverse transcriptase polymerase chain reaction (RT-PCR) from
embryonic heart RNA using degenerate primers based on the sequence of other LEK family
members (Goodwin et al., 1999). These clones were then used as probes to screen a whole
embryo cDNA library. A Southern blot analysis of mouse genomic DNA using a LEK1 probe
reveals a single band, suggesting the presence of only one LEK family member in mouse.
Interestingly, a Northern blot displays two closely-spaced bands of 10 kb each. Thus, the LEK1
mRNA may be alternatively spliced. Previous studies in our laboratory demonstrate that the
LEK1 protein undergoes a post-translational cleavage event (Figure 2), at an unknown site, to
produce two peptide products: N-terminal cytLEK1 and C-terminal nucLEK1 (Pabon-Pena et al.
unpublished data). Most work has focused on the smaller nucLEK1, which is predominantly
found in the nuclei of cells.
During embryogenesis, LEK1 is expressed at highest levels during early development
(E8.5) in all tissues, not just myocytes as for CMF1, and its expression diminishes as
development proceeds (Goodwin et al., 1999). The protein and mRNA cannot be readily detected
in adult mice with the exception of the oocyte in females. Interestingly, expression in the heart
and liver differs from other tissues, as the LEK1 mRNA level progressively increases in these
organs during the course of embryonic development. In the heart specifically, LEK1 mRNA is
detected until neonatal day 4 (N4), after which point it abruptly disappears. NucLEK1 protein
expression follows with a similar decrease after neonatal day 5. Very interestingly, this reduction
in LEK1 expression coincides with the period when cardiomyocytes are undergoing permanent
cessation of mitosis and terminal differentiation (Soonpaa et al., 1996; Soonpaa and Field, 1998).
It was thus postulated that LEK1 may a play a role in this process during cardiac development.
A function for LEK1 in terminal differentiation of cardiomyocytes was supported by the
discovery that nucLEK1 binds to all three known Rb family members (Rb, p107, p130) both in
vitro and in vivo (Ashe et al., 2004). This interaction occurs within the critical pocket region of
these proteins. In addition to their important effects on cell cycle regulation, Rb family members
have been implicated more recently in the control of apoptosis and differentiation during
development (Tam et al., 1995). It is currently postulated that nucLEK1 may serve as an
inhibitor of Rb family member function by binding and sequestering these proteins, thus
maintaining cells in a proliferative, non-differentiative state during development. With
*Proposed cleavage site
Spec1 863
*
Spec1 863
*Spec1 863
cytLEK1
nucLEK1
Figure 2. Cleavage of LEK1 into two peptide products. LEK1 is post-translationally cleaved into N-terminal cytLEK1 (containing Spec1
antibody epitope) and C-terminal nucLEK1 (863 epitope).
7
8downregulation of LEK1, the anti-proliferative function of Rb family members is then restored
and differentiation can proceed.
Indeed, experiments disrupting LEK1 expression support this hypothesis. Cell culture
studies in 3T3 fibroblasts reveal that LEK1 depletion using morpholino antisense oligomers
results in a G1/S cell cycle arrest consistent with activation of Rb family member function (Ashe
et al., 2004). Additionally, cells are also delayed in G2/M phase entry. However, cells are
eventually able to overcome the cell cycle arrest but cannot maintain this recovery and instead
begin to undergo apoptosis. Thus, proper LEK1 expression is required for 3T3 fibroblast
proliferation and survival. Additional evidence of a role for LEK1 in cell proliferation and
differentiation comes from studies with C2C12 skeletal myoblasts (Ashe et al. unpublished data).
It has been observed that these cells express LEK1 in their myoblast state but expression of the
protein is downregulated as they undergo differentiation upon serum deprivation. Depletion of
LEK1 using morpholino oligomers in C2C12 cells results in premature differentiation as
measured by sMHC expression and myotube formation. In summary, these experiments on
LEK1 suggest that the protein plays an important role in the regulation of proliferative and
differentiative processes during embryonic development.
The Spectrin Repeat
Prior to examination of the specific role of the cytoplasmic cytLEK1 protein, we initially
hypothesized that it may have a cytoskeletal function. Our hypothesis of a cytoskeletal role was
supported by the presence in cytLEK1 of a single spectrin repeat, which is a domain composed
of three antiparallel a-helices in a coiled-coil assembly that is found in a wide array of proteins
(Djinovic-Carugo et al., 2002). Typically, a heptad periodicity is evident at the level of the
primary sequence, and several aromatic residues within the hydrophobic core of the domain are
conserved. The repeats are best known for their presence in multiple copies (4-20) in the spectrin
superfamily (a- and b-spectrin, a-actinin, dystrophin, and utrophin) whose members are
primarily involved in actin cross-linking. However, they are found in other diverse proteins as
well. Various proteins, including the Dbl family, contain single or multiple spectrin repeats that
are postulated to act in conjunction with a neighboring Rho-GEF domain but are not always
directly involved in cytoskeletal function (Alam et al., 1997; Estrach et al., 2002). As is evident,
the roles of spectrin repeats, as well as their exact sequences, are quite varied (Djinovic-Carugo
9et al., 2002). Long chains of repeats often separate functional parts of the protein where length
can be critical for actin cross-linking. At the same time, repeats of any length can serve as
docking regions for proteins involved in cytoskeletal and signal transduction functions. Repeats
can also play a role in the formation of protein dimers. In addition, the spectrin repeat is
structurally elastic, so it often found in structures such as the sarcomere that are subject to
intense amounts of mechanical stress. There are many examples in the literature of known
interactions occurring via spectrin repeats: b-spectrin binds ankyrin (Kennedy et al., 1991); a-
actinin binds integrins, titin, a LIM protein, and a rho kinase (Otey et al., 1990; Mukai et al.,
1997; Xia et al., 1997; Young et al., 1998); and dystrophin binds actin (Rybakova et al., 1996).
Thus, it is clear that the spectrin repeat, which is also found in cytLEK1, may serve as a binding
site for various proteins, most of which have a cytoskeletal role.
The Role of LIS1
The microtubule network of cells is a key cytoskeletal element and plays a critical role in
a range of functions (Lodish, 2004). One of its main partners of action is dynein, a large minus
end-directed motor protein. Dynein is important for basic cellular functions in all organisms and
has been the subject of extensive research (Gibbons, 1996; Hirokawa, 1998; Banks and Heald,
2001). The process of mitosis is especially reliant on dynein, which plays critical roles in
chromosome alignment, spindle orientation, and chromosome movement toward poles.
Additionally, dynein function is important for both nuclear and cellular migration. Many vesicles
and organelles, such as the Golgi, utilize dynein motor function for proper positioning and
trafficking within the cell. However, the precise regulation and mechanism of function of
microtubules and dynein remain poorly understood, despite knowledge of their involvement in
specific molecular pathways and their interaction with several important partner proteins.
One such partner is LIS1, a 45 kDa microtubule-associated protein with seven WD
(tryptophan-aspartic acid) repeats. LIS1 initially generated interest due to the discovery that
mutations in the protein are associated with type I lissencephaly in humans (Reiner et al., 1993;
Chong et al., 1997; Lo Nigro et al., 1997; Pilz et al., 1998). This disorder is characterized by
developmental neuronal defects that result in agyria (smooth brain surfaces) and disordered
cortical layering. These abnormalities cause mental retardation, seizures, and other neurological
conditions. Interestingly, LIS1 was first studied in the fungus Aspergillus nidulans, where the
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NudF protein is the homolog to LIS1 and shares 62% identity. Mutation of NudF in fungi causes
defects in nuclear migration, a process that is especially critical in this organism, and results in
decreased colony size (Xiang et al., 1995). Notably, this phenotype is identical to that which
results from mutations of dynein and dynactin in fungi (Beckwith et al., 1998). In fact, a dynein
(NudA) mutant is able to suppress the NudF mutation (Willins et al., 1997). Thus, dynein and
LIS1 appear to operate in the same genetic pathway. Of interest with respect to our work, NudE
mutants exhibit the same nuclear migration phenotype and suppression ability, and NudE has
been shown to directly bind NudF (Efimov and Morris, 2000). In support of the phenotype
observed in these experiments in fungi, mutations in the yeast homolog of LIS1, Pac1, were
examined and discovered to result in an inability to properly orient the nucleus during cell
division (Geiser et al., 1997; Lee et al., 2003). These mutant yeast also exhibit defects in mitotic
spindle function.
Defects in nuclear positioning and migration are intriguing because of the observed
neuronal defects associated with LIS1 mutations in humans. Nuclear migration in fungi bares a
significant similarity to the movement of nuclei within migrating neurons during mammalian
development. Such neurons first extend leading processes and then require their nuclei to
relocate to a final position in the formed nervous system (Wynshaw-Boris and Gambello, 2001).
Aberrations in this process lead to improper cellular migration and thus developmental defects.
In order to examine the function of LIS1 during mammalian development, a homozygous null
mouse for LIS1 was developed (Hirotsune et al., 1998). LIS1 is ubiquitously expressed during
development and adulthood, but highest levels of the protein are found in neurons. In fact,
neurons contain 15 to 30 times as much of the protein as most other cell types. Complete absence
of the LIS1 protein results in post-implantation lethality. Thus, LIS1 is absolutely required for
embryonic development, especially before E9.5. Animals heterozygous for LIS1 mutations are
viable but exhibit defects in brain structure similar to those observed in humans with
lissencephaly (Hirotsune et al., 1998). Compound heterozygous mice have a more severe
phenotype and generally die within a few days of birth. The severe brain defects observed consist
of enlarged ventricles and disorganization of layers of the cortex and hippocampus. The mutant
neurons migrate more slowly in vitro and in vivo, suggesting that defects in migration are at least
partially responsible for the neuronal defects. This is a cell autonomous effect, as migration
abilities are not rescued by co-culturing the neurons with wild-type neurons. A different targeted
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deletion of LIS1 in mice has also been created that leads to the generation of a shorter LIS1
protein (Cahana et al., 2001). While the homozygous mice are again lethal, the heterozygous
mice are viable and confirm the previous results by displaying abnormalities in brain structure.
Mutant neurons from these animals also display decreased migration speeds and, additionally,
have aberrant morphology. Finally, LIS1 is also essential in Drosophila melanogaster, as mutant
flies exhibit defects in nuclear positioning and early embryonic lethality (Liu et al., 1999; Swan
et al., 1999; Lei and Warrior, 2000; Liu et al., 2000). Notably, these flies have severe
deficiencies in the proliferation of several types of cells, including neuroblasts. In summary,
these genetic experiments have shown that mutations of LIS1 likely result in lissencephaly due to
defective migration and proliferation of neuronal precursors.
The binding partners of LIS1 provide clues as to how the protein functions in processes
such as movement and cell division. While LIS1 is also known as Pafah1b1 for being a non-
catalytic subunit of platelet-activating acetylhydrolase isoform Ib (Hattori et al., 1994), its non-
enzymatic interactions appear to be of more importance. As was initially suspected in fungi and
later confirmed in mammalian cells, LIS1 directly binds to dynein to form a complex that also
contains the p150glued subunit of dynactin (Willins et al., 1997; Faulkner et al., 2000; Sasaki et al.,
2000; Smith et al., 2000; Tai et al., 2002). Specifically, dynamitin, which is a component of the
dynactin complex, and the intermediate and heavy chains of dynein have been shown in these
studies to directly interact with the WD repeats of LIS1. Not surprisingly given the relationship
between microtubules and dynein, LIS1 is associated, albeit not exclusively, with the
microtubule fraction of cell supernatants (Sapir et al., 1997; Smith et al., 2000). Additionally,
LIS1 has been shown to bind to the C-terminus of CLIP-170 (Coquelle et al., 2002), a protein
involved in dynactin regulation at growing microtubule ends and the kinetochore. LIS1 can also
potentially homodimerize, although any importance of such an association is not yet clear.
Finally, LIS1 interacts with the two murine isoforms of NudE: NudE and Nudel (Feng et al.,
2000; Niethammer et al., 2000; Sasaki et al., 2000). This important set of interactions will be
discussed in more detail shortly.
The subcellular distribution of LIS1 fits well with the known characteristics of its binding
partners. In neurons of the developing mouse, LIS1 initially has a punctate distribution pattern
with a portion of the protein being centrosomal (Sasaki et al., 2000; Tanaka et al., 2004). By
neonatal stages, the protein shifts to the axon, where it is predominantly found in adult neurons
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in vivo. In neuronal cell cultures, LIS1 is also cytoplasmic with highest concentrations located at
cell bodies and growth cones (Smith et al., 2000). The most detailed analyses of the subcellular
distribution of LIS1, however, come from studies of non-neuronal cells, especially fibroblasts. In
such cells, LIS1 exhibits a predominantly perinuclear punctate localization (Niethammer et al.,
2000; Smith et al., 2000). It is found at regions of high microtubule density, including the
centrosome, and the protein can also be detected on microtubule tracks (Smith et al., 2000).
However, the colocalization between LIS1 and microtubules is not conclusive (Faulkner et al.,
2000). In support of co-immunoprecipitation data, both dynein and dynactin colocalize with
LIS1 near the nucleus (Smith et al., 2000). However, this colocalization is not complete,
especially toward the cell periphery, suggesting that LIS1 does not associate with all dynein and
dynactin complexes in a cell. Additionally, LIS1 is present, along with dynein and related
proteins, at the leading edge of the cell cortex in migrating fibroblasts, as expected considering
its putative role in cell movement (Faulkner et al., 2000; Dujardin et al., 2003). Finally, LIS1 is
found, through an interaction with dynein, at the kinetochores of early mitotic cells (Faulkner et
al., 2000), which is consistent with a role in dynein-mediated spindle functions during cell
division.
The most enlightening data on the function of LIS1 come from experiments looking at its
role in various cell culture environments. Emphasizing the critical importance of LIS1 for
cellular functions in a wide variety of cell types, these data have been obtained using cells
ranging from fibroblasts to neurons to epithelial cells. Overexpression and knockdown studies of
LIS1 have revealed a large array of alterations in the localization of LIS1 partner proteins. For
example, dynein, dynactin, and Nudel are mislocalized in such experiments (Faulkner et al.,
2000; Sasaki et al., 2000; Smith et al., 2000), thus revealing the importance of LIS1 function for
the proper cellular distribution of key proteins of the dynein pathway. However, the responses to
LIS1 alteration are not consistent among various publications. For example, fibroblasts from
LIS1 heteryzogous mice have been shown to have a more perinuclear accumulation of dynein as
a result of this decreased level of LIS1 protein (Sasaki et al., 2000). Paradoxically,
overexpression of LIS1 in cultured fibroblasts also results in an inward redistribution of dynein
towards the nucleus (Smith et al., 2000). Such seemingly conflicting results, which are very
common in the LIS1 field, may perhaps be explained by differences in expression levels or cell
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types. However, clearly more work is necessary to determine the exact role of LIS1 in the
localization of its binding partners.
As would be expected from a protein interacting with dynein and the microtubule
network, LIS1 functional studies have revealed its critical importance with regards to the
cytoskeleton. Overexpression of LIS1 has been shown to result in microtubule disarray in
interphase cells (Faulkner et al., 2000; Smith et al., 2000). The uniform distribution of
microtubules from centrosomes is lost, and the usual radiating arrays from this organizing center
are now absent. Importantly, g-tubulin, a key component of the centrosome, remains intact in
these cells (Smith et al., 2000), suggesting that the centrosomes are presumably formed and
localized properly. Thus, LIS1 is critical for interaction of the centrosome with microtubules but
not for the stability of the centrosome itself. The importance of LIS1 in microtubule organization
and formation is reinforced by experiments examining microtubule network repolymerization
after addition of nocodazole, a microtubule depolymerizing agent. In LIS1-overexpressing cells,
microtubule networks are able to reform after nocodazole challenge but in an aberrant fashion
(Smith et al., 2000). Fewer of the microtubules are attached to the centrosomes, and, instead,
there is an increase in unattached fragments at the cell periphery. Thus, LIS1 may play a role in
stabilizing microtubules at the organizing center and also transporting microtubule segments to
the periphery.
Since LIS1 is important for microtubule formation and transport, it may also be expected
to be involved in the positioning of organelles, usually membranous ones, dependent on dynein
and microtubule function. One such organelle is the Golgi apparatus, whose perinuclear
localization near the centrosome relies on movement by dynein motors on microtubule tracks
(Allan and Vale, 1991; Corthesy-Theulaz et al., 1992). Indeed, alteration of LIS1 function
disrupts the normal positioning of the Golgi as observed by using markers specific for this
organelle. In fibroblasts heterozygous for LIS1, the Golgi is less tightly perinuclear and instead
more dispersed throughout the cell (Sasaki et al., 2000; Smith et al., 2000). This defect can be
corrected by overexpressing LIS1 in these cells and thus positioning the Golgi closer to the
nucleus (Smith et al., 2000). These results suggest that LIS1 plays an important role in the
dynein-mediated process of organelle positioning. Once again, however, conflicting results are
present, as other studies have revealed no effect on Golgi localization when overexpressing full-
length or truncated LIS1 in cells (Faulkner et al., 2000; Tai et al., 2002).
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Another key aspect of LIS1 function, based on early in vitro and in vivo experiments,
involves regulation of cell migration (Hirotsune et al., 1998; Cahana et al., 2001). Cell culture
experiments have confirmed the importance of LIS1 in cell movement and shed light on the
mechanisms involved. Overexpression of LIS1 results in increased migration of neurons (Tanaka
et al., 2004), in agreement with the presumed role of LIS1 in enhancing cell movement. Indeed,
expression of a dominant negative LIS1 protein in fibroblasts interferes with cell migration
(Dujardin et al., 2003). Similar phenotypes are observed in this set of experiments when
inhibiting the function of dynactin and dynein, thus suggesting a common role for all these
proteins in regulating cell movement. Indeed, all three proteins localize to the leading cell cortex
during healing of wounded fibroblast monolayers (Dujardin et al., 2003). Other experiments
have suggested that the localization of dynactin to microtubule tips, including at the leading
edge, may be dependent on LIS1 (Faulkner et al., 2000). However, recent studies have proposed
that other proteins, such as CLIP-170, may be more critical for this process (Lansbergen et al.,
2004). Further insight into the mechanism of LIS action on neuronal migration specifically has
come from experiments revealing defective coupling of the nucleus and centrosome in migrating
neurons from LIS1 heterozygous mice (Tanaka et al., 2004). These results coincide with the
well-known role of LIS1 in nuclear movement in various organisms (Xiang et al., 1995; Geiser
et al., 1997; Lei and Warrior, 2000; Lee et al., 2003) and support the model that positioning of
the nucleus is important for neuronal motility. Recent data have provided further confirmation of
this nucleus-centrosome uncoupling in neurons through the examination of embryos
electroporated with LIS1 RNAi (Shu et al., 2004). Notably, doublecortin (DCX) has been
revealed to have a similar function to LIS1 with regard to this coupling process in neurons and
can even rescue LIS1 mutants (Tanaka et al., 2004).
The final important role of LIS1 in cellular processes involves another critical dynein-
regulated microtubule process: mitosis. Overexpression of both full-length and dominant
negative LIS1 proteins in cells has severe effects on spindle organization and mitotic progression
(Faulkner et al., 2000; Tai et al., 2002). The phenotypes observed are very similar to those
resulting from overexpression of the dynamitin subunit of dynactin, a key regulator of spindle
function (Echeverri et al., 1996). An overall increase in mitotic index is observed, and the cells
have disrupted spindle organization with abundant multipolar spindles evident (Tai et al., 2002).
Additionally, unaligned chromosomes are prominent, suggesting that LIS1 plays a role both in
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spindle formation and in spindle attachment to the kinetochores of chromosomes. Further
experiments utilizing injection of anti-LIS1 antibodies reveal similar mitotic defects, such as an
increased duration of prometaphase and misalignment of chromosomes (Faulkner et al., 2000).
Notably, removal of endogenous LIS1 from the kinetochore does not alter the attachment of
other critical components within that structure (Tai et al., 2002), thus suggesting that LIS1 plays
a separate role in kinetochore function from affecting kinetochore formation. Indeed, LIS1 may
bind to the kinetochore through direct interactions with motor proteins, especially the dynein-
dynactin complex (Tai et al., 2002).
In summary, a crude model for LIS1 function can be proposed at this point from the
current body of literature. Throughout the cell, the primary effects of LIS1 appear to result from
its interactions with dynein-mediated processes. In the cytoplasm, LIS1 promotes the outward
movement of microtubule segments, which is critical for migration, through its interaction with
non-translocating dynein motors. Conversely, non-tethered motors act with LIS1 to bring dynein,
dynactin, and membranous organelles, such as the Golgi, towards the centrosome. Similar
processes may be at work in retrograde axonal transport within neurons. Additionally, LIS1
plays a role at the centrosome in both the organization of the microtubule network and the
coupling of the centrosome to the nucleus as part of a critical process for neuronal migration.
The exact function of LIS1 at microtubule ends near the cell cortex remains unclear at the
moment. In mitotic cells, LIS1 is involved in spindle formation and maintenance, kinetochore
attachment to the spindle, and chromosome organization. Whether LIS1 is required for the
dynein-mediated process of chromosomal kinetochore-to-pole movement is still unknown,
because the severe effects of LIS1 dysfunction at early mitotic stages have precluded
examination of later mitotic events. Importantly, each of these functions of LIS1 listed above is
still not well-understood and significant gaps remain as to the exact nature of interactions that are
involved in each process. However, considerable progress has been made in recent years in better
understanding the exact mechanism of LIS1 action, and the LIS1-interacting proteins NudE and
Nudel have emerged as important players in several of these cellular events.
NudE(L) Function in the LIS1 Pathway
NudE and Nudel are protein isoforms that are mammalian homologs of the nudE gene
product of A. nidulans. As has been previously mentioned, nudE is a genetic suppressor of
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mutations in the LIS1-dynein pathway in this organism (Efimov and Morris, 2000), and thus is
considered to be an important member of this pathway. NudE and Nudel are highly conserved
among all mammals, although their murine isoforms will be the primary focus of this discussion,
and share 55% sequence identity. As will be explained in further detail, these proteins have
slightly different expression patterns and distinct but overlapping functions. It is still unclear
exactly what their separate roles are, and thus they are sometimes grouped together here and
referred to as NudE(L). Nudel mRNA is present throughout the mouse but is found at highest
levels in the brain, kidney, ovary, and heart (Sasaki et al., 2000). Nude mRNA exhibits a similar
pattern with overall lower levels of expression, except in the brain and ovary (Feng et al., 2000;
Sasaki et al., 2000). NudE and Nudel proteins have a similar distribution to each other with
highest levels found in the brain, heart, skeletal muscle, and testis (Niethammer et al., 2000;
Sasaki et al., 2000; Yan et al., 2003). Although there is not complete agreement on this point,
Nudel may be slightly more abundant overall in the mouse than NudE (Feng and Walsh, 2004).
Notably, there is a difference in the timing of expression of these two isoforms during
development. Nudel is first detected at embryonic day 13.5, and it begins to accumulate until
neonatal day 5 (Niethammer et al., 2000; Sasaki et al., 2000). After that point, it is expressed in a
fairly stable fashion throughout adulthood. On the other hand, NudE appears at embryonic day
11 and peaks five days later (Feng et al., 2000). It then begins to slowly decrease to a low level
maintained through adulthood. This difference in expression timing alone suggests that NudE
may be more important during early to mid embryonic development, whereas Nudel may play a
larger role in late embryonic development continuing into adulthood. However, such delineation
in the roles of these two proteins during development has not yet been achieved.
The binding partners of NudE and Nudel shed light onto their expected subcellular
distributions and functions. Both proteins were discovered in yeast two-hybrid screens for LIS1
interactors (Feng et al., 2000; Niethammer et al., 2000; Sasaki et al., 2000). Interestingly, the two
proteins were also detected in two-hybrid assays as interactors of Mitosin/CENP-F, the human
member of the LEK family (Feng et al., 2000; Yan et al., 2003). However, this interaction was
not pursued any further by the relevant laboratories. Additional yeast two-hybrid and co-
immunoprecipitation studies have confirmed the interaction of NudE(L) with LIS1 and revealed
an additional interaction with dynein (Feng et al., 2000; Niethammer et al., 2000; Sasaki et al.,
2000). While each experiment notes a different dynein chain (heavy, intermediate, and light), the
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importance of this observation is not especially significant, as the interaction of NudE(L) with
the larger dynein complex is the critical finding. Studies utilizing truncated Nudel proteins have
narrowed the LIS1-binding domain to the N-terminal coiled coil of Nudel, which is a highly
conserved region (85% identity) with NudE (Sasaki et al., 2000). In fact, the interaction of LIS1
with NudE also requires the coiled coil domain of NudE (Feng et al., 2000). Interestingly, the
dynein-binding domain in Nudel is C-terminal and interacts with two separate domains within
the dynein heavy chain (Sasaki et al., 2000). Only one of these domains in dynein is involved in
LIS1-dynein binding, suggesting that Nudel may possibly play a complex role in regulating
interactions of other proteins with dynein. Sciatic nerve ligation studies suggest that LIS1 and
Nudel do indeed associate with dynein motors during retrograde transport (Sasaki et al., 2000).
In addition to the interaction with dynein and LIS1, there are other less studied interactions worth
noting. It has been shown that both NudE and Nudel can homodimerize, likely through an N-
terminal region, which does not overlap any other known functional domains (Sasaki et al.,
2000; Feng and Walsh, 2004). The importance of this observation is just now being unraveled.
Finally, NudE specifically can be co-immunoprecipitated with g-tubulin, a key component of the
centrosome (Feng et al., 2000). However, it is unclear whether this interaction is direct or
whether both proteins are simply part of the same larger complex.
The known protein interactions of NudE and Nudel are in agreement with results from
further biochemical experiments. For example, Nudel is primarily isolated in the insoluble
fraction of cell lysates (Niethammer et al., 2000), consistent with a protein that is part of
membranous or cytoskeletal structures. Additionally, the importance of the NudE-LIS1
interaction is reinforced by the fact that missense mutations in LIS1 related to lissencephaly
abolish the binding between these two proteins (Feng et al., 2000). This result suggests that
interference with NudE function may be partially responsible for the defects observed in that
disease.
As would be expected from their homology and similar binding partners, NudE and
Nudel also exhibit fairly similar subcellular distributions in a wide variety of cell types. In
embryonic neurons, Nudel is first detected in a perinuclear region around the centrosome, but it
slowly migrates to the axon in postnatal stages and remains there throughout adulthood (Sasaki
et al., 2000). In general, in most cell types examined, NudE and Nudel have a perinuclear
distribution with concentration of the protein around the centrosome (Feng et al., 2000;
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Niethammer et al., 2000; Yan et al., 2003). However, it is worth reiterating that the proteins have
both a centrosomal and non-centrosomal distribution and do not exhibit an exclusive preference
for either. The exact nature of the distribution seems to be related to the cell cycle, as will be
discussed shortly, and to the cell type, as COS-7 cells have more NudE at centrosomes (Yuanyi
Feng, personal communication) while mouse embryonic fibroblasts have little evident
centrosomal localization of Nudel (Niethammer et al., 2000). Consistent with the binding data,
Nudel has been shown to colocalize throughout the cell, including the periphery, with dynein
(Niethammer et al., 2000). Interestingly, this colocalization with dynein away from the nucleus is
specific to Nudel, as it is not evident with LIS1 (Smith et al., 2000). Clearly, however, the
localization and function of LIS1 are important for the distribution of Nudel, as overexpressing
LIS1 leads to increased accumulation of Nudel near the nucleus (Niethammer et al., 2000).
Conversely, fibroblasts from LIS1 heterozygous mice have more dispersed Nudel within the cell,
although this result has not been consistently observed (Sasaki et al., 2000).
Since the LIS1 pathway is important for cell division, the subcellular distribution of
NudE and Nudel has also been examined in mitotic cells. Very interestingly, both proteins have
been observed on mitotic spindles and colocalize on these structures with dynein (Yan et al.,
2003; Feng and Walsh, 2004). While one laboratory has observed NudE on chromosomal
kinetochores (Feng and Walsh, 2004), as has been noted for other LIS1 family members, another
group did not detect Nudel on kinetochores (Yan et al., 2003). It remains unclear whether this is
due to actual differences between NudE and Nudel or due to variations in techniques and
reagents used. NudE has further been observed at the cleavage furrow of dividing cells (Feng and
Walsh, 2004). Both NudE and Nudel have been detected at the spindle poles of mitotic cells, but
the localization of the latter there is not as prominent (Yan et al., 2003; Feng and Walsh, 2004).
Interestingly, localization of NudE(L) to sites such as the spindle poles may be dependent
upon phosphorylation status. It was initially observed that Nudel exists as a doublet on Western
blots from brain lysate (Niethammer et al., 2000; Sasaki et al., 2000), suggesting the presence of
a post-translational modification. Indeed, Nudel is a phosphorylation substrate of cyclin-
dependent kinase 5 (cdk5), a serine/threonine kinase involved in neuronal migration
(Niethammer et al., 2000; Sasaki et al., 2000). Interestingly, it has been shown that inhibition of
this phosphorylation event in neurons results in a more focused distribution of Nudel within the
cell (Niethammer et al., 2000; Sasaki et al., 2000). More recent data suggest that 14-3-3 proteins
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may also play a role in regulating Nudel phosphorylation by cdk5 (Toyo-oka et al., 2003).
Further experiments have revealed that Nudel may be a phosphoprotein in various cell types
during mitosis, specifically, due to cell cycle-dependent phosphorylation by cdc2 and/or Erk2
(Yan et al., 2003). Notably, cdc2 kinase is involved in control of the G2/M transition (Smits and
Medema, 2001). Studies using mutant Nudel proteins suggest that this phosphorylation event
may be responsible for translocating Nudel from the centrosome/spindle poles to the spindle
itself upon the onset of mitosis (Yan et al., 2003). Additionally, phosphorylated Nudel has
increased affinity for LIS1 (Yan et al., 2003), so this modification may function to regulate
interactions between various LIS1 family members. It is unclear, however, whether
phosphorylation of NudE has any role endogenously. While transfected NudE protein can be
phosphorylated by cdc2, there are no data utilizing a NudE-specific antibody against endogenous
protein (Yan et al., 2003). Additionally, endogenous NudE, unlike Nudel, is detected as a single
band on Western blot (Feng et al., 2000). Thus it would appear that, unlike for Nudel, there is
little direct evidence to suggest that phosphorylation of NudE normally occurs and is important
for NudE function.
Recently, NudE and Nudel knockout mice have been generated. The Nudel -/- mice are
early embryonic lethal and have not yet been thoroughly examined (Hirotsune et al. unpublished
data). The absolute necessity of Nudel is not surprising, as depletion of Nudel in cell culture
using RNAi results in massive cell death (Liang et al., 2004). Interestingly, NudE is able to
partially rescue the defect in this system, even though its presence in Nudel knockout mice is not
sufficient to eliminate or severely delay embryonic lethality. NudE knockout mice, on the other
hand, are viable into adulthood (Feng and Walsh, 2004). The primary phenotype examined so far
relates to development of the brain, even though the mice also have defects in other tissues
(Yuanyi Feng, personal communication). The NudE -/- mice have significantly smaller brains
than wild-type or NudE +/- littermates, as a result of a thinner and smaller cortex (Feng and
Walsh, 2004). Notably, this is not due to an increase in apoptosis. Instead, the microcephaly is a
result of defective neuronal migration and neurogenesis, which are processes also disrupted in
LIS1 mutant organisms (Hirotsune et al., 1998; Liu et al., 2000). More specifically, there is a
decrease in the number of cortical progenitor cells in the brains of NudE -/- mice due to mitotic
defects (Feng and Walsh, 2004). These abnormalities consist of altered cleavage planes,
mislocalized chromosomes, and abnormal spindle assembly and structure. Once again, many of
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these defects have been observed when disrupting LIS1 function (Faulkner et al., 2000; Tai et al.,
2002). Supporting data on NudE function come from Xenopus laevis experiments. Injecting
truncated NudE mRNA coding for only the LIS1-binding domain into embryos results in severe
defects in formation of the brain and eyes (Feng et al., 2000). Although the authors did not
observe any abnormalities in other tissues, they attribute this to a possible dosage effect,
suggesting that NudE may be most critical for development of head structures.
Cell culture studies provide further evidence as to the cellular roles of NudE and Nudel.
Overexpression of Nudel, but not LIS1 in the same set of experiments, has been shown to shift
dynein localization more to the periphery (Niethammer et al., 2000). These data suggest that
Nudel may play a role in directing the motor protein to its proper subcellular position. However,
other experiments have shown the exact opposite result where there is no effect on dynein
placement from full-length Nudel, while LIS1 does have an effect (Sasaki et al., 2000; Smith et
al., 2000). Instead, expression of a dominant negative form of Nudel causes a change in dynein
localization (Sasaki et al., 2000). Under these conditions, dynein becomes more concentrated
around the nucleus, consistent with LIS1 +/- cell data from the same laboratory but not other
independent experiments on LIS1 (Sasaki et al., 2000; Smith et al., 2000). With regard to NudE,
overexpression of the protein in cells results in disordered microtubule arrays that radiate from
the areas of highest NudE expression, rather than the centrosomes (Feng et al., 2000).
Additionally, the normal distribution of g-tubulin is disrupted and this centrosomal protein
diffuses throughout the cytoplasm. These data are consistent with a protein that is part of the
LIS1 pathway of microtubule regulation and that also has been shown to be a component of the
centrosome. The authors suggest that NudE may thus regulate formation of the centrosome.
Notably, other studies on Nudel mutants do not reveal, albeit in data not shown, any
disorganization of microtubules (Liang et al., 2004). Once again, it is unclear if this represents a
fundamental difference between NudE and Nudel functions or differences in underlying
experimental techniques.
Building upon the data concerning localization changes of LIS1 pathway proteins,
research has begun to examine the broader role of NudE and Nudel in cellular functions of this
pathway. As has been previously mentioned, dynein is essential for the positioning of many
membranous organelles near the nucleus in a microtubule-dependent fashion. To examine the
role of Nudel on such processes, a dominant negative approach was used (Liang et al., 2004).
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Nudel mutants lacking either the dynein-binding or LIS1-binding domain exhibited notable
phenotypes, whereas full-length Nudel and, interestingly, double mutant Nudel (both dynein- and
LIS1-binding domains absent) showed less severe effects. Thus, the function of Nudel in LIS1
pathway processes appears to require both binding domains, suggesting that the interplay of
dynein, LIS1, and Nudel is critical for dynein activity. Studies utilizing Nudel RNAi support this
model by revealing that Nudel knockdown results in decreased association of LIS1 with dynein
(Shu et al., 2004). The phenotypes observed from expression of the dominant negative Nudel
binding domain mutants consist of fragmentation and dispersion of lysosomes, endosomes, and
the Golgi (Liang et al., 2004). There is also a reduction in protein secretion. Interestingly, these
effects are specific to the function of minus end-directed motors, such as dynein, as vesicles
relying on kinesin motors for movement remain unaffected. Additionally, lysosome trafficking
was observed in living cells and found to be inhibited, but only with respect to inward dynein-
dependent motion. These results are supported by Nudel RNAi experiments that reveal Golgi
fragmentation due to Nudel knockdown (Liang et al., 2004).
Further experiments utilizing Nudel RNAi have revealed additional effects on LIS1
pathway functions. Nudel knockdown results in an accumulation of microtubules near the
nucleus after a combination nocodazole/vinblastine treatment (Shu et al., 2004). Thus, Nudel is
important for microtubule transport to the periphery, as has been noted for LIS1 in similar
experiments (Smith et al., 2000). Nudel is also required for neurofilament assembly and
transport, and thus neuronal integrity (Nguyen et al., 2004). Administration of Nudel RNAi to a
neuroblastoma cell line results in changes similar to those observed in neurodegenerative
processes. Another important phenotype arising from Nudel knockdown relates to processes
critical for neuronal migration. Depletion of Nudel using RNAi results in an inhibition of nuclear
translocation, as measured by nuclear migration distance, and causes nuclei to oscillate randomly
(Shu et al., 2004). As a reminder, movement of neurons requires leading process extension,
nuclear translocation, and trailing process retraction (Wynshaw-Boris and Gambello, 2001). The
microtubule network forms a connection from the cell cortex to the centrosome to the nucleus
that is critical for this migration process. Careful examination of the Nudel-depleted cells reveals
that there is a loss of this critical microtubule structure normally surrounding the nucleus and
connected to the centrosome (Shu et al., 2004). As a result, the distance between centrosome and
nucleus is significantly increased in these cells, as has been previously observed in LIS1 +/-
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neurons (Tanaka et al., 2004). Somewhat surprisingly, there are no changes in microtubules at
the leading edge, despite the presence of several LIS1 pathway members there.
To further study these processes in an in vivo environment, Nudel RNAi was
administered in utero and formation of the brain examined (Shu et al., 2004). As expected, the
authors observe severe defects in positioning of neurons due to abnormalities in neuronal
migration. However, there are no changes in proliferation, which is surprising given other NudE
and LIS1 studies (Faulkner et al., 2000; Tai et al., 2002; Feng and Walsh, 2004), or in leading
process movement. Instead, an increase in the nucleus-centrosome distance is again observed,
suggesting an uncoupling of these two structures (Shu et al., 2004). This Nudel-knockdown
phenotype can be partially rescued by overexpressing LIS1. Conversely, however, Nudel is
unable to abrogate effects caused by LIS1 depletion. A model is proposed where Nudel and LIS1
activate dynein, and, in turn, dynein sustains microtubule bundles between the nucleus and the
centrosome. Dynein then moves along this microtubule network towards the centrosome, thus
also pulling the nucleus along and allowing neuronal migration to proceed. The role of
doublecortin, which has been shown to also regulate nucleus-centrosome distance (Tanaka et al.,
2004), in relation to Nudel is currently unclear.
Finally, the role of NudE in mitotic processes has been more carefully examined in cell
culture to better understand the cell division defects observed in NudE knockout mice (Feng and
Walsh, 2004). A novel approach was taken that emphasized examining the function of the
homodimerization domain in NudE. The authors used dominant negative constructs that were
deficient for self-association but contained all other known binding domains within NudE. The
effects of such mutants would then presumably be primarily the result of inhibiting self-
association of NudE. The authors do note, however, that due to the high homology (90%) of the
truncated region to Nudel, some effects may also be caused by Nudel dysfunction. Also, any
currently unknown interactions involving this domain would be disrupted. Interestingly,
expression of these dominant negative mutants, and full-length NudE to a lesser extent, results in
severe mitotic arrest of cells in culture (Feng and Walsh, 2004). Mono- and multi-polar spindles
are observed, as well as mispositioned spindles. Since expression of the NudE mutants very
quickly results in abnormal centriole numbers, defective centrosome duplication may be
occurring and at fault for many of the defects. Notably, there is no increase in microtubule
depolymerization, suggesting that the effects noted may indeed be specific to the role of the self-
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association domain of NudE. The authors also do not observe any mitotic defects with LIS1
overexpression in their experimental system, despite reports to the contrary (Faulkner et al.,
2000), and suggest that NudE may perhaps be more required for mitotic progression than LIS1.
In combination with the NudE knockout mouse data (Feng and Walsh, 2004), the above results
suggest that NudE plays a critical role in spindle formation and function, and disruption of this
pathway is especially detrimental to progenitor cells and their subsequent migration and
differentiation.
In summary, an early model for NudE(L) function is emerging from these published data
(Figure 3). While the exact nature of the difference between NudE and Nudel is not yet well-
understood, the two isoforms share significant similarities and are grouped together for our
purposes here. The characterized interactions for NudE(L) are with dynein and LIS1. The three-
way interplay of these proteins is crucial for proper LIS1 pathway function, although any role of
phosphorylation in regulating these interactions remains unclear. The localization of NudE(L),
and thus presumably its site of action, in non-dividing cells is predominantly around the nucleus
with a fraction of the protein located at the centrosome. Its presence on the spindle apparatus
during mitosis underlies its importance in directing proper cellular division. While it plays an
important role during brain development, NudE(L) function extends to other tissues, signifying
its importance in many aspects of embryonic development. In a wide range of cell types,
NudE(L) has been shown to be involved in activities of the LIS1 pathway, such as microtubule
organization and organelle positioning. Its critical developmental functions primarily encompass
the processes of migration and proliferation. More specifically, its role in nucleus-centrosome
coupling is essential for proper nuclear translocation during cell movement. Additionally, it
regulates spindle assembly and function, potentially through homodimerization. Despite recent
progress in this research field, the precise role of NudE(L) within the still-evolving family of
LIS1 pathway members remains unclear. Importantly, while several functions of NudE(L) have
been derived experimentally, the mechanisms behind these effects are almost completely
unknown. Discovery of additional binding partners may be required in order to generate a true
model for NudE(L) action.
Figure 3. Model of LIS1 pathway. See text for details. Adapted from Wynshaw-Boris et al., 2001.
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Summary of this Thesis
In the studies presented here, we reveal that cytLEK1 binds NudE and is a novel member
of the LIS1 pathway. Thus, examination of cytLEK1 may be a key factor to better understanding
the functions of this pathway, which is extremely important for a diverse set of developmental
processes. LIS1 pathway members play a critical role in fundamental cellular processes, such as
differentiation, proliferation, and migration. Therefore, determining the precise nature of their
actions will lead to significant insight into the complex process of embryogenesis. However, the
functions of LIS1 pathway members, despite their importance, remain poorly understood at the
present time. Our studies here provide additional insight into the proteins involved in the
regulation of the LIS1 pathway. In chapter II, we present data on the expression and localization
of cytLEK1 in various cells and tissues. In addition to revealing, for the first time, the exact
nature of cytLEK1 distribution, experiments in this chapter provide further evidence suggestive
of the action of cytLEK1 as a regulator of the LIS1 pathway. In chapter III, we show that
cytLEK1 and NudE interact through distinct domains in each protein. We confirm the validity of
this interaction through detailed colocalization studies. Finally, in chapter IV, we reveal the
functional importance of this cytLEK1-NudE interaction on the LIS1 pathway, especially with
regard to morphology and microtubule regulation. Finally, we discuss the implications of our
research within a model for cytLEK1 action and elaborate on future experiments needed to
further examine the role of cytLEK1. Taken together, our studies reveal that cytLEK1 is essential
for cellular functions regulated by the LIS1 pathway and thus may play a critical role in
fundamental processes during development.
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CHAPTER II
CHARACTERIZATION OF
LEK1 EXPRESSION AND DISTRIBUTION
Introduction
The LEK family of proteins consists of molecules with diverse expression patterns and
functions (see Introduction). Mitosin/CENP-F has a cell cycle-specific expression pattern and
localizes predominantly to the chromosomal kinetochore during mitosis (Liao et al., 1995; Zhu et
al., 1995b). CMF1 expression, on the other hand, is regulated during embryonic development
with a tissue specificity for striated myocytes (Wei et al., 1996; Dees et al., 2000; Pabon-Pena et
al., 2000). It has a dynamic localization that changes from the nucleus to the cytoplasm as the
chick embryo matures. In addition to its own unique expression pattern, LEK1 exhibits an added
level of complexity, as it is post-translationally cleaved to produce two peptide products:
cytLEK1 and nucLEK1. Initial studies have focused almost exclusively on examination of
nucLEK1 (Goodwin et al., 1999; Ashe et al., 2004). This protein localizes to the nucleus of cells
in most developing tissues. Its expression diminishes as development proceeds until it is
essentially absent in adult mice (Goodwin et al., 1999). In the heart, the nucLEK1 protein rapidly
disappears after neonatal day 5, which coincides with the period when cardiomyocytes are
undergoing permanent cessation of mitosis and terminal differentiation (Soonpaa et al., 1996;
Soonpaa and Field, 1998). Unlike nucLEK1, the expression pattern and localization of cytLEK1
in the developing mouse and in cultured cells has never been previously examined in detail.
Thus, we wished to characterize the distribution of cytLEK1 in order to compare it to other LEK
family members, including nucLEK1, and to gain insight into its function. Importantly, the
discovery of its interaction with NudE, a LIS1 pathway member, directed us to more carefully
examine the presence of cytLEK1 on certain subcellular structures related to this pathway.
In this chapter, we present data investigating the expression and distribution of cytLEK1
in several cell lines and tissues during murine development. Similar to nucLEK, cytLEK1
exhibits a dramatic decline in protein level in the heart at postnatal stages. Importantly, this
decrease coincides with a distinct change in the localization of cytLEK1 in this tissue.
Examination of cytLEK1 and nucLEK1 expression in additional developing tissues provides
insight into the wide distribution of these proteins and helps direct further functional studies.
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Observations from cultured cells confirm and build upon previous data concerning the general
subcellular distribution pattern of cytLEK1 and nucLEK1. The results from 3T3 fibroblasts and
C2C12 myoblasts additionally provide novel and important insights into the localization of these
proteins on the spindle apparatus during mitosis. Pre-extraction studies support the role of
cytLEK1 in the cytoskeletal functions that are discussed in later chapters. Additionally,
transfected cytLEK1 protein exhibits a colocalization with the microtubule network, suggestive
of an important link to the cytoskeleton. In order to create further reagents for these types of
experiments, five new polyclonal antibodies to cytLEK1 and nucLEK1 were developed and
characterized. In summary, the experiments in this chapter, for the first time, study cytLEK1
expression and localization. These data reveal that cytLEK1 exhibits a developmentally-
regulated distribution with some tissue-specific differences and that it appears to interact with
key cytoskeletal components. Both cytLEK1 and nucLEK1 also have the potential to function in
mitotic processes based on their presence on the spindle apparatus. These results are consistent
with data presented in this document on cytLEK1 regulation of the LIS1 pathway and help guide
future functional experiments.
Materials and Methods
Tissue preparation for immunohistochemical analysis
Mouse embryonic tissues were isolated and washed in PBS prior to placement in O.C.T
compound (Sakura). This mixture was then frozen in a methanol/dry ice bath and stored at –20˚C
until sectioning. Frozen tissues were cryosectioned with a thickness of 7 mm on a Jung CM 3000
cryostat (Leica). Successive sections were collected on gelatin coated slides and stored at –20˚C
until immunohistochemical analysis.
Tissue preparation for western blot analysis
Mouse embryonic tissues were isolated and washed in PBS. Samples were mixed with
5X sample buffer (0.312 M Tris-HCl pH 6.8, 10% sodium dodecyl sulfate, 25% 2-
mercaptoethanol, 0.05% bromophenol blue) prior to three rapid pulses on a sonicator (Virtis) on
ice. Samples were then placed at 95˚C for 5 min and stored at –80˚C until Western blot analysis.
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Affinity purification of rabbit polyclonal antibodies
Five polyclonal antibodies to LEK1 peptides were generated in rabbits (Biosynthesis).
Three of these antibodies were against cytLEK1 peptides and were named based on the letter
“C” followed by the approximate amino acid location of the injected peptide in the LEK1
sequence. Their names and peptide sequences were as follows: C264
(DCSSLPGEPHSAQLLHQA), C1127 (NTNKHSMSATD), and C1403
(LSSKEVRVHFAELQEKF ). Two of the antibodies were against nucLEK1 peptides and were
named based on the letter “N” followed by the approximate amino acid location of the injected
peptide in the LEK1 sequence. They were as follows: N2088 (ECEKQTISKALEVALK), and
N2690 (SCRQLEGEKEMLQKEL).
The antisera were affinity purified using the injected peptide and a SulfoLink kit (Pierce).
The manufacturer’s protocol was modified to accommodate standard published methods
(Backstrom and Sanders-Bush, 1997). Briefly, the SulfoLink Coupling Gel was equilibrated with
Coupling Buffer. The peptide (Biosynthesis) was coupled to the column by mixing with the
Coupling Gel for a 2 h incubation followed by three washes with Coupling Buffer. To block
nonspecific binding sites, the coupled column was incubated with 0.05 M cysteine in Coupling
Buffer for 30 min with mixing. The coupled column was then washed four times with Wash
Buffer, three times with high salt (500 mM NaCl) Tris pH 7.6, and three times with Elution
Buffer. The coupled column was then equilibrated by washing three times with TBS. Each
antiserum was diluted with an equal volume of TBS prior to filtration (0.25 mm pore size). The
filtered antiserum was then added to the coupled column and allowed to flow through. This was
followed by three washes of the coupled column with Sample Preparation Buffer and three with
high salt TBS. The protein was eluted by applying glycine buffer (50 mM pH 2.7). Eluate was
collected in 1 mL fractions. Protein concentration of each fraction was estimated by determining
the OD280 (Shimadzu). Fractions of interest were pooled and neutralized by the addition of 1 M
Tris pH 9.5.
To confirm specificity, all antibodies were subject to peptide competition for both
immunofluorescence and Western blot applications. To ensure complete competition, a one
hundred molar excess of peptide was added, as calculated by determining antibody concentration
and total number of epitope binding sites. Antibody was mixed with peptide in 1% BSA in PBS
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(immunofluorescence) or TBST (Western blot) for 1 h during sample incubation. Testing was
conducted against endogenous LEK1 and transfected protein.
Cloning of cytLEK1
Since the full cytLEK1 cDNA had never been cloned, a reverse transcription polymerase
chain reaction (RT-PCR)-based approach was utilized to complete this project. Attempted
cloning from bacteriophage cDNA libraries was not fruitful due to the large size of the cytLEK1
transcript (approximately 6.5 kb). Additionally, the length and A/T-richness of the transcript
required the use of special RT-PCR systems adapted for such conditions. As the yield of full-
length cytLEK1 from RT-PCR was insufficient for further cloning, a two-step approach was
used to amplify two overlapping fragments of cytLEK1. Thus, one RT-PCR reaction utilized a
FLAG-and-MluI-containing forward primer complementary to the start site of LEK1 and a
reverse primer complementary to a unique SphI site at 3185 bp of LEK1. The second reaction
consisted of a forward primer complementary to this same SphI site and a reverse primer
containing a complementary stop codon and SalI site. Together, these two fragments covered the
1-6630 bp region of LEK1 and thus slightly more than the predicted size of full length cytLEK1.
Each fragment was amplified on an iCycler gradient PCR machine (Bio-Rad) from 200 ng E10.5
mouse heart RNA (provided by Dr. Mabelle Ashe) using the Superscript One-Step RT-PCR
system (Invitrogen). Each RT-PCR product was gel purified using a QiaQuick kit (Qiagen) and
cloned into the pCR-XL-TOPO vector for large inserts (Invitrogen). Clones were then fully
sequenced and compared to each other and the at-the-time incomplete LEK1 sequence from
NCBI and Celera. The two clones with the most accurate sequences were selected for further
experiments. This analysis revealed four total point mutations, which were not silent, likely
caused by the high fidelity Taq polymerase utilized in the Superscript kit. Each of these point
mutations was corrected through a PCR-based site-directed mutagenesis approach. A triple
ligation (MluI/SphI/SalI) was then performed to join the two cytLEK1 fragments in pCI-neo
(Promega). Sequencing confirmed the success of the ligation in forming pCI-neo-cytLEK1
containing the 1-6630 bp region of LEK1 with a 5’ FLAG tag. The final sequence of full-length
LEK1 had now been obtained for the first time and was submitted to NCBI.
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Cell culture
COS-7 and NIH 3T3 cells (ATCC) were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM; Cellgro) supplemented with 10% fetal bovine serum, 100 mg/mL
penicillin/streptomycin, and L-glutamine. C2C12 cells (ATCC) were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 20% fetal bovine serum, 100 mg/mL
penicillin/streptomycin, and L-glutamine. All cell lines were maintained in a 95% air-5% CO2
humidified atmosphere at 37˚C.
Transfections
3T3, COS-7, and C2C12 cells were grown to 40-60% confluency and transfected using
FuGENE6 (Roche) per manufacturer’s instructions. Briefly, FuGENE was added to a tube
containing OptiMEM medium (Cellgro) and gently mixed. DNA was then added and gently
mixed. After a 15 min incubation, the FuGENE-DNA mixture was pipetted into wells containing
cells and fresh medium. For each well of a 4-well slide, 0.25 mg of total DNA was utilized for
transfection. For each 10 cm plate, 3 mg of total DNA was utilized for transfection. Cells were
generally grown for 24-48 h prior to collection for further examination.
Western blotting
Lysates were incubated with 5X sample buffer (0.312 M Tris-HCl pH 6.8, 10% sodium
dodecyl sulfate, 25% 2-mercaptoethanol, 0.05% bromophenol blue) for 5 min at 95˚C. After
boiling, samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). Proteins on the gel were transferred overnight on ice to 0.45 mm pore size
Immobilon-P PVDF transfer membrane (Millipore). Membranes were blocked with 2% BSA in
TBST for 1-2 h at room temperature. Primary antibody was then applied for 1-2 h with shaking.
After three washes with TBST, the membrane was incubated with alkaline phosphatase-
conjugated secondary antibody for 1 h with shaking. This was followed with three TBST washes
and one alkaline phosphatase buffer wash. Membranes were developed using NBT-BCIP
(Roche) in alkaline phosphatase buffer and scanned into digital format (Hewlett-Packard).
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Immunochistochemistry and microscopy
Cells grown on glass chamber slides (Nalge Nunc) or frozen tissues on gelatin coated
slides were gently washed with PBS and fixed with 70% ethanol for 20 min. Samples were then
washed briefly in PBS, permeabilized with 0.25% Triton X-100 in PBS for 10 min, and blocked
in 2% BSA in PBS for a minimum of 1 h. Primary antibodies in 1% BSA in PBS were applied
overnight at 4˚C. After three PBS washes, secondary antibodies were applied for 1 h at room
temperature. The slides were washed three times with PBS and twice with water before cover
slips were attached with Aqua Poly/Mount (PolySciences). Cells were visualized by fluorescence
microscopy on an AX70 (Olympus) or, for confocal analysis, an LSM510 (Zeiss) microscope.
Digital images were captured and processed using Magnafire (Optronics), Metamorph (Universal
Imaging), and Photoshop (Adobe) software.
Antibodies
A polyclonal anti-FLAG antibody was acquired from Sigma. The monoclonal antibody against
b-tubulin was also manufactured by Sigma. The polyclonal antibodies against dynein and CENP-
A were purchased from Santa Cruz. Polyclonal antibody Spec1 to a cytLEK1 peptide (aa 1826-
45) was generated in rabbits (Biosynthesis) and affinity purified using the injected peptide
(Backstrom and Sanders-Bush, 1997). Polyclonal antibody 863 to a nucLEK1 peptide (aa 2872-
88 aa) was similarly prepared. Alexa 488 and Alexa 568 conjugated secondary antibodies were
obtained from Molecular Probes. Anti-mouse alkaline phosphatase conjugated secondary
antibodies for Western blot were purchased from Sigma. DAPI was used to visualize nuclei
(Boehringer Mannheim).
Results
Characterization of LEK1 antibodies
For reference, an initial series of characterization studies of the previously established
cytLEK1 (Spec1) and nucLEK1 (863) antibodies was conducted and is presented here. Both of
these antibodies have been extensively and successfully examined in the past for specificity to
LEK1, including through expression library screens and in vitro translational studies (Goodwin
et al., 1999; Pabon-Pena et al. unpublished data). Creation of a full-length cytLEK1 construct
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(see Materials and Methods) allows testing of antibodies, for the first time, with transfected
cytLEK1 protein. The cytLEK1 antibody detects on Western blot the product of a FLAG-tagged
cytLEK1 construct transfected into COS-7 cells (Figure 4 A). No band is observed in non-
transfected COS-7 cells, confirming specificity for cytLEK1. Additionally, the cytLEK1 and
nucLEK1 antibodies recognize endogenous cytLEK1 and nucLEK1 in lysates from 3T3
fibroblasts and C2C12 myoblasts on Western blot (Figure 4 B). The larger cytLEK1 and smaller
nucLEK1 bands are also visible in embryonic day 12.5 murine hearts (Figure 4 C). To confirm
immunoreactivity in immunofluorescence assays, FLAG-tagged cytLEK1 or nucLEK1
constructs were transfected into COS-7 cells. The cytLEK1 antibody correctly detects the
transfected cytLEK1 protein in the cytoplasm (Figure 5 A). Additionally, the nucLEK1 antibody
identifies the transfected nucLEK1 protein, which contains an NLS, within the nucleus. These
distribution patterns match the localization of endogenous proteins in C2C12 myoblasts (Figure
5 B). CytLEK1 is present in the cytoplasm with a higher concentration near the nucleus, whereas
nucLEK1 localizes to the nucleus of these cells.
Examination of LEK1 expression in the murine heart during development
While expression of nucLEK1 in the developing heart has previously been examined
(Goodwin et al., 1999), the expression pattern of cytLEK1 is unknown. Thus, experiments were
undertaken to study the cytLEK1 protein at key stages during heart development. Tissue sections
were examined from mice at the following stages of development: embryonic day 16.5 (E16.5),
neonatal day 2 (N2), neonatal day 4 (N4), neonatal day 7 (N7), neonatal day 10 (N10), and adult
(Figure 6). Distribution of nucLEK1 is confirmed to be predominantly nuclear at all stages, as
has been previously published (Goodwin et al., 1999). The only change observed is a decrease in
the percentage of nuclei staining positive for nucLEK1 during progression of postnatal
development. In adult hearts, nucLEK1 cannot be readily detected, although occasionally a few
cells with low levels of expression are present. Similar to nucLEK1, cytLEK1 is mostly absent in
adult hearts. However, an unexpected distribution pattern is observed for cytLEK1. In agreement
with data from cell culture experiments, cytLEK1 is distributed primarily in the cytoplasm at all
embryonic stages of the heart examined. However, surprisingly, much of the protein seemingly
localizes to the nucleus beginning at neonatal day 2, where it remains throughout postnatal
development. Upon higher-power examination of these postnatal cardiomyocytes, a difference in
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Figure 4. Western blot characterization of LEK1 antibodies. A) COS-7 cells were 
transfected with a FLAG-tagged cytLEK1 construct. Lysates were collected and blots were 
probed with the antibody to cytLEK1 (Spec1). The antibody detects only the FLAG-cytLEK1 
band from these cells and no band is seen in non-transfected COS-7 cells, confirming its 
specificity for cytLEK1. B) 3T3 fibroblast and C2C12 myoblast cell lysates were collected for 
detection of endogenous cytLEK1 and nucLEK1 on Western blot. The larger cytLEK1 and 
smaller nucLEK1 (863) bands are visualized by the appropriate antibody and no other bands 
are seen. C) Heart tissue was collected for detection of endogenous cytLEK1 and nucLEK1. 
Once again, the cytLEK1 and nucLEK1 bands are visualized by the antibodies.
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Figure 5. Immunofluorescence characterization of LEK1 antibodies. A) FLAG-cytLEK1 or 
FLAG-nucLEK1 was transfected into COS-7 cells. Each transfected protein was detected with the 
appropriate antibody against LEK1 (red) in addition to a FLAG antibody (green). As expected, 
cytLEK1 (Spec1) is cytoplasmic while nucLEK1 (863), which contains a NLS, is found in the 
nucleus. The specific colocalization shows proper detection of LEK1 protein by the LEK1 
antibodies without nonspecific fluorescence. E) C2C12 myoblasts were examined for endogenous 
localization of cytLEK1 and nucLEK1. Whereas cytLEK1 is distributed in the cytoplasm of cells, 
nucLEK1 exhibits a primarily nuclear localization. DAPI (blue) was used to visualize nuclei. 
Bars, 10 µm.
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the nuclear localization of the two LEK1 protein products is observed. Whereas nucLEK1 is
found throughout most of the nucleus, similar to experiments with C2C12 myoblasts, cytLEK1
has a significantly more punctate nuclear staining pattern (Figure 7). Therefore, despite both
proteins being localized to the nucleus during these postnatal stages, their distribution patterns
are not identical. This discrepancy suggests that these results are not a consequence of an
increase in uncleaved LEK1 detected by both antibodies, although direct experiments testing this
theory would require the existence of both monoclonal and polyclonal LEK1 antibodies. Future
confocal analysis may be of assistance and help distinguish between true nuclear labeling and
tight perinuclear staining. In summary, the surprising change in localization at neonatal day 2 for
cytLEK1 is intriguing, since it correlates with the period when cardiomyocytes are undergoing
permanent cessation of mitosis and terminal differentiation (Soonpaa et al., 1996; Soonpaa and
Field, 1998).
To complement the immunofluorescence data, analysis of expression levels of nucLEK1
and cytLEK1 was conducted by Western blot. Although LEK1 mRNA in the heart has been
shown to be dramatically downregulated after neonatal day 4 (Goodwin et al., 1999), there have
been no studies examining whole-organ protein expression level. Our results here reveal that the
highest levels of expression of both cytLEK1 and nucLEK1 proteins occur at late embryonic
stages (Figure 8). This is then followed with a subsequent decrease in expression levels, most
dramatic for cytLEK1, throughout postnatal development until adulthood, when neither protein
can be detected on Western blot. Thus, the presence and, presumably, function of LEK1 in the
adult heart is significantly reduced compared to its developmental role. Importantly, full-length
LEK1 is not detected at any stage by Western blot, suggesting that cleavage of the protein is
complete.
Examination of LEK1 expression in the murine intestine during development
Studies were undertaken to examine the distribution of cytLEK1 and nucLEK1 in the
developing mouse intestine. Such experiments have not been previously conducted for any LEK
family member and are interesting due to the important nature of proliferative processes in
intestinal function. In this organ, enterocytes undergo cell division throughout the entire life of
the organism (Ross et al., 1995). This scenario provides a useful contrast with the heart where
proliferation ceases relatively abruptly at postnatal stages (Soonpaa et al., 1996; Soonpaa and
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Figure 6. Immunohistochemical analysis of LEK1 expression in embryonic day 16.5 to adult murine hearts. NucLEK1 expression (red) is
always nuclear throughout development and is not clearly detected in adult hearts. CytLEK1 expression (red) is predominantly cytoplasmic at
embryonic stages. However, beginning at N2, the expression becomes nuclear until adulthood when cytLEK1 is not detected.
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Figure 7. Immunohistochemical analysis of LEK1 expression in embryonic day 16.5 to
neonatal day 7 murine hearts. NucLEK1 expression (red) throughout development is always
nuclear. CytLEK1 expression (red) is predominantly cytoplasmic at E16.5. However, beginning
at N2, the expression becomes nuclear although it is less widespread in the nucleus than
nucLEK1. DAPI (blue) was used to visualize nuclei.
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Figure 8. Western blot analysis of LEK1 expression in embryonic day 16.5 to adult murine
hearts. The highest levels of expression for cytLEK1 and nucLEK1 occur at embryonic stages.
This is followed by a subsequent decrease in expression levels, most dramatic for cytLEK1,
throughout postnatal development. Neither protein can be detected in adult hearts.
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Field, 1998). Thus, any role of LEK1 in these two distinct settings of cell division processes can
be better understood. Small intestine tissue sections were analyzed from various postnatal mice
with the appropriate LEK1 antibodies. Notably, nucLEK1 seems to be expressed at a higher level
than cytLEK1 in this tissue based on immunofluorescence data. CytLEK1 is detected at a fairly
low level within most cells in a diffuse cytoplasmic distribution at neonatal day 2 and then
quickly disappears at later timepoints (Figure 9 A). Conversely, nucLEK1 has strong expression
in the nucleus at neonatal days 2 and 4 throughout the villi of the small intestine (Figure 9 B).
While there may be increased nucLEK1 immunofluorescence in some intestinal crypts, there is
no clear pattern throughout multiple sections. Interestingly, the level of nucLEK1 expression
dramatically declines by neonatal day 7, despite the fact that enterocytes remain proliferative
through adulthood. These data thus appear to reinforce the hypothesis that LEK1, or at least
nucLEK1 in this setting, plays a critical role in proliferation during embryonic development but
not in later adult stages (Goodwin et al., 1999; Ashe et al., 2004).
Examination of LEK1 expression throughout the developing embryo
In order to examine the expression of cytLEK1 in a wide variety of tissues throughout
murine development, an expansive Western blot approach was undertaken. There were no
previous studies that had carefully examined the protein levels of either LEK1 cleavage product
in a diverse set of tissues. Liver, heart, skeletal muscle, and brain tissues were collected from
mice at the following stages of development: embryonic day 12.5 (E12.5), embryonic day 18.5
(E18.5), neonatal day 1 (N1), neonatal day 4 (N4), neonatal day 10 (N10), and adult (Figure 10).
Notably, cytLEK1 is detected at E12.5 in the heart and in skeletal muscle but not in any other
tissues. By E18.5, robust expression is also seen in the brain. Interestingly, there are multiple
evenly-spaced bands in all positive samples from the brain, suggesting the potential for
oligomerization of cytLEK1 in this tissue. By N1, cytLEK1 protein is also detected in the liver.
Expression of cytLEK1 in all four tissues continues through N4. By this time point, liver
expression is robust but there has been a slight decrease in the heart and skeletal muscle.
CytLEK1 can only be readily detected in the liver and brain at N10, albeit at a lower level than
previous postnatal stages. Notably, there is a very faint band in the heart lysate lane. In the adult
mouse, cytLEK1 is not detected in any of the four tissues examined, consistent with previous
work showing that the highest levels of LEK1 expression occur in the developing mouse
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Figure 9. Immunohistochemical analysis of LEK1 expression in neonatal day 2 to day 7 murine
intestine. A) CytLEK1 expression (red) is detected at a low level at N2 and then quickly disappears
by N4. B) NucLEK1 expression (red) is strong at N2 to N4 throughout the nucleus of most cells in
the intestinal villi. The expression level dramatically declines by N7. DAPI (blue) was used to
visualize nuclei.
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Figure 10. Western blot analysis of cytLEK1 expression in multiple tissues during
murine development. CytLEK1 expression is initially detected only in the heart and skeletal
muscle. The protein is later also observed in the liver and brain. After neonatal day 4, a low
level of expression remains only in the liver and brain. CytLEK1 cannot be detected in any
adult tissues examined.
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(Goodwin et al., 1999). Additionally, immunofluorescence data support this Western blot
analysis and reveal, for example, that cytLEK1 is highly expressed in the cytoplasm of liver cells
at neonatal days 1 through 10. Conversely, nucLEK1 is not well detected in such cells at these
timepoints.
Localization of cytLEK1 in murine cells
In order to better characterize cytLEK1 distribution in cells, immunofluorescence studies
were conducted in various murine cell lines. Analysis of both 3T3 fibroblasts (Figure 11 A) and
C2C12 myoblasts (Figure 11 B) reveals a predominantly cytoplasmic distribution pattern for the
protein. Additionally, cytLEK1 localizes more intensely to a perinuclear location within cells.
During mitosis, cytLEK1, like nucLEK1 is mostly excluded from regions containing DNA
(Figure 11 B inset). The exact distribution of cytLEK1 in dividing cells will be discussed shortly.
These results here confirm that cytLEK1 is a cytoplasmic protein with an increased
concentration near the nucleus.
Change in cytLEK1 subcellular distribution upon pre-extraction
Since cytLEK1 is shown in later chapters to be a member of the LIS1 pathway,
experiments were undertaken to determine if the endogenous protein is associated with the
cytoskeleton. A detergent extraction approach was utilized for these experiments (Sapir et al.,
1997; Toomre et al., 1999; Giodini et al., 2002). A specific region of cytLEK1 (C domain)
confers detergent resistance (chapter IV), thus at least a subset of endogenous cytLEK1 would be
expected to persist after detergent pre-extraction. Indeed, in both 3T3 fibroblasts and C2C12
myoblasts, partial resistance is observed (Figure 12). Very interestingly, cytLEK1 around the
nucleus remains after detergent pre-extraction, while the majority of protein towards the
periphery is washed out. This result is in agreement with our data showing that cytLEK1
colocalizes strongly with LIS1 family members near the nucleus but significantly less towards
the periphery (chapter III). Additionally, in cells undergoing cytokinesis, it appears that insoluble
cytLEK1 localizes to the midbody region, similar to tubulin (Figure 12 C). Our control
experiments reveal that this selective resistance based on subcellular localization is specific to
cytLEK1, as dynein exhibits little change after pre-extraction. Thus, it appears that perinuclear
A B
Figure 11. Distribution of cytLEK1 in murine cell lines. CytLEK1 is distributed widely in the 
cytoplasm of both 3T3 fibroblasts (A) and C2C12 myoblasts (B). The protein is concentrated 
more highly around the nucleus. In mitotic cells, cytLEK1 is excluded from regions containing 
DNA (inset of B). DAPI (blue) was used to visualize nuclei. Intense nuclear puncta are a 
secondary antibody artifact. Bars, 10 µm.
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Figure 12. Endogenous cytLEK1 is partially resistant to detergent pre-extraction.
CytLEK1 is in green. A) In 3T3 fibroblasts, the detergent resistant pool of cytLEK1 is located
tightly around the nucleus. B) In C2C12 myoblasts, a similar pattern is detected with a less
tightly perinuclear distribution. C) In dividing C2C12 cells, the insoluble cytLEK1 is observed
at the midbody region, similar to tubulin (red). DAPI (blue) was used to visualize nuclei.
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cytLEK1 likely has a stronger cytoskeletal association than peripheral cytLEK1, which may have
different, currently unknown, binding partners.
Localization of cytLEK1 and nucLEK1 in dividing cells
Initial studies on nucLEK1 suggested that the protein does not colocalize with the DNA
material in mitotic cells (Goodwin et al., 1999). Further low-power experiments generally
confirm this result for cytLEK1, in addition to nucLEK1, in various murine cells (Figure 11 B
inset). However, while the majority of each protein does not colocalize with the DNA material,
detailed studies have never been conducted to examine the precise localization of the two
proteins in cells undergoing mitosis. Since LIS1 family members have been shown to be present
on the spindle apparatus of mitotic cells (Faulkner et al., 2000; Yan et al., 2003; Feng and Walsh,
2004), experiments were undertaken to more carefully analyze the distribution of cytLEK1 and
nucLEK1 in dividing 3T3 fibroblasts.
These experiments reveal that, although the majority of cyLEK1 and nucLEK1 protein is
indeed not found on the mitotic apparatus, a subset of each protein population is localized to the
spindles and spindle poles. For cytLEK1, the most prominent localization of the protein is at the
spindle poles (Figure 13), as can be observed through various stages of mitosis. Based upon
these data, however, cytLEK1 appears to be most abundant at the spindle pole during early
mitotic stages and then decreases as cell division proceeds. Although more difficult to visualize,
cytLEK1 is also distributed on the spindle itself in a punctate distribution (Figure 14). Notably,
no cytLEK1 can be clearly detected on kinetochore structures, as most of the relevant protein
appears to be on the spindle itself. Colocalization studies with antibodies to a centromeric protein
(CENP-A) were uninformative due to poor labeling by these antibodies. However, conclusively
proving the absence of cytLEK1 from kinetochores will likely require the increased resolution
available from deconvolution microscopy. It is not surprising though that this labeling of the
spindle apparatus described here was missed in initial studies due to the high amount of cytLEK1
protein located outside the area of the mitotic apparatus.
NucLEK1 can also be found on the mitotic spindle, although it is significantly less
prominent than cytLEK1 on the same structures. It can be detected faintly on the spindle itself
and also at the spindle poles (Figure 15 A). Interestingly, in at least one case, nucLEK1 labels
two very distinct dots within the spindle pole, suggestive of the two centrioles (Figure 15 B).
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Figure 13. CytLEK1 localizes to the spindle and spindle poles of mitotic murine cells. CytLEK1
is in green and tubulin is in red. A-B) CytLEK1 is visualized at the spindle poles and the nearby
spindle region of dividing 3T3 fibroblasts. Arrowheads indicate general regions of colocalization.
DAPI (blue) was used to visualize nuclei.
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Figure 14. CytLEK1 localizes to the spindle and spindle poles of dividing murine cells.
CytLEK1 (green) is distributed in distinct puncta along the microtubule spindle (red) in dividing
3T3 fibroblasts. Arrowheads indicate general regions of colocalization. DAPI (blue) was used to
visualize nuclei.
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Figure 15. NucLEK1 localizes to the spindle and spindle poles of mitotic murine cells. A)
NucLEK1 (green) is distributed in distinct puncta along the microtubule spindle (red) in dividing
3T3 fibroblasts. B) NucLEK1 localizes to two distinct puncta at the spindle pole of this mitotic cell.
Arrowheads indicate general regions of colocalization. DAPI (blue) was used to visualize nuclei.
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Once again, nucLEK1 labeling of the mitotic apparatus is not visible without careful
examination, thus likely explaining how it had been missed until now (Goodwin et al., 1999).
These results identifying both cytLEK1 and nucLEK1 on the spindle are supportive of LEK1
being a LIS1 family member and playing a role in cell division. Higher resolution confocal
deconvolution analysis of mitotic cells will be helpful in better determining the precise
localization of cytLEK1 and nucLEK1 on the spindle apparatus.
Examination of cytLEK1 distribution in wounded monolayers
Dynein and its partner proteins have been shown to be important in directed cell
movement (Dujardin et al., 2003). Notably, in wounded 3T3 fibroblast monolayers, dynein,
dynactin, and LIS1 localize to the leading edge of cells where they assist in reorientation of the
microtubule network. We thus examined whether cytLEK1 exhibits a similar change in
localization under these conditions. Seven hours after wound formation (utilizing a pipette tip),
cytLEK1 is distributed in its usual cytoplasmic pattern (Figure 16). No additional cytLEK1 is
present on the leading edge of the presumably migrating cells at the wound border. Additionally,
there is no detectable change in the overall level of cytLEK1 protein, as compared to cells
located in the unperturbed confluent region of the slide. These results suggest that there is no
dramatic shift in cytLEK1 distribution as a consequence of monolayer wounding. However, they
do not exclude the possibility that more subtle changes may be occurring, as other researchers
have relied on total internal reflection fluorescence microscopy to observe variations (Dujardin et
al., 2003).
Characterization of newly-generated LEK1 antibodies
Additional polyclonal antibodies against cytLEK1 and nucLEK1 were generated in order
to provide future reagents for the laboratory. Peptide domains were chosen throughout cytLEK1
and nucLEK1 (Figure 17) with the assistance of the manufacturer (Biosynthesis). An effort was
made to generate antibodies specific to regions of LEK1 not identified by the current cytLEK1
and nucLEK1 polyclonal antibodies. For reference, the Spec1 antibody to cytLEK1 was
generated using a peptide at the 1826 aa region of LEK1. The 863 polyclonal antibody, which
has been used extensively for nucLEK1 studies, is directed against a region 2872 aa into LEK1.
Three new cytLEK1 antibodies were generated against the following amino acid regions: 264 aa
AB
Figure 16. Examination of cytLEK1 distribution in wounded 3T3 fibroblast monolayers. No
significant change in subcellular localization or expression level of cytLEK1 (green) is detected in
cells near the wound border (A), even upon higher power observation (B). DAPI (blue) was used
to visualize nuclei.
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Figure 17. Binding epitopes for the LEK1 polyclonal antibodies with respect to the
LEK1 functional domains and putative cleavage site. The established antibodies
(Spec1 and 863) are shown in blue. The newly-generated antibodies are in red.
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(C264), 1127 aa (C1127), and 1403 aa (C1403). Two new nucLEK1 antibodies were created
from peptide sequences at the following locations of LEK1: 2088 aa (N2088) and 2690 aa
(N2690). Notably, the N2088 antibody recognizes a region of LEK1 that is just C-terminal to the
presumed cleavage site of the protein. As the exact location of the cleavage event is not known
and may be slightly C-terminal to current predictions, it remained unclear upon design whether
this antibody would be specific for endogenous nucLEK1 or, instead, cytLEK1. Two of the
antibodies (C264 and N2690) were directed against conserved epitopes among LEK family
members to generate potentially cross-reactive reagents that could be used in various species.
The remaining antibodies (C1127, C1403, N2088) have epitopes that are relatively specific to
LEK1 and thus should not be cross-reactive with other known LEK family members.
After affinity purification as described in the Materials and Methods section, tests were
undertaken first to determine the ability of these antibodies to recognize cytLEK1 and nucLEK1
expressed from transfected constructs in COS-7 cells. It is important to note that as currently
generated, the cytLEK1 construct extends past the epitope of the N2088 antibody (Figure 18 D).
Conversely, the nucLEK1 construct includes the epitope of the Spec1 antibody. When expressed
in COS-7 cells, the cytLEK1 protein is properly detected by all expected antibodies based on
immunofluorescence: C264, C1127, C1403, Spec1, and N2088 (Figure 18 B). Importantly, the
protein is not detected by the N2690 and 863 antibodies, thus providing negative controls for this
set of experiments. When nucLEK1 is expressed in COS-7 cells, this protein is recognized by all
the appropriate antibodies in immunofluorescence assays: Spec1, N2088, N2690, and 863.
However, the C1127 antibody also detects nucLEK1, despite its epitope being absent in this
protein. A possible explanation is that there could be a structural similarity between two different
epitopes in cytLEK1 and nucLEK1. Alternatively, this antibody may react to some degree with
any protein expressed at a high level in cells. Another unexpected observation is that the N2690
antibody results in strong cytoplasmic labeling of non-transfected COS-7 cells (Figure 20 B). As
these cells presumably lack murine LEK1, this result suggests that the antibody has additional
reactivity for a different protein. It is unknown currently whether this protein would be a LEK
family member in this cell type or a completely unrelated molecule. Thus, the usefulness of the
N2690 antibody in immunofluorescence assays is limited. All other antibodies, however, do not
exhibit any cross-reactivity and do not label non-transfected COS-7 cells (Figure 18 A). In
summary, all five new polyclonal antibodies, with the caveats noted above, are able to detect in
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Figure 18. Reactivity of LEK1 antibodies to transfected cytLEK1 expressed in COS-7 cells. LEK1 antibodies are in red. A) The
antibodies do not exhibit any labeling of non-transfected COS-7 cells. B) All five antibodies whose epitopes are contained within the cytLEK1
construct (see D) detect the protein in transfected COS-7 cells in immunofluorescence assays. C) Western blot analysis confirms detection of
the cytLEK1 protein (arrow) by the appropriate antibodies but not by two nucLEK1 antibodies (N2690 and 863). D) Diagram displays
antibodies whose epitopes are contained within the cytLEK1 construct. Notably, the sequence extends past the presumed cleavage site. DAPI
(blue) was used to visualize nuclei.
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immunofluorescence experiments the appropriate LEK1 proteins containing their epitope
regions.
Additional experiments were undertaken to determine the ability of these antibodies to
detect LEK1 proteins from transfected cells via Western blot (Figure 18 C). COS-7 cells were
again transfected with either a cytLEK1 or nucLEK1 construct. All expected antibodies, similar
to the immunofluorescence results, were able to detect the cytLEK1 protein: C264, C1127,
C1403, N2088, and Spec1. Conversely, a nucLEK1 band was present for all the correct
antibodies: Spec1, N2088, N2690, and 863. Interestingly, the unexpected observations seen
previously in the immunofluorescence experiments were also observed in these Western blot
data. The C1127 antibody yet again detects the nucLEK1 protein, despite the lack of a specific
epitope in that protein. Additionally, while the N2690 antibody does identify nucLEK1, it also
reveals a large (> 250 kDa) band in non-transfected COS-7 cells. This is likely the same protein
product resulting in the cytoplasmic labeling of non-tranfected COS-7 cells by
immunofluorescence. Although not conclusively proven, the large size of the detected band
suggests that this protein may indeed be a LEK family member in these monkey fibroblast cells,
especially since the N2690 epitope was selected to be conserved among all known LEK family
members in an attempt to generate an antibody reactive across all species. Once again, all other
antibodies do not display any cross-reactivity and do not label non-transfected COS-7 cells. To
summarize these data, all five newly-generated polyclonal antibodies can detect cytLEK1 or
nucLEK1, as appropriate, in Western blot assays.
The next step in characterization of these antibodies involved examination of their ability
to detect endogenous cytLEK1 or nucLEK1 in murine cells. For these experiments, all methods
were undertaken in both 3T3 fibroblasts and C2C12 myoblasts, as the subcellular distributions
and molecular sizes of cytLEK1 and nucLEK1 in these cell lines have been extensively studied.
In immunofluorescence characterizations (Figure 19), there is no gross difference in labeling
pattern for any of the LEK1 antibodies between 3T3 fibroblasts and C2C12 myoblasts, as
expected. While results are consistent between experiments, the data obtained are not completely
in line with expectations for LEK1-specific antibodies. The C264 antibody displays a very faint
cytoplasmic distribution with an intense pan-nuclear labeling in approximately one out of every
three cells. The remainder of the cells have no nuclear labeling. The C1127 antibody pattern
consists of a visible cytoplasmic distribution with the presence of distinct nuclear puncta in all
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Figure 19. Distribution of newly-generated cytLEK1 antibodies in murine cells. The patterns
of the three cytLEK1-directed antibodies (red) do not exhibit significant differences between
C2C12 myoblasts and 3T3 fibroblasts. C264 is faintly cytoplasmic with an occasional nuclear
distribution. C1127 and C1403 are predominantly cytoplasmic, although C1127 also exhibits
distinct nuclear puncta. DAPI (blue) was used to visualize nuclei.
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cells. In myoblasts, there are usually two uniformly-shaped dots per nucleus. Fibroblast nuclei,
conversely, tend to have a larger number of more irregularly-shaped dots. These nuclear puncta
are clearly not secondary antibody artifacts, as C1127 is the only primary antibody that
visualizes them in combination with the same common secondary antibodies used in all
experiments. The C1403 antibody displays a pattern very similar to that established for cytLEK1
with the Spec1 antibody. There is a primarily cytoplasmic distribution with a higher intensity in
the perinuclear region. It is worth noting that the C1403 epitope is the closest of the new
cytLEK1 antibodies to the Spec1 epitope.
The results from the nucLEK1 antibody studies also present new labeling patterns (Figure
20 A). The distribution of the N2088 antibody is not nuclear but, instead, cytoplasmic. The
cytoplasmic staining is most intense near the nucleus, similar to Spec1, as is best visualized in
C2C12 myoblasts. As previously mentioned, the epitope of N2088 is very close to the presumed
cleavage site of LEK1 and is likely part of cytLEK1 based on our complete LEK1 sequence data.
N2088 may, in fact, be an antibody specific to cytLEK1, not nucLEK1. Thus, it is not surprising
that the distribution observed is very similar to that of Spec1, whose epitope is only 200 aa
upstream. Finally, N2690, surprisingly, results in cytoplasmic labeling very similar to that of
Spec1 also. Despite the fact that N2690 can detect nucLEK1 expressed in transfected cells, there
is no endogenous nuclear staining visible. A caveat of the N2690 antibody, however, is that it
also detects a cytoplasmic protein in non-transfected COS-7 cells, and thus it may have greater
affinity for another protein than nucLEK1. Once again, it remains unclear if such a protein would
be a LEK family member or an unrelated cytoplasmic protein with a relatively similar
distribution to cytLEK1. Clearly, additional factors, such as uncleaved full-length LEK1 and
epitope masking, may also be important for better understanding the diverse pattern of labeling
seen with the new antibodies. Notably, however, all antibodies do not display substantial
colocalization with the DNA material in mitotic cells. This phenotype is consistent with that
previously observed for nucLEK1 and cytLEK1 in mitotic cells. Overall, these
immunofluorescence results are encouraging since the majority of LEK1 antibodies show a
cytoplasmic distribution similar to that of the established cytLEK1 antibody, Spec1.
An initial series of tests was performed to examine the pattern of the new antibodies in
tissue sections from murine hearts. The studies were conducted with hearts collected from
embryonic day 18.5 and adult mice. Overall, the subcellular labeling of each antibody in E18.5
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Figure 20. Distribution of newly-generated nucLEK1 antibodies in murine cells. A) The patterns of
the two nucLEK1-directed antibodies (red) do not exhibit significant differences between C2C12
myoblasts and 3T3 fibroblasts. N2088 and N2690 both exhibit cytoplasmic distributions with no
noticeable nuclear labeling. B) N2690 also detects a cytoplasmic protein in non-transfected COS-7 cells.
DAPI (blue) was used to visualize nuclei.
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hearts is grossly similar to that for cells in culture. C264, for example, stains the nucleus of
approximately one out of every twenty cells with a faint cytoplasmic background in all cells. The
patterns for C1403 and N2088 are cytoplasmic and similar to Spec1. N2690 labeling is both
cytoplasmic and nuclear. The only notable change is that C1127 predominantly labels the
nucleus, not the cytoplasm, of cells. Importantly, in adult hearts, all antibodies show substantially
decreased fluorescence to near-background levels. Thus, these antibodies detect proteins that are
more highly expressed in embryonic tissues, suggesting at least some specificity to LEK1.
These new polyclonal antibodies were also tested for their ability to detect endogenous
cytLEK1 and nucLEK1 in Western blot assays. C2C12 myoblasts, 3T3 fibroblasts, and
embryonic or adult hearts were used for the studies. However, consistent results were not
obtained when utilizing these antibodies. Although at times the new cytLEK1 antibodies produce
a band similar to Spec1, they also result in various other bands that differ with each experiment.
Additionally, individual tests could not be repeated to generate the same result, unlike with the
established Spec1 and 863 antibodies. Peptide competition assays showed, somewhat
surprisingly, that all bands disappear with the addition of the original injected peptide. Thus, the
antibodies do appear to work specifically on Western blot, although whether this specificity is
solely to LEK1 is unclear. In summary, although the new polyclonal antibodies are able to detect
transfected LEK1 proteins, they cannot consistently detect in a reproducible fashion the
endogenous protein collected from various sources. Since the Spec1 and 863 antibodies are
effective in all assays, have been well-characterized, and have been previously tested for
specificity through various experiments, including expression library screening, they remain the
primary reagents for examination of LEK1.
Distribution of transfected cytLEK1 protein in murine cells
Since certain LIS1 pathway members have been shown to be associated with the
microtubule network specifically (Feng et al., 2000; Smith et al., 2000) albeit not always in a
reproducible fashion (Faulkner et al., 2000), we wished to examine whether cytLEK1 exhibits
similar characteristics. Attempts to examine the potential colocalization of endogenous cytLEK1
with microtubules were unsuccessful for various technical reasons related to specific fixation and
extraction conditions required for individual antibodies. Thus, we transfected a FLAG-tagged
cytLEK1 construct into cells in order to characterize the distribution of the protein product.
59
Results were identical in both C2C12 myoblasts and 3T3 fibroblasts. Interestingly, in many, but
not all, cells transfected with this cytLEK1 construct, the transfected protein exhibits a very
fibrous-like distribution pattern (Figure 21). CytLEK1 is distributed throughout the cytoplasm in
long thin tracks separated by gaps lacking any detectable protein.
Colabeling experiments were conducted to determine if these tracks of cytLEK1 coincide
with the microtubule network. Indeed, although the microtubule network is not clearly visible
throughout the entire cell, the distribution of cytLEK1 is coincident with observable microtubule
tracks (Figure 21 A). Except for certain instances on the periphery of cells, nearly every location
where a microtubule track is visible it is overlaid with a cytLEK1 track. Thus, it appears that this
transfected cytLEK1 protein does distribute along the microtubule network of the cell,
suggesting that cytLEK1 has the ability to interact with either microtubules directly or with
microtubule-associated proteins. These results are in agreement with the observation that
endogenous cytLEK1 exhibits resistance to detergent extraction and is presumably interacting
with cytoskeletal structures (Figure 12). Very likely, association with microtubule network
structures may be the primary link of cytLEK1 to the cytoskeleton.
However, additional experiments to more precisely examine this colocalization of
transfected cytLEK1 and the microtubule network revealed an unexpected result. Pre-extraction
to better visualize the microtubule network results in the accumulation of transfected protein into
clumps throughout the cytoplasm (Figure 22 A). Notably, there is no clear colocalization
between these large cytLEK1 puncta and microtubules. Thus, even though cytLEK1 under
normal fixation conditions appears to be distributed along microtubules, the association may not
be strong enough to resist detergent pre-extraction. Fixation using cold methanol provides an
intermediate phenotype where some cytLEK1 puncta are visualized but there is also a very
diffuse cytoplasmic distribution of the transfected protein (Figure 22 B). This highly dispersed
nature of cytLEK1 prevents any substantial colocalization analysis. As a whole, these
experiments suggest that transfected cytLEK1 protein colocalizes with the microtubule network
under certain conditions but such an association has not yet been determined to be definitive and
strong.
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Figure 21. Transfected cytLEK1 protein colocalizes with the microtubule network in murine
cells. 3T3 fibroblasts were transfected with a FLAG-tagged cytLEK1 construct and colocalization
studies were conducted. The cytLEK1 protein (green) exhibits a fibrous distribution in cells (A-B).
A) Transfected cytLEK1 colocalizes with the visible microtubule network (red) in these cells. B) A
fibrous pattern for transfected cytLEK1 is observed in many cells. DAPI (blue) was used to
visualize nuclei.
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Figure 22. Distribution of transfected cytLEK1 protein is dependent upon fixation and
extraction conditions. 3T3 fibroblasts were transfected with a FLAG-tagged cytLEK1
construct (green) and colocalization studies with tubulin (red) were conducted. A) Pre-
extraction results in large cytLEK1 puncta that exhibit no clear codistribution with the
microtubule network. B) Fixation with methanol reveals an intermediate pattern where
cytLEK1 is found in both distinct puncta and diffusely in the cytoplasm. DAPI (blue) was
used to visualize nuclei.
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Discussion
LEK family members share a similar domain structure yet display unique expression
patterns and activities (see Introduction). Their specific distributions relate to their putative
functions in each different organism. Mitosin/CENP-F is a key component of the chromosomal
kinetochore complex and plays an important role in proper completion of mitosis (Liao et al.,
1995; Zhu et al., 1995b). As such, the protein is detected in a wide variety of human cells
without any known tissue specificity, although available in vivo data is limited. It is expressed in
a cell cycle-dependent manner with an important phosphorylation event occurring prior to its
distribution to the kinetochore (Liao et al., 1995; Zhu et al., 1995b). However, the protein can
also be detected on the spindle apparatus itself, suggesting that it may function at more than just
the kinetochore. Not surprisingly, given its role in mitosis, Mitosin/CENP-F expression is
upregulated in many human cancers (de la Guardia et al., 2001; Esguerra et al., 2004).
Farnesylation is being examined as a potentially important post-translational modification in
such settings (Russo et al., 2004). In summary, the expression pattern of Mitosin/CENP-F
matches its role as a component of the mitotic apparatus in a wide variety of cells.
CMF1, however, has a significantly different distribution than Mitosin/CENP-F, thus
providing the first clues of an alternative function. Notably, the protein is localized only to
cardiac and skeletal myocytes of the developing chick embryo (Wei et al., 1996; Dees et al.,
2000). Its expression is temporally regulated during development with highest levels at early
embryonic stages and no protein detected in adult animals (Wei et al., 1996; Dees et al., 2000).
Additionally, CMF1 undergoes a change in subcellular localization from the nucleus to the
cytoplasm during embryogenesis (Dees et al., 2000), suggestive of a potential alteration in
function. These observations imply an important role for CMF1 during development, not
adulthood. Indeed, this hypothesis, which is based on distribution pattern, is confirmed by
experiments that reveal the importance of CMF1 for myocyte differentiation (Wei et al., 1996;
Dees et al., 2000).
Determination of the cytLEK1 expression pattern is thus a critical part of discovering the
function of the protein. For this reason, experiments are presented here that uncover for the first
time the distribution of this protein in a wide variety of tissues and cells. Previous studies have
shown that nucLEK1 is expressed in nearly all cells in the developing embryo (Goodwin et al.,
1999). Similar to CMF1, it cannot be detected in adult animals with the exception of the oocyte.
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However, its distribution is confined to the nucleus throughout embryogenesis, unlike CMF1.
Due to its disappearance in the heart during the critical postnatal period of terminal
differentiation of cardiomyocytes, nucLEK1 has been suggested to function in regulating the
processes of proliferation and differentiation. Indeed, nucLEK1 binds to all three known Rb
family members, and LEK1 depletion results in proliferation and differentiation defects (Ashe et
al., 2004). Expression studies have thus yet again aided in the determination of protein function.
Therefore, analysis of cytLEK1 localization should provide important clues as to the role of this
protein product.
Since the downregulation of nucLEK1 during terminal differentiation of cardiomyocytes
is a key event in cardiac development, it is interesting to note that cytLEK1 expression levels
also decline during this period (Figure 8). In fact, the decrease appears to be even more abrupt
than for nucLEK1, suggesting that the cardiac function of cytLEK1 is confined to events
occurring predominantly at embryonic stages. Thus, cytLEK1 may have important effects on the
widely-occurring proliferation and migration processes of cardiomyocytes at such developmental
stages (Mikawa et al., 1992). These functions would be consistent with those of LIS1 pathway
members, including NudE(L), which have been shown to be critical for proper cell division and
migration during development (Feng and Walsh, 2004; Shu et al., 2004). However, some
cytLEK1 protein still remains at postnatal stages so a direct role in terminal differentiation
processes may also be possible. Importantly, the dramatic change in localization of cytLEK1 that
occurs by neonatal day 2 is very intriguing and suggests that cytLEK1 may switch to a different
function during postnatal stages. As this altered distribution is specific to cytLEK1 and not
observed with nucLEK1, such a dual effect may represent a wider role for the larger cytLEK1
peptide than for the smaller nucLEK1 one. Another possibility is that the protein detected in the
nucleus is uncleaved LEK1. With currently available reagents, it is difficult to determine if this
seemingly nuclear-localized cytLEK1 represents uncleaved protein. It may be that regulation of
the cleavage event is a method for specifying the function of LEK1. However, current Western
blot evidence does not support this idea, as a ~300 kDa band equivalent to uncleaved LEK1 is
not observed. As this may be an issue of detection level, future immunofluorescence studies
utilizing LEK1 monoclonal antibodies currently under development will resolve this cleavage
event.
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An additional intriguing question related to this postnatal change in localization is
whether cytLEK1 is truly nuclear or very tightly perinuclear. While the tissue sections are thin (<
7 mm), confocal studies are needed to confirm the exact distribution. If cytLEK1 is truly nuclear
at these stages and there is no alteration in cleavage of LEK1, then the protein is likely serving
an unknown function in the nucleus at certain developmental stages, similar to CMF1 with its
dual subcellular localization (Dees et al., 2000). If instead the confocal analysis reveals that there
is a perinuclear localization, then this result is intriguing since this location represents the
predominant site of LIS1 pathway proteins (see Introduction; Figures 27-30) and also the area
where cytLEK1 is most resistant to detergent extraction (Figure 12). Thus, the pool of cytLEK1
protein that interacts with LIS1 pathway members may persist longer during cardiac
development than the subset of protein that serves an as-yet-unknown function at the periphery.
Regardless of the exact result, this change in localization suggests a need for distinct cytLEK1
functions at different developmental stages in the murine heart.
Examination of cytLEK1 expression in other tissues yields further clues as to its role
during development. In the small intestine, there is a noticeable difference between the
fluorescent intensity of the cytLEK1 and nucLEK1 antibodies at all stages inspected. These data
suggest that nucLEK1 may possibly play a more important role, or be required at higher
expression levels, than cytLEK1 in this tissue. As nucLEK1 is currently postulated to have a
primarily proliferative function, this observation may be consistent with the high level of cell
division occurring during formation of the intestine. However, another possibility is that the
epitope of the cytLEK1 antibody is partially blocked in the intestine, perhaps due to a tissue-
specific protein interaction, or that the antibody simply exhibits less affinity for its antigen than
the nucLEK1 antibody does. A quantitative Western blot analysis may help confirm these
putative expression differences. It is important to note, however, that both cytLEK1 and
nucLEK1 are downregulated in the postnatal intestine based on these immunofluorescence data,
even though this tissue remains highly proliferative through adulthood (Ross et al., 1995). Thus,
we confirm in the intestine that cytLEK1, similar to nucLEK1, plays a specific role in the
developing embryo that is not maintained or required during adulthood.
This pattern is also observed in multiple other tissues by an extensive Western blot
analysis (Figure 10). In adult animals, cytLEK1 protein, consistent with heart and intestine
studies, is not detected in the brain, skeletal muscle, or liver. The intensity of bands in the brain
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and liver, especially at late embryonic and early postnatal stages, suggests that these tissues are
important sites of cytLEK1 function. The incidence of multiple bands in the brain implies a
potentially intriguing oligomerization of cytLEK1. In general, the presence of cytLEK1 in this
tissue is of interest, as the brain is a key site of LIS1 pathway member function (see
Introduction). It would be unexpected for cytLEK1 regulation of the LIS1 pathway during
development to not extend to this organ. The processes of proliferation, migration, and
differentiation are occurring throughout this organ during embryogenesis, and we postulate that
cytLEK1 is likely required for proper formation of the brain. It will be very interesting for future
studies to examine cytLEK1 function in neuronal cells, as well as the effect of a neuronal-
specific LEK1 -/- mouse.
Just as LIS1 pathway members play a role in more tissues than only the brain (see
Introduction), we expect cytLEK1 to have a similar function. In fact, the results we present in
this chapter and those of previous LEK1 studies (Goodwin et al., 1999) reveal that LEK1,
including its cytLEK1 peptide product, shares significant expression similarities with NudE(L).
Like cytLEK1, NudE and Nudel proteins are expressed at their highest levels in the brain, heart,
and skeletal muscle (Niethammer et al., 2000; Sasaki et al., 2000; Yan et al., 2003). Thus,
cytLEK1 has the potential to interact with NudE(L) in the wide range of tissues where the two
proteins are coexpressed at high levels. Nudel is first detected in the mouse at embryonic day
13.5 and expression reaches a plateau at neonatal day 5 (Niethammer et al., 2000; Sasaki et al.,
2000). While protein data are lacking, NudE appears at embryonic day 11 and peaks five days
later (Feng et al., 2000). It then begins to decrease to a low level maintained throughout
adulthood. Thus, the expression pattern of NudE, especially, suggests that, similar to cytLEK, its
presence is most important during development, not adulthood. The fact that Nudel is maintained
throughout adulthood differs from cytLEK1, but may partially explain why we have uncovered
an interaction of NudE, not Nudel, with cytLEK1 (chapter III). It is possible that cytLEK1
specifically interacts with NudE and that Nudel is not relevant to cytLEK1 function. However,
this proposal has not been tested, as direct binding studies have not been conducted and all the
cytLEK1 domains are not yet characterized. Nonetheless, it is clear that cytLEK1 and NudE
interact and share a similar expression pattern in a time- and tissue-specific fashion. Thus, they
are potentially partner proteins in a wide variety of cell types during development. CytLEK1
regulation of the LIS1 pathway may therefore be a critical component of embryogenesis.
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Additional studies in chapter IV building upon the expression studies presented here begin to
address the role of the cytLEK1-NudE interaction in various tissues and cell types.
Experiments examining the subcellular distribution of cytLEK1 support the idea of an
important link between cytLEK1 and the LIS1 pathway. Notably, the perinuclear concentration
of cytLEK1 in non-dividing cells (Figure 11) is consistent with the pattern of most LIS1 pathway
members (see Introduction). Thus, cytLEK1 is located at the proper position to interact with and
regulate these proteins. It is evident that cytLEK1 is not exclusively perinuclear, similar again to
many LIS1 pathway members, and this suggests that there may be additional functions of
cytLEK1 that have not yet been determined. In fact, the large size and wide cytoplasmic
distribution of cytLEK1 make it unlikely that the only role of the protein is to regulate
components of the LIS1 pathway near the nucleus. Importantly, a subset of cytLEK1 protein is
resistant to detergent pre-extraction, suggesting a link with the cytoskeleton. This is a key
observation for a protein postulated to function in the LIS1 pathway. The fact that the resistant
cytLEK1 pool is present specifically near the nucleus supports the proposal that cytLEK1 has a
LIS1-related role in perinuclear regions and an unknown function at the periphery.
The analysis of LEK1 distribution in mitotic cells is especially exciting, as it marks the
first time any significant observation has been made for cytLEK1 or nucLEK1 localization in
dividing cells. While they clearly only represent a minority of each total protein population, the
cytLEK1 and nucLEK1 proteins present on the spindle itself and the spindle poles are important
because they place these molecules at critical locations for regulation of mitotic functions. Once
again, this localization pattern matches that of other LIS1 pathway members (Faulkner et al.,
2000; Yan et al., 2003; Feng and Walsh, 2004). Considering the dramatic disruption of
proliferation resulting from LEK1 depletion (Ashe et al., 2004), these data begin to suggest an
additional mechanism for LEK1 regulation of mitosis, independent of any interactions with Rb
family members. It may be that cytLEK1 plays a role in spindle formation, similar to its binding
partner NudE (Feng and Walsh, 2004), and/or in dynein-directed movement of chromosomes. It
will be interesting to see in future studies if cytLEK1, similar to NudE(L), is transported along
the spindle through an association with dynein (Yan et al., 2003). Based on its prominent
localization at the centrosome of dividing cells, cytLEK1 dysfunction may disrupt spindle
attachment to this organizing center, thus inhibiting mitotic progression. The fact that expression
of the myc-C dominant negative protein has never been detected in a mitotic cell is an interesting
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observation in this context. However, it has also introduced difficulties in designing experiments
to examine cytLEK1 dysfunction in dividing cells. Clearly, this is an important area for future
studies.
Any discussion of LEK1 localization in mitotic cells requires a comparison with
Mitosin/CENP-F, the human kinetochore-binding protein related to LEK1. In our experiments,
we cannot detect cytLEK1 or nucLEK1 on chromosomal kinetochores. However, considering the
overall low levels of these proteins localized to the mitotic apparatus, a higher resolution
detection method, such as confocal deconvolution analysis, in combination with a chromosome
spread may be required. There are discrepancies even in the detection of LIS1 pathway members
on the kinetochore due to similar issues (Yan et al., 2003; Feng and Walsh, 2004).
Mitosin/CENP-F has also been detected on the spindle (Liao et al., 1995; Zhu et al., 1995b),
however, and this is in agreement with our observations for LEK1. Examination of the
Mitosin/CENP-F and LEK1 protein sequences reveals that the kinetochore-binding domain of
the former (Zhu, 1999) appears to be intact in nucLEK1. A large region N-terminal to that
domain is absent in nucLEK1, though, which may affect protein conformation and thus mask or
disrupt any potential kinetochore-binding domain. Additionally, LEK1 lacks the
homodimerization region of Mitosin/CENP-F (Zhu, 1999). It thus appears that while LEK1 and
Mitosin/CENP-F do share some similarities, such as presence on the spindle apparatus, their
functions and domains are significantly divergent. Our expression studies confirm the substantial
differences between the two proteins. Most importantly, cytLEK1 and nucLEK1, unlike
Mitosin/CENP-F (Liao et al., 1995; Zhu et al., 1995a), are present in non-mitotic cells and do not
appear to be significantly upregulated prior to cell division. It is currently unknown what human
protein may serve to compensate for the function of LEK1 and vice-versa. Answering this
question will likely be very difficult due to the inherent problems in examining the role of a
protein during human embryonic development.
Our final examination of endogenous cytLEK1 localization consists of studying
fibroblasts in vitro during monolayer wound healing. The results do not reveal any substantial
change in cytLEK1 distribution or expression in these cells, despite one previous study revealing
an alteration for some LIS1 pathway members (Dujardin et al., 2003). At this point, it is difficult
to discern whether there truly is no change in cytLEK1 localization or whether we are unable to
detect it using current techniques. It is worthwhile to note that the previous study required total
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internal fluorescence microscopy to observe the alterations (Dujardin et al., 2003). Based on its
interaction with NudE, it is highly likely that cytLEK1 plays a role in cell migration, although a
redistribution of the protein may not be required for this function. Future live imaging studies
examining the effects of cytLEK1 dysfunction on migration will help provide a more direct assay
for determining such a role for the protein.
As evidenced from the results in this chapter, the two antibodies we currently use for
cytLEK1 and nucLEK1 detection have been useful in a wide range of assays. Previous work in
our laboratory, in addition to experiments here, has shown that these antibodies are capable of
specifically detecting the LEK1 peptide products in immunofluorescence assays, Western blots,
expression library screens, and in vitro translation studies (Pabon-Pena et al. unpublished data;
Figures 4-5). Additionally, morpholino studies of LEK1 knockdown serve as additional controls
for specificity (Ashe et al., 2004; Figure 38). However, the new sets of antibodies we generate
and characterize here are not as robust. The fact that the majority of new antibodies reveal a
pattern similar to that previously observed for cytLEK1 is reassuring for the cytLEK1 studies
that are the main focus of this document. We are surprised, though, at the inability of any newly-
designed antibody to detect a localization pattern similar to that of our current nucLEK1
antibody. There are several potential explanations for this result. First, it appears that only one
antibody (N2690) is truly directed against an epitope in nucLEK1. The N2088 antibody near the
putative cleavage site likely detects cytLEK1 based on our results. Thus, this discrepancy may
simply be the result of a single unsuccessful antibody design.  Second, epitope masking is always
a potential issue, so we may have designed the antibody against a region of nucLEK1 that is not
exposed endogenously. Third, the N2690 antibody may have additional specificity for another
protein. Notably, it is able to detect protein in non-transfected COS-7 cells. It is currently
unknown whether this effect is due to a completely unrelated protein or, in fact, a LEK family
member in primates.
An additional issue is the strange localization detected by certain of the new cytLEK1
antibodies. The occasionally nuclear distribution of the C264 antibody is intriguing, as it
suggests the possibility that cytLEK1 may sometimes enter the nucleus of cells. However, as
such a localization is not observed with any other antibody, we are hesitant to place much value
on such a scenario. Another possibility is that the extreme N-terminus of cytLEK1 is additionally
cleaved and thus has a different and unique distribution. Unfortunately, the inability of these
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newly-designed antibodies to consistently work on a Western blot prevents a thorough testing of
this hypothesis. As we have shown in this document, cytLEK1 is at least partially associated
with the cytoskeleton and resistant to detergent extraction. Thus, the amount of endogenous
cytLEK1 present in the soluble fraction of cell lysate may be low and require an antibody with
very high affinity on Western blot for consistent detection. Finally, with regard to the C1127
antibody, the nuclear puncta detected are intriguing due to the observation of cytLEK1 puncta in
the nucleus during postnatal heart development (Figure 7). However, the fact that the C1127
antibody is also able to detect transfected nucLEK1 protein suggests that its specificity is not
high and may explain this result. Additional studies are required to resolve these discrepancies
with the new antibodies, and the ongoing generation of a LEK1 -/- mouse will be of great
assistance.
The final observations on cytLEK1 localization come from studies of transfected
cytLEK1 protein. The fibrous-like distribution of the protein in many cells is very suggestive of a
cytoskeletal link. Even with the limited resolution obtained in these experiments due to fixation
issues, it is clear that this transfected cytLEK1 is located on microtubule tracks and is generally
absent from other areas. While we are unable to unambiguously detect endogenous cytLEK1 on
the microtubule network, this is primarily the result of fixation/extraction incompatibilities with
the cytLEK1 antibody and is not a conclusive result. Thus, these transfection experiments
overcome such restrictions. However, the dramatic change in localization of transfected
cytLEK1 protein with alteration of the fixation and extraction protocol is somewhat puzzling.
The results from methanol fixation are inconclusive due to the widespread distribution of the
protein. However, the large cytLEK1 puncta that appear with detergent pre-extraction do not
exhibit any colocalization with the clearly-detected microtubule network. A partial explanation is
that the transfected cytLEK1 protein does indeed associate with microtubules but that this link is
not strong. Thus, the pre-extraction conditions are harsh enough to disrupt this interaction and
remove any transfected cytLEK1 from the cytoskeleton. The lack of strong binding may be a
consequence of the fact that the full length cytLEK1 protein expressed is not the same size as the
endogenous protein due to the unknown location of the cleavage site. Thus, this transfected
protein may not be able to properly fold and interact with the same structures as endogenous
cytLEK1. An additional possibility, which is difficult to directly test, is simply that inherent
artifacts in each fixation/extraction technique are obscuring similarities between the results. Such
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an artifact issue may explain the large cytLEK1 puncta that accumulate after pre-extraction, as
they have not been seen under any other conditions. It may be that the high amount of transfected
protein aggregates during the pre-extraction procedure and thus appears as clumps.
In conclusion, the results on the localization and expression of cytLEK1 presented in this
chapter provide important clues as to the nature of cytLEK1 function. It is evident that cytLEK1
has the potential to interact with LIS1 pathway members in many tissues and cell types in the
developing mouse. The heart and brain remain the most intriguing organs for future study. These
data suggest that the subcellular location of any interactions between cytLEK1 and LIS1
pathway members is likely near the nucleus in non-dividing cells. In mitotic cells, cytLEK1 may
play a role in spindle formation and function. Additionally, cytLEK1 associates with the
cytoskeleton predominantly around the nucleus, consistent with its role as a regulator of the LIS1
pathway. This interaction likely specifically involves the microtubule network of cells based on
our results. Experiments in later chapters elaborate further on the function of cytLEK1 in these
various tissues and subcellular locations.
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CHAPTER III
EXAMINATION OF
CYTLEK1 PROTEIN BINDING PARTNERS
Introduction
Previous studies on LEK1 suggest that it plays a role in proliferation and differentiation
processes in the developing embryo (Goodwin et al., 1999; Ashe et al., 2004). This hypothesis
was initially based on the observation that disruption of CMF1, the chick member of the LEK
family, inhibits myocyte differentiation (Wei et al., 1996; Dees et al., 2000). This was supported
by the observation that, in the heart specifically, LEK1 mRNA is detected until neonatal day 4
and then abruptly disappears (Goodwin et al., 1999). We show in chapter II that the cytLEK1
protein undergoes an interesting change in localization during this same time period. This
alteration in cytLEK1 distribution and subsequent reduction in LEK1 expression coincide with
the period when cardiomyocytes are undergoing permanent cessation of mitosis and terminal
differentiation (Soonpaa et al., 1996; Soonpaa and Field, 1998). Additional studies have shown
that nucLEK1 binds to all three known Rb family members (Rb, p107, p130) both in vitro and in
vivo (Ashe et al., 2004). Through such interactions, nucLEK1 has the potential to be a critical
regulator of proliferation and differentiation. Indeed, depletion of LEK1 expression in murine
cells results in a disruption of proliferation and differentiation (Ashe et al., 2004). However, the
distinct roles of cytLEK1 and nucLEK1 in these important cellular processes are not clear. In
fact, no function at all had been attributed to the cytLEK1 protein prior to the work presented
here. Thus, we wished to examine the role of cytLEK1 by first determining its key binding
partners.
We initially hypothesized that cytLEK1 may have a cytoskeletal role due to its
cytoplasmic distribution pattern (Figure 11) and the presence of a spectrin repeat, a domain
shown in other proteins to be involved in cytoskeletal functions (Djinovic-Carugo et al., 2002).
Thus, we utilized the spectrin repeat region of cytLEK1 as bait in a yeast two-hybrid screen. The
major interacting protein identified in this assay is NudE, a member of the LIS1 pathway (Feng
et al., 2000). LIS1 pathway members function in dynein-related processes of the microtubule
network (see Introduction). This interaction with NudE supports our hypothesis of a cytoskeletal
role for cytLEK1 through the spectrin repeat region. We define the exact binding domains within
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each protein and reveal that an 80 aa “C domain” in cytLEK1 is critical for the cytLEK1-NudE
interaction to occur. Co-immunoprecipitation studies of cytLEK1 and NudE confirm the validity
of the yeast two-hybrid results. Also, these two protein products colocalize after cotransfection.
We show that the C domain alone is capable of directing the interaction with NudE, especially at
the centrosome, as determined by localization studies in COS-7 cells. Finally, extensive confocal
deconvolution analysis of endogenous proteins in murine cells reveals that cytLEK1 colocalizes
with NudE, in addition to LIS1 and dynein, the two known binding partners of NudE. In
summary, these data show that cytLEK1 binds to NudE and codistributes with several key
members of the LIS1 pathway. Thus, cytLEK1 has the potential to regulate critical interactions
between LIS1 pathway members.
Materials and Methods
Yeast two-hybrid screen
The yeast two-hybrid (Y2H) screen was conducted by utilizing the Matchmaker Y2H
System 3 (BD Biosciences Clontech). The spectrin repeat region (SRR) of cytLEK1 (aa 1906-
2149) was PCR amplified on an iCycler PCR machine (Bio-Rad) using Pfu Turbo polymerase
(Stratagene) from a full-length cytLEK1 vector (aa 1-2210) with primers containing a 5’ NcoI
and 3’ EcoRI site. The pGBKT7 vector (BD Biosciences Clontech) and the resulting SRR
fragment were digested with NcoI/EcoRI and ligated to generate pGBKT7-SRR. This plasmid
was transformed into AH109 yeast per manufacturer’s instructions and tested for toxicity and
growth on SD/-Trp/X-a-Gal, SD/-His/-Trp/X-a-Gal, and SD/-Ade/-Trp/X-a-Gal. Mating
efficiency of the pGBKT7-SRR-containing yeast was comparable to controls. The AH109 yeast
containing this bait plasmid were subsequently mated per manufacturer’s instructions with Y187
yeast pretransformed with a whole mouse embryonic day 11 cDNA library (BD Biosciences
Clontech). The mating reaction was grown overnight at 30˚C with gentle swirling (50 rpm). The
colonies were then plated onto TDO without Gal (SD/-His/-Leu/-Trp; first screen performed) or
QDO without Gal (SD/-Ade/-His/-Leu/-Trp; second screen performed) 150 mm plates and
grown for 4 days (TDO) or 7 days (QDO) at 30˚C. Library mating mixtures and negative
controls were also conducted in parallel per manufacturer’s instructions. Colonies were replica
plated manually onto QDO plates (SD/-Ade/-His/-Leu/-Trp /X-a-gal) a minimum of three times
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to retest phenotypes. Segregation was observed upon streaking, and only blue colonies were
selected for further analysis.
Bait and prey plasmids were simultaneously isolated from these yeast using the
Yeastmaker Yeast Plasmid Isolation Kit (BD Biosciences Clontech) per manufacturer’s
instructions. Successful isolation of prey plasmid was confirmed via Taq polymerase (Promega)
PCR amplification using the Matchmaker AD LD Insert Screening Amplimer Set (BD
Biosciences Clontech). Plasmids were then electroporated into XL-1 Blue Electrocompetent E.
coli (Stratagene), and prey plasmid-containing bacteria were selected for by growth on ampicillin
LB plates. Plasmids were isolated from the bacteria via Wizard Plus SV MiniPreps (Promega)
and sequenced using the GAL4 AD Sequencing Primer (BD Biosciences Clontech). Resulting
sequences were identified via NCBI Blast (Altschul et al., 1990). To confirm the validity of
interactions, false positive tests were conducted per manufacturer’s instructions. Briefly, each
unique prey clone was transformed into AH109 yeast and mated with Y187 yeast containing
pGBKT7-SRR, pGBKT7-53, or pGBKT7 before plating onto QDO medium. Only yeast that
grew with pGBKT7-SRR but not the other two plasmids were deemed to be true positives and
considered candidates for further biochemical examination.
Deletion constructs
In order to determine precisely which region of the SRR of cytLEK1 interacts with
NudE, a deletion approach was followed in the yeast two-hybrid system. The SRR was further
divided into the N domain (aa 1906-64), the repeat (R) domain (aa 1964-2071), and the C
domain (aa 2071-2149). Deletion constructs were created by Pfu Turbo polymerase PCR
amplification and subsequent cloning into pGBKT7 using NcoI/EcoRI. Variations of these
domains were created as shown in Figure 23. AH109 yeast were transformed with each SRR
deletion construct. Conversely, NudE deletion constructs were created as shown in Figure 23.
After cloning into pGADT7 using EcoRI/XhoI, the plasmids were transformed into Y187 yeast.
Matings of the various SRR and NudE deletion construct-containing yeast were conducted and
grown on QDO plates while being tested for Gal expression to determine viable interactions.
In order to confirm results by co-immunoprecipitation (co-IP) in mammalian cells, the
relevant cytLEK1 and NudE yeast plasmid inserts were cloned, respectively, into pCMV-myc
and pCMV-HA mammalian expression vectors (BD Biosciences Clontech). The SRR and N+R
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cytLEK1 fragments were ligated into pCMV-myc using MscI/SalI. NudE was ligated into
pCMV-HA using SfiI/XhoI. Since pCMV-HA-NudE did not yield high-level expression, GFP-
mNudE (Feng et al., 2000) was used for transfection studies.
Cloning of dysbindin
The murine dysbindin coding sequence was PCR amplified on an iCycler PCR machine
(Bio-Rad) using Pfu Turbo polymerase (Stratagene) from an IMAGE dysbindin cDNA clone
(Invitrogen) with primers containing a 5’ EcoRI site and 3’ XhoI site. The resulting insert was
then cloned into pGADT7 and transformed into AH109 yeast. Additionally, the insert was
ligated with the mammalian expression vector pEGFP-C1 (BD Biosciences Clontech) to create a
GFP-dysbindin fusion.
Cell culture
COS-7 and NIH 3T3 cells (ATCC) were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM; Cellgro) supplemented with 10% fetal bovine serum, 100 mg/mL
penicillin/streptomycin, and L-glutamine. C2C12 cells (ATCC) were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 20% fetal bovine serum, 100 mg/mL
penicillin/streptomycin, and L-glutamine. All cell lines were maintained in a 95% air-5% CO2
humidified atmosphere at 37˚C.
Transfections
COS-7 cells were grown to 40-60% confluency and transfected using FuGENE6 (Roche)
per manufacturer’s instructions. Briefly, FuGENE was added to a tube containing OptiMEM
medium (Cellgro) and gently mixed. DNA was then added and gently mixed. After a 15 min
incubation, the FuGENE-DNA mixture was pipetted into plates containing cells and fresh
medium. For each 10 cm plate, 3 mg of total DNA was utilized for transfection. Cells were
grown for 24-48 h prior to collection for further examination.
Co-immunoprecipitation
COS-7 cells grown on 10 cm plates were harvested 48 h after transfection for use with
the ProFound Mammalian c-Myc Tag Co-IP Kit (Pierce) according to manufacturer’s protocol.
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Briefly, cells were washed once with ice-cold TBS, incubated with gentle shaking in M-PERTM
(Pierce) plus protease inhibitor (Sigma), and spun down at 16,000 x g for 20 min at 4˚C. Protein
concentration was determined using a bicinchoninic acid solution assay (Smith et al., 1985) from
Pierce. Lysates (250 mg/column) were incubated overnight with 10 mL anti-c-myc agarose slurry
with gentle end-over-end mixing at 4˚C. After 3 washes with TBS-Tween, protein was eluted
with 2X non-reducing sample buffer (Pierce) at 95˚C. 2-mercaptoethanol was added to the eluate
for SDS-PAGE analysis followed by immunoblotting. Lysate (10 mg/lane) was used to confirm
protein expression.
Western blotting
Lysates were incubated with 5X sample buffer (0.312 M Tris-HCl pH 6.8, 10% sodium
dodecyl sulfate, 25% 2-mercaptoethanol, 0.05% bromophenol blue) for 5 min at 95˚C. After
boiling, samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). Proteins on the gel were transferred overnight on ice to 0.45 mm pore size
Immobilon-P PVDF transfer membrane (Millipore). Membranes were blocked with 2% BSA in
TBST for 1-2 h at room temperature. Primary antibody was then applied for 1-2 h with shaking.
After three washes with TBST, the membrane was incubated with alkaline phosphatase-
conjugated secondary antibody for 1 h with shaking. This was followed with three TBST washes
and one alkaline phosphatase buffer wash. Membranes were developed using NBT-BCIP
(Roche) in alkaline phosphatase buffer and scanned into digital format (Hewlett-Packard).
Immunocytochemistry and microscopy
Cells grown on glass chamber slides (Nalge Nunc) were gently washed with PBS and
fixed with Histochoice (Amresco), 70% ethanol (for Spec1), or -20˚C methanol (for g-tubulin)
for 20 min. Cells were then washed briefly in PBS, permeabilized with 0.25% Triton X-100 in
PBS for 10 min, and blocked in 2% BSA in PBS for a minimum of 1 h. Primary antibodies in 1%
BSA in PBS were applied overnight at 4˚C. After three PBS washes, secondary antibodies were
applied for 1 h at room temperature. The slides were washed three times with PBS and twice
with water before cover slips were attached with Aqua Poly/Mount (PolySciences). Cells were
visualized by fluorescence microscopy on an AX70 (Olympus) or, for confocal analysis, an
LSM510 (Zeiss) microscope. Digital images were captured and processed using Magnafire
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(Optronics), Metamorph (Universal Imaging), and Photoshop (Adobe) software. Deconvolution
analysis was performed on confocal Z stacks (0.5 mm optical thickness) using a blind 3-D
deconvolution algorithm (AutoQuant Imaging).
Antibodies
Polyclonal antibodies against LIS1 and dynein were purchased from Santa Cruz. Anti-
GFP and anti-myc monoclonal antibodies were from BD Biosciences. A polyclonal anti-myc
antibody was acquired from Novus. The monoclonal antibodies against g-tubulin, vimentin, and
desmin were manufactured by Sigma. The MF20 antiserum to sarcomeric myosin heavy chain
was a generous gift of Donald A. Fischman at Cornell Medical College. Polyclonal antibody
Spec1 to a cytLEK1 peptide (aa 1826-45) was generated in rabbits (Biosynthesis) and affinity
purified using the injected peptide (Smith et al., 1985). The N-terminal 14 residues of murine
NudE protein were synthesized, coupled to KLH, and used to immunize chicken. IgY from egg
yolks was purified to > 90% purity (QED Bioscience) and screened for specific
immunoreactivity against both recombinant and endogenous murine NudE protein (antibody
obtained from Dr. Christopher A. Walsh at Harvard University; Feng and Walsh, 2004). Alexa
488 and Alexa 568 conjugated secondary antibodies, as well as Phalloidin-488, were obtained
from Molecular Probes. Anti-mouse alkaline phosphatase conjugated secondary antibodies for
Western blot were purchased from Sigma. DAPI was used to visualize nuclei (Boehringer
Mannheim).
Results
Identification of cytLEK1-interacting proteins
In order to identify cytLEK1 binding partners and place the protein in a molecular
pathway, a yeast two-hybrid approach was utilized. The region chosen as bait was based on
sequence analysis and on our hypothesis for a cytoskeletal function of cytLEK1. The spectrin
repeat region of cytLEK1 contains both a spectrin repeat, which can serve as a cytoskeletal and
signal transduction docking region (Djinovic-Carugo et al., 2002), and numerous leucine zippers,
which generally play a role in protein-protein and protein-DNA interactions (O'Shea et al.,
1989). For this reason, the spectrin repeat along with ~80 aa flanking sequence on each side (aa
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1906-2149; termed SRR for spectrin repeat region) was used as a bait to screen a whole mouse
embryonic day 11 cDNA library. The screen was performed twice and yielded 117 and 94
clones, in turn. Of these, 12 and 19 clones, respectively, were found to contain the full coding
sequence of NudE. After conducting retransformations to eliminate false positives, all of the
NudE clones, unlike the majority of the remaining clones, showed a specific interaction with the
SRR of cytLEK1. Two additional proteins pass the false positive test: dysbindin (3 clones) and a
hypothetical protein (6 clones). Since the known embryonic and tissue expression, as well as the
cytoplasmic distribution and function, of NudE generally coincided with that of cytLEK1 and the
hypothesis of a cytoskeletal function for the spectrin repeat region, there was enough evidence to
pursue this putative interaction.
Identification of the binding domains of cytLEK1 and NudE
In order to determine precisely which region of the SRR of cytLEK1 interacts with
NudE, a deletion approach was followed with the two-hybrid system. The SRR was further
divided into the N domain (aa 1906-64), the repeat (R) domain (aa 1964-2071), and the C
domain (aa 2071-2149). Deletion constructs were created that combined variations of these
domains as shown in Figure 23. Similar myc-tagged plasmids were constructed for mammalian
transfection and are referred to by this nomenclature system (myc-SRR, myc-C, myc-N+R).
Interestingly, all constructs containing the C domain, not necessarily the R domain itself, were
capable of binding to full length NudE. In fact, a construct containing only the C domain was
sufficient for interaction. No other proteins were detected during screening that were capable of
specifically associating with the C domain alone. Attempting to further truncate the C domain
eliminated all binding, suggesting that aa 2071-2149 of cytLEK1 are critical for interaction with
NudE. In order to determine the region of NudE binding to the C domain of cytLEK1, deletional
constructs of NudE were utilized (Figure 23). These studies revealed that a C-terminal region of
NudE (aa 167-290) was required and sufficient for the interaction with the C domain of the SRR.
This region in NudE coincides with the dynein-binding domain of its isoform, Nudel, and
encompasses a specific region essential for dynein binding (Sasaki et al., 2000; Liang et al.,
2004). The homology between NudE and Nudel suggests a conservation of the function of this
domain, thus revealing that the cytLEK1-binding domain in NudE partially overlaps the dynein-
binding domain.
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Figure 23. Examination of cytLEK1-NudE interaction and identification of binding domains. Deletion 
constructs of SRR were transformed into yeast and mated with yeast expressing full-length NudE. The 
spectrin repeat is represented by the gray box while the N and C domains are depicted with hemisected and 
white rectangles, respectively. Matings that grew on quadruple dropout medium are listed as “+”. The C 
domain of SRR (aa 2071-2149) is required and sufficient for interaction with NudE. Similarly, deletion 
constructs of NudE were transfected into yeast and mated with yeast expressing SRR. The LIS1- and 
putative dynein-binding domains of NudE(L) are shown. CytLEK1 binds to aa 167-290 of NudE. These 
domains were confirmed by mating yeast expressing this region of NudE with yeast expressing the C 
domain of SRR. The N+R and C constructs used in the dominant negative studies are labeled. 
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To determine whether cytLEK1 and NudE interact in mammalian cells, COS-7 cells were
cotransfected with myc-SRR and GFP-mNudE for co-immunoprecipitation analysis. As seen in
Figure 24 A, GFP-mNudE co-immunoprecipates with myc-SRR, confirming the two-hybrid data
and demonstrating the interaction between cytLEK1 and NudE. Importantly, GFP-mNudE is
unable to be co-immunoprecipitated with myc-N+R, which lacks the C domain (Figure 24 B).
Therefore, the C domain is indeed required for the binding of cytLEK1 and NudE. Taken
together, these results demonstrate the interaction of cytLEK1 and NudE in mammalian cells and
map this interaction to a specific domain.
CytLEK1 colocalizes with NudE and g-tubulin in COS-7 cells
As cytLEK1 and NudE interact on a biochemical level, we next examined whether the proteins
colocalize within individual cells. Initially, COS-7 cells were cotransfected with either myc-SRR
or myc-C and GFP-mNudE to examine their cellular distribution. As seen in Figure 25 A, myc-
SRR and GFP-mNudE exhibit extensive overlap in staining, predominantly in distinct
cytoplasmic puncta, previously shown to be related to the centrosome (Feng et al., 2000).
Importantly, presence of the C-domain alone is sufficient to direct this colocalization to a
cytoplasmic spot in both COS-7 and 3T3 fibroblasts (Figure 25 B). We confirmed that myc-C
indeed does localize most intensely to the centrosome based on g-tubulin staining (Figure 26 A).
Additionally, myc-C colocalizes with endogenous NudE protein present at the centrosome
(Figure 26 B), reiterating the specificity of the C domain for binding to NudE. Confirming the
critical importance of the C domain for NudE colocalization, myc-N+R does not colocalize with
GFP-mNudE in COS-7 cells (Figure 25 C).
CytLEK1 colocalizes with NudE binding partners in murine cells
Since cytLEK1 and NudE interact biochemically and have overlapping
immunocytochemical distributions after cotransfection (Figures 24-26), we examined the
endogenous localization of cytLEK1 with NudE and, additionally, with the known NudE partner
proteins, LIS1 and dynein (Feng et al., 2000), using cell lines previously shown to be susceptible
to disruption of LEK1, Nudel, and LIS1 (Dujardin et al., 2003; Ashe et al., 2004; Shu et al.,
2004). As seen in Figure 27, cytLEK1 displays significant colocalization with dynein in both
3T3 and C2C12 cells. The confocal images reveal a similar and overlapping distribution pattern
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Figure 24. Examination of cytLEK1-NudE interaction through co-immunoprecipitation. A) 
COS-7 cells were transfected with either GFP-mNudE alone or GFP-mNudE and myc-SRR. 
Lysates were collected and immunoprecipitated with an anti-myc antibody. Blots were then 
probed with anti-GFP. Protein expression was confirmed by blotting lysate lanes. GFP-mNudE is 
co-immunoprecipitated with myc-SRR when coexpressed while GFP-mNudE is not co-
immunoprecipitated in its absence. B) When COS-7 cells are cotransfected with GFP-NudE and 
myc-N+R, GFP-mNudE is not detected in the precipitant. Thus, the C domain in myc-SRR is 
required for the interaction between cytLEK1 and NudE.
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Figure 25. CytLEK1 colocalizes with GFP-mNudE in COS-7 cells. GFP-mNudE is in green 
and myc-tagged proteins are in red. A) COS-7 cells were cotransfected with myc-SRR and GFP-
mNudE. The merged image shows clear colocalization of these two proteins. B) COS-7 cells were 
cotransfected with myc-C and GFP-mNudE. The merged image reveals colocalization of this 
small cytLEK1 protein containing the NudE-binding domain with GFP-mNudE at a distinct 
cellular spot. C) Notably, when COS-7 cells were cotransfected with GFP-mNudE and myc-N+R, 
which lacks the NudE-binding domain, no colocalization can be detected. DAPI (blue) was used 
to visualize nuclei. Bar, 10 µm. 
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Figure 26. CytLEK1 colocalizes with NudE and γ-tubulin in COS-7 cells. Arrowheads mark the γ-
tubulin and NudE centrosomal spots. A) Myc-C (red) was transfected into COS-7 cells to examine 
colocalization with endogenous γ-tubulin (green) at the centrosome. Myc-C localizes most intensely to 
the centrosome. B) COS-7 cells were transfected with myc-C (green) and the protein colocalizes with 
endogenous NudE (red) present at the centrosome. DAPI (blue) was used to visualize nuclei.
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of cytLEK1 and dynein throughout most of the cell, including perinuclear regions of intense
labeling. As will be discussed in detail shortly, the perinuclear staining is not simply an artifact
of high protein concentrations in these regions, since colabeling of cytLEK1 with markers for
other cytoplasmic proteins does not reveal any noticeable colocalization (Figure 31). We further
analyzed the colocalization of dynein and cytLEK1 by conducting deconvolution analysis of
confocal images (Figure 27 B). These studies revealed that the codistribution of cytLEK1 and
dynein is not absolute. While there is substantial colocalization near the nucleus, it becomes less
apparent toward the periphery of cells. This finding is expected as dynein is a protein with a vast
array of cellular functions, while the LIS1 pathway is postulated to affect only a subset of these
functions (Vallee et al., 2001). Indeed, LIS1 does not colocalize completely with dynein,
especially near the cell periphery (Smith et al., 2000). With regard to the distribution between
cytLEK1 and LIS1, a high degree of colocalization is observed in both 3T3 and C2C12 cells
(Figure 28). Furthermore, deconvolution analysis reveals that the amount of overlap is not
complete and is highest in perinuclear regions. Thus, cytLEK1 colocalizes with two key
members of the LIS1 pathway predominantly around the nucleus.
CytLEK1 colocalizes with NudE in murine cells
In order to examine colocalization between endogenous cytLEK1 and NudE, a
previously-unpublished (at the time) antibody was obtained from Dr. Christopher A. Walsh at
Harvard University (Feng and Walsh, 2004). Although extensive assays had been performed by
the Walsh laboratory, a series of tests was conducted here to determine its specificity for
detection of NudE in immunofluorescence assays. The antibody successfully recognizes GFP-
mNudE transfected into COS-7 cells. Additionally, it detects endogenous NudE located at the
centrosome in these cells (Figure 26 B), although this localization to the organizing center is not
consistently observed and requires following a strict fixation protocol. More often, staining
consists of a diffuse perinuclear pattern. Even in those COS-7 cells where centrosomal labeling
is observed, there remains a non-centrosomal population, as has been reported in the literature
(Feng et al., 2000; Yan et al., 2003; Feng and Walsh, 2004). In summary, this antibody appears
to specifically detect both endogenous and transfected NudE protein.
The NudE antibody exhibits a more robust and easily-visualized pattern in 3T3
fibroblasts (Figure 29). Fixation requirements are not as strict and thus allow for colabeling
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Figure 27. CytLEK1 colocalizes with the NudE binding partner dynein in murine cells. Confocal microscopy was utilized to 
examine colocalization of endogenous proteins in 3T3 fibroblasts. Deconvolution analysis (0.5 mm optical sections) of confocal data 
was conducted to provide a higher level of detail (B). CytLEK1 is in green and dynein is visualized in red. A) The merged image 
reveals an overlapping distribution pattern of cytLEK1 and dynein. B) Colocalization is most evident near the nucleus and is less 
apparent towards the cell periphery. The arrow provides a point of reference for the enlarged image. Intense nuclear puncta are a 
secondary antibody artifact. Bars, 5 µm.
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Figure 28. CytLEK1 colocalizes with the NudE binding partner LIS1 in murine cells. Confocal microscopy was utilized to examine 
colocalization of endogenous proteins in 3T3 fibroblasts. Deconvolution analysis (0.5 mm optical sections) of confocal data was conducted 
to provide a higher level of detail (B). CytLEK1 is in green and LIS1 is visualized in red. A) The merged images display colocalization 
between cytLEK1 and LIS1 in 3T3 cells. B) Deconvolution analysis confirms a significant perinuclear colocalization of the two proteins. 
The arrow provides a point of reference for the enlarged image. Intense nuclear puncta are a secondary antibody artifact. Bars, 5 µm.
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studies with cytLEK1. This is the first time the distribution of NudE has been specifically
examined in this cell line. Our initial studies reveal a perinuclear distribution of NudE in these
murine fibroblasts (Figure 29 A), a pattern similar to cytLEK1, other members of the LIS1
pathway, and Nudel in this cell type (Niethammer et al., 2000; Sasaki et al., 2000; Shu et al.,
2004). Clearly, NudE is present at more than just the organizing center, as the protein is
predominantly perinuclear with no clear centrosomal labeling. CytLEK1 and NudE exhibit a
similar distribution in our confocal studies (Figure 29 B). Interestingly, on occasion, there is
colocalization of the two proteins seemingly on the cell membrane or periphery (unpublished
data). Deconvolution analysis (Figure 30) further defines the highest amount of colocalization to
be near the nucleus, as described above for the two other LIS1 family members. Taken together,
our results here suggest that cytLEK1 has the potential to influence dynein-mediated processes,
such as microtubule regulation, through the LIS1 pathway.
Colocalization studies with cytLEK1 and additional cytoplasmic proteins
Since cytLEK1 is a protein with a cytoplasmic distribution and a putative cytoskeletal
role, colocalization experiments were conducted with antibodies against various potential partner
proteins unrelated to the LIS1 pathway. In total, components of the thick, thin, and intermediate
filament networks were studies in myoblasts and other cell types, since their general cytoplasmic
pattern could coincide with that of cytLEK1. First, various intermediate filament proteins were
examined. Vimentin clearly does not colocalize with cytLEK1 in 3T3 fibroblasts. Additionally,
although there is at times slight overlap, the overall distribution of cytLEK1 does not coincide
with that of desmin in C2C12 myoblasts (Figure 31 A). High concentrations of one protein do
not match areas with large quantities of the other protein. For visualization of actin networks, a
component of thin filaments, phalloidin was utilized. There is no correlation between the
punctate cytLEK1 pattern and the actin network within 3T3 fibroblasts and C2C12 myoblasts
(Figure 31 B). Finally, the MF20 antibody against myosin was utilized for examination of the
thick filament network in differentiating myocytes. Once again, there is no colabeling of
cytLEK1 and myosin of myofibrils. These results are in agreement with previous studies
examining the distribution of CMF1 in cardiac myocytes (Pabon-Pena et al., 2000). While
negative in nature, these data here provide an important control for our positive colocalization
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Figure 29. Examination of NudE localization in murine cells. Confocal microscopy was employed 
to examine colocalization of endogenous proteins in 3T3 fibroblasts (B). CytLEK1 is in green and 
NudE is visualized in red. A) NudE is distributed in the cytoplasm of 3T3 fibroblasts and is 
concentrated more highly around the nucleus. B) The merged image reveals a similar and overlapping 
distribution pattern of cytLEK1 and NudE. Intense nuclear puncta in (B) are a secondary antibody 
artifact. Bars, 5 µm.
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Figure 30. CytLEK1 colocalizes with NudE in murine cells. Confocal microscopy was employed to 
examine colocalization of endogenous proteins in 3T3 fibroblasts. Deconvolution analysis (0.5 mm 
optical sections) of confocal data was utilized to provide a higher level of detail. CytLEK1 is in green 
and NudE is visualized in red. A) Deconvolution analysis confirms signficant colocalization of 
cytLEK1 and NudE in perinuclear regions. B) Colocalization becomes less evident away from the 
nucleus. The arrows provide reference points for the enlarged images. Intense nuclear puncta are a 
secondary antibody artifact. Bars, 5 µm.
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studies with LIS1 pathway components. Clearly, cytLEK1 distribution exhibits a similarity
specifically related to LIS1 family members, not just any cytoplasmic protein.
Examination of putative cytLEK1-dysbindin interaction
The other putative interacting protein to cytLEK1 discovered through the yeast two-
hybrid screen is dysbindin (dystrobrevin-binding protein). This result is interesting due to the
similarities in expression of dysbindin and LEK1. Both are most highly expressed in heart,
skeletal muscle, and brain (Goodwin et al., 1999; Benson et al., 2001). They also play important
roles during development. Dysbindin interacts with dystrophin and dystrobrevin, both of which
are members of the dystrophin-associated protein complex in muscle (Benson et al., 2001). This
complex is involved in membrane scaffolding for muscle integrity and in signal transduction
pathways, and its dysfunction results in Duchenne muscular dystrophy (Blake and Martin-
Rendon 2002). Additionally, dysbindin has also been associated with abnormalities in brain
function as related to schizophrenia (Numakawa et al., 2004). More recently, roles for dysbindin
outside of the dystrophin complex in muscle have been suggested. The protein appears to
regulate vesicular trafficking to organelles as part of the BLOC-1 (biogenesis of lysosome-
related organelles) complex (Li et al., 2003). While the actions of dysbindin relate broadly to the
proposed hypothesis for cytLEK1 function, the localization of dysbindin to the muscle
sarcolemma does not match the observed distribution of cytLEK1 in such tissues. However,
since dysbindin is a recently discovered protein that has not been thoroughly studied yet, its
localization in cardiac myocytes and the possible existence of a cytoplasmic pool of protein
remain unknown.
Since we were unable to obtain an antibody to dysbindin for localization studies, we
utilized commercial antibodies to its primary binding partner, dystrobrevin. Experiments were
conducted to examine the localization of a- and b-dystrobrevin in muscle cells and tissues
(Figure 32). In general, both proteins exhibit similar patterns with b-dystrobrevin having a more
diffuse distribution. To confirm the efficacy of the antibodies, they were first used on adult
mouse skeletal muscle tissue sections, and they successfully label the muscle sarcolemma, as
well as the cytoplasm for b-dystrobrevin. Experiments then proceeded to examine C2C12
myoblasts, which have not been carefully studied in the past for dystrobrevin localization.
Interestingly, in undifferentiated C2C12 myoblasts, dystrobrevin is cytoplasmic and localizes
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Figure 31. CytLEK1 does not colocalize with several cytoplasmic proteins in murine
cells. A) CytLEK1 is visualized in green and desmin is in red. No colocalization is
observed between these two cytoplasmic proteins in C2C12 myoblasts. B) CytLEK1 is in
red and the actin network is visualized with phalloidin (green). No colocalization is
observed in C2C12 cells.
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Figure 32. Distribution of dystrobrevin in murine skeletal muscle and myoblasts.
Dystrobrevin is visualized in red. In adult skeletal muscle, α-dystrobrevin is predominantly
localized to the muscle sarcolemma, while β-dystrobrevin has a wider distribution throughout
the cytoplasm. In C2C12 skeletal myoblasts, α- and β-dystrobrevin are both cytoplasmic and
exhibit a perinuclear concentration, especially with regard to the former. DAPI (blue) was
used to visualize nuclei.
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primarily to a perinuclear region. Very little membrane labeling is observed. In differentiated
C2C12 myocytes, dystrobrevin is distributed in a similar cytoplasmic pattern. Interestingly, a
few cells express very high levels of dystrobrevin, although the significance of this observation
is unknown. Since dystrobrevin and dysbindin have not been well-characterized in muscle cells
in culture, these results revealing a cytoplasmic population of dystrobrevin suggest that there
may be potential for interaction of dystrophin-related proteins with cytLEK1 based on an overlap
in distribution.
During the course of false positive screening for dysbindin in the yeast two-hybrid assay,
it was observed that all three obtained clones contained extraneous DNA within the dysbindin
coding region. Thus, while each of these dysbindin clones passed the false positive test, the
interaction could not be truly verified until an error-free dysbindin clone was generated and used
in a yeast mating experiment. To achieve this, a cDNA clone (Invitrogen) was utilized to create a
proper dysbindin-expressing yeast colony. Surprisingly, mating of this yeast with the SRR-
expressing yeast results in only minimal growth on QDO plates. However, control experiments
conducted in parallel using the incorrect dysbindin clones exhibit a similar phenotype, despite
previously showing robust growth under such conditions. Colocalization studies conducted with
myc-SRR and a newly-generated GFP-dysbindin construct in COS-7 cells do not yield useful
additional data. GFP-dysbindin is distributed throughout the cytoplasm and thus does not exhibit
any specific codistribution with myc-SRR. Notably, since the interaction of dysbindin with
cytLEK1 cannot be properly confirmed in a yeast two-hybrid setting, experiments studying this
interaction have been delegated to a lower priority than the NudE studies. The initial results are
promising enough though to warrant additional examination in the future.
Discussion
Despite their functional differences, LEK family members share a similar domain
structure (see Introduction). In the cytLEK1 portion of LEK1, the key conserved domains consist
of numerous leucine zippers and a spectrin repeat. As leucine zippers are a generic protein-
protein interaction motif found in many different proteins (O'Shea et al., 1989), we decided to
focus instead on the spectrin repeat region of cytLEK1 for our studies. Notably, this repeat
region contains several leucine zippers of its own. It does not, however, share any significant
sequence homology with the spectrin repeats of other LEK1 family members, although these
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repeats are likely structurally similar due to their coiled-coil assembly. In general, spectrin
repeats have been shown to serve as binding sites for various proteins involved in cytoskeletal
and signal transduction functions (Djinovic-Carugo et al., 2002). As cytLEK1 is a cytoplasmic
protein that is partially resistant to detergent extraction (chapter II), we hypothesized that the
repeat region of cytLEK1 may mediate a cytoskeletal role for the protein.
Thus, we utilized the spectrin repeat region (SRR) as bait in a yeast two-hybrid screen of
an embryonic whole mouse cDNA library. Since cytLEK1 is present in most tissues in early
murine development (Goodwin et al., 1999; chapter II), a whole mouse library enables detection
of all potential interacting proteins in various embryonic locations. Two separate screens were
conducted to ensure the detection of putative interactions. The positive hits are consistent among
both screens, confirming the reproducibility of our results. While the false positive rate, as
determined by control matings, is surprisingly high, this factor does not influence the importance
of our true positives. The interaction with NudE is by far the most prevalent positive hit with 31
total clones isolated. While all the clones contain the full length NudE sequence and thus do not
provide any information on the specific cytLEK1 binding site within NudE, the high number of
hits is nonetheless reassuring. The two other positive hits are a hypothetical protein (6 clones)
and dysbindin (3 clones). It is difficult to determine whether the lower number of clones obtained
with these molecules is the result of a weaker interaction with cytLEK1 or simply an indication
of a lower abundance of these specific cDNAs in the library. We focus our efforts here on the
interaction with NudE for several reasons. First, NudE is the most prevalent positive result in our
screen. Additionally, NudE(L) is expressed at highest levels in the brain, heart, and skeletal
muscle, similar to cytLEK1 (Niethammer et al., 2000; Sasaki et al., 2000; Yan et al., 2003). The
NudE mRNA is most abundant at embryonic stages and decreases during postnatal development,
yet again like LEK1 (Goodwin et al., 1999; Feng et al., 2000). NudE is a cytoplasmic protein
with a predominantly perinuclear distribution around the centrosome (Feng et al., 2000). This
localization is similar to that described for cytLEK1 in various cells in chapter II. Finally, NudE
has a cytoskeletal role due to its association with LIS1 pathway members, and this pathway plays
a role in proliferation, migration, and differentiation processes during development (see
Introduction). Thus, this function is analogous to our hypothesis of a cytoskeletal role for
cytLEK1 in such cellular processes.
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Our additional studies in this chapter primarily focus on the characterization of the
cytLEK1-NudE interaction. The importance of the discovery cannot be overstated, as this is the
first time that a binding partner of cytLEK1 has been identified. The cytLEK1 protein can thus
be placed in a molecular pathway. Detailed cytLEK1 functional studies conducted in chapter IV
are a direct result of the data presented in this chapter. Characterization of the exact binding
domains within cytLEK1 and NudE is a key result. The yeast two-hybrid deletional analysis
reveals, somewhat surprisingly, that the region C-terminal to the cytLEK1 spectrin repeat itself
(C domain) is necessary and sufficient for binding to NudE. The repeat does not play a direct
role in this interaction, although it may possibly be important for binding to a different protein.
In fact, the cytLEK1-dysbindin association appears to require the entire spectrin repeat region.
Thus, the repeat region may indeed bring together another protein with cytLEK1 and NudE.
Proteins of the Dbl family contain spectrin repeats that act in conjunction with a neighboring
Rho-GEF domain, for example (Alam et al., 1997; Estrach et al., 2002). Another possibility is
that the spectrin repeat of cytLEK1 is simply providing a tertiary structure conducive to binding
of proteins at the neighboring C domain. Additional studies are required to test these various
ideas. It is clear, however, that the small (80 aa) C domain of cytLEK1 is critical for the
interaction with NudE. This discovery enables the dominant negative studies in chapter IV that
separate this C domain from all other regions of the intact cytLEK1 molecule. In this way, the
function of the cytLEK1-NudE interaction can be isolated from any other currently-unknown
roles of the cytLEK1 protein.
Conversely, determination of the cytLEK1-binding domain within NudE also yields an
interesting result. This region in NudE partially overlaps the putative dynein-binding domain of
its isoform, Nudel (Sasaki et al., 2000; Liang et al., 2004). While the specific dynein-related
studies have not yet been conducted with NudE, the high degree of homology between NudE and
Nudel, including in this region, suggests a conserved function for this domain. Thus, the overlap
between the cytLEK- and dynein-binding domains within NudE presents the interesting
possibility of a complex regulation of protein-protein interactions. Given the large size of
cytLEK1, it is possible that its association with NudE may block the dynein-NudE interaction.
Thus, cytLEK1 would control the binding of NudE to one of its key partner proteins.
Alternatively, cytLEK1 may in fact bind dynein itself through a different domain and play a role
in bringing cytLEK1, dynein, and NudE together into a functional complex. In either scenario,
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cytLEK1 has an important function in directing interactions of LIS1 pathway members.
Disrupting the association of Nudel with dynein has been shown to affect many cellular
processes (Liang et al., 2004). Interestingly, only mutants that lack either the dynein- or LIS1-
binding domain, but not both, exhibit a phenotype. Given our results, deletion of the dynein-
binding region would also potentially disrupt any association with cytLEK1. Thus, these Nudel
data suggest that proper coordination of the interactions occurring at each of these domains is
critical. CytLEK1 may specifically be involved in regulating the association of NudE(L) with
dynein, as it has not yet been found to interact with the LIS1-binding domain of NudE. Detailed
biochemical studies in the future will help reveal the exact role of cytLEK1. An additional
complicating factor, however, is the unclear nature of the differences between NudE and Nudel
(see Introduction). In our experiments, cytLEK1 has been shown to associate with NudE, but an
interaction with Nudel has not been examined. Given the homology between the NudE and
Nudel sequences and their similarities in known binding partners (LIS1 and dynein), a cytLEK1-
Nudel interaction seems likely. However, no Nudel clones were obtained in our yeast two-hybrid
screens, although this is likely due to the lack of Nudel transcription at the embryonic day 11
stage of our screening library (Sasaki et al., 2000). Directed binding studies are needed in the
future to directly test for any potential association.
The cytLEK1-NudE interaction is confirmed by co-immunoprecipitation (co-IP) studies
of cotransfected proteins in COS-7 cells (Figure 24). These results clearly show that GFP-
mNudE co-immunoprecipitates with myc-SRR. We further define this interaction by confirming
the importance of the C domain identified in the yeast two-hybrid deletion studies. Removal of
this C domain eliminates the ability of GFP-mNudE to co-immunoprecipitate with the resulting
myc-N+R protein. This result is of high value, as the primary challenge in co-IP studies is to
differentiate between specific and non-specific binding. Whereas simply looking for co-
immunoprecipitation of GFP-mNudE and myc-C may result in identification of a non-specific
band as a positive result, determining the absence of any band in a co-IP with myc-N+R is more
challenging and experimentally relevant. Ideally, we would like to confirm these co-IPs using
endogenous proteins from murine cell lysates. However, there are numerous technical challenges
that cannot yet be overcome. The NudE antibody from the Walsh laboratory is ineffective in both
immunoprecipitation and Western blot assays (Yuanyi Feng, personal communication). We thus
have no way to collect or detect endogenous NudE within a protein complex, and this makes a
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co-IP impossible. If at a later stage a different NudE antibody becomes available, there will
likely still be additional challenges. Both cytLEK1 and NudE are associated with the
cytoskeleton, and an endogenous complex between the two proteins may thus not be soluble. In
fact, endogenous NudE is very difficult to isolate from cell lysates due to its lack of solubility
(Yuanyi Feng, personal communication). Additionally, our current cytLEK1 antibody has never
been tested in immunoprecipitation experiments and may be ineffective in such assays. An
alternative method for examining interaction between full length cytLEK1 and NudE is to
conduct a co-IP using transfected full length cytLEK1 and NudE proteins. However, this
presents different challenges, as the transfection efficiency of our very large cytLEK1 construct
is low. It is also important to note that this construct is not the same size as endogenous
cytLEK1, since the exact endogenous molecular weight is unknown due to the lack of specific
cleavage site data. Thus, this discrepancy may possibly inhibit fully proper protein-protein
interactions. Regardless, an additional result using transfected proteins yet again would not
substantially add to the co-IP and detailed colocalization data we already have.
To support our biochemical data, codistribution experiments were conducted that initially
focus on transfected proteins in COS-7 cells. We chose this approach for two reasons. First, it
allows us to confirm our co-IP results using the same transfected proteins in a substantially
different assay. Second, COS-7 cells are uniquely suited for visualization of the centrosome and
any proteins located at this structure. Our results reveal that myc-SRR colocalizes with GFP-
mNude in these cells, confirming our co-IP data. Importantly, this colocalization occurs at
distinct dots that we show to be related to centrosomes. This pattern is identical to that observed
for cells transfected with GFP-mNudE alone, suggesting that the SRR directs a specific
interaction with NudE. It is worthwhile to note that the amount of GFP-mNude localizing to the
centrosome appears to be directly related to the level of expression. High amounts of protein
within a cell result in a more pancytoplasmic distribution. Thus, while NudE is located more
preferentially at the centrosome in these cells, it is not exclusively there. Deletion of the C
domain once again eliminates any relationship with NudE, as seen in the myc-N+R studies.
Importantly, the myc-C protein also colocalizes with GFP-mNudE in transfected COS-7
cells. In fact, it appears to exhibit an even higher codistribution with NudE than seen in the myc-
SRR experiments. These data are consistent with the biochemical studies showing that the C
domain alone directs a specific and apparently exclusive interaction with NudE. Further analysis
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of the distribution of myc-C reveals that the protein also colocalizes with endogenous NudE
present at the centrosome. This result is very important due to the inability to co-
immunoprecipitate endogenous NudE for reasons already noted. Thus, these data show that the C
domain is capable of directing a codistribution with, not just transfected NudE protein, but also
endogenous NudE. It is interesting to note that even in specific COS-7 cells where the
centrosome can be easily visualized, endogenous NudE exhibits a predominantly perinuclear
distribution with a somewhat higher abundance at the centrosome. It is clear that NudE has a
localization and, thus, likely, function at both centrosomal and non-centrosomal areas. The
propensity of myc-C to similarly be perinuclear with a concentration at the centrosome, as
evidenced by g-tubulin staining, coincides with its strong affinity for NudE. Since studies
conducted in murine cells make centrosome visualization difficult, these data in COS-7 cells
importantly show that myc-C is specifically directed to the centrosome and perinuclear regions
and colocalizes with NudE. Thus, this protein has the potential to disrupt key NudE-related
functions in this subcellular area in a dominant negative fashion, as discussed in chapter IV.
In order to also test the association of endogenous cytLEK1 and NudE, we conducted
colocalization experiments in murine cells. Since the two known binding partners of NudE are
important members of the LIS1 pathway, the distributions of dynein and LIS1, as well as NudE,
were examined in relation to cytLEK1 in C2C12 myoblasts and 3T3 fibroblasts. For each of
these proteins, we observe a general similarity in localization pattern when compared to
cytLEK1. All of the proteins are cytoplasmic with somewhat perinuclear distributions, as has
been previously observed (see Introduction). Since the resolution of confocal microscopy alone
is not sufficient to clearly detect colocalization among such cytoplasmic proteins, deconvolution
analysis was performed to provide unambiguous results. These data reveal substantial
colocalization between each of the LIS1 pathway members (dynein, LIS1, NudE) and cytLEK1
in 3T3 cells. This codistribution is most evident in the perinuclear region of cells, which is an
interesting result for two reasons. First, this is the subcellular area where the known LIS1 family
members most commonly associate and colocalize (Smith et al., 2000). Second, endogenous
cytLEK1 near the nucleus is detergent resistant and presumably linked to the cytoskeleton. This
association may in fact be a direct consequence of its interaction with LIS1 pathway members in
the perinuclear region. As has been noted previously, examining the colocalization of proteins at
the centrosome is difficult in murine cells. However, the importance of achieving this is minimal,
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as these specific LIS1 pathway members have been repeatedly shown to be present at and
important in a wide perinuclear region (Niethammer et al., 2000; Sasaki et al., 2000; Smith et al.,
2000; Shu et al., 2004). Even NudE(L), which has the strongest centrosomal localization of any
LIS1 pathway member, is observed in these referenced studies to not exhibit a substantial
distribution at the centrosome of murine cells. Thus, our results are in complete agreement with
the literature. We also occasionally witness colocalization of cytLEK1 with LIS1 pathway
members near the plasma membrane, although this is not consistently detected. This observation
should be more carefully examined in the future, however, to discern if cytLEK1 functions in
leading edge processes. Additionally, LIS1 pathway members play important roles in mitotic
cells at various locations on the spindle and kinetochores (Faulkner et al., 2000; Yan et al., 2003;
Feng and Walsh, 2004). CytLEK1 has a similar distribution, as described in chapter II. It will be
interesting in future studies to examine colocalization of pathway members and cytLEK1 at such
structures in dividing cells.
Our data here do not reveal a complete colocalization of cytLEK1 with LIS1 pathway
members. In fact, such a result would be unexpected and troubling. None of the pathway
members have previously been shown to completely codistribute with each other. For example,
LIS1 does not fully colocalize with dynein, especially near the periphery of the cell (Smith et al.,
2000). This result is attributed to the fact that the LIS1 pathway is postulated to affect only a
subset of the vast array of dynein functions (Vallee et al., 2001). Similarly, cytLEK1 is a very
large protein with presumably several important functional domains. Thus, it likely binds to
many different proteins and has roles in various cellular processes and molecular pathways.
Interaction with LIS1 pathway members may only be a part of the function of endogenous
cytLEK1. In fact, our results support this idea, as cytLEK1 does not substantially colocalize with
pathway members near the periphery of cells. We have shown in chapter II that the resistance to
detergent extraction of cytLEK1 at the periphery is different than for perinuclear protein, thus
implying distinct functions for these subpopulations. Even near the nucleus, the codistribution of
cytLEK1 and LIS1 pathway members is high but not exact, suggesting that other interactions of
cytLEK1 are important in this region of the cell. Additionally, cytLEK1 may not immediately
bind to NudE in cells due to important regulation of this interaction. This would result in an
isolated subpopulation of cytLEK1 molecules that either have been temporarily sequestered or
are simply newly-translated. Such proteins would not colocalize with LIS1 family members.
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Nonetheless, in order to be certain of the importance of the high but partial colocalization
that we observe, we conducted experiments with many other cytoplasmic proteins unrelated to
the LIS1 pathway. These studies examined the distribution of cytLEK1 in relation to vimentin,
desmin, actin, and myosin in various cell lines. Notably, no significant colocalization can be
observed between cytLEK1 and any of these proteins. In fact, even the general pattern of protein
distribution within the cell is highly divergent from that of cytLEK1 and LIS1 pathway
members. Importantly, no clear perinuclear localization is observed for these other proteins.
Regions of high concentration of desmin, for example, are unrelated to similar areas of high
cytLEK1 levels. These studies provide important negative controls and reveal that our
colocalization results are specific to cytLEK1 and LIS1 family members.
Although experiments are in a preliminary stage, a short discussion of the potential
interaction between cytLEK1 and dysbindin is warranted. Detailed examination of this
interaction was postponed due to various technical difficulties. The existence of extraneous DNA
within each unique clone obtained from the screening library required the creation of a separate
dysbindin cDNA clone for use in yeast two-hybrid assays. Surprisingly, this new dysbindin clone
does not exhibit a strong interaction with the SRR of cytLEK1 in such assays. However, the
original clones containing the extraneous DNA also do not associate with the SRR in parallel
experiments, despite our previous results. As dysbindin clones have been isolated from two
separate yeast two-hybrid screens and subject to numerous successful independent false positive
tests, there is a distinct possibility that the inability to replicate the interaction at this later
timepoint is due to issues with the growth and maintenance of yeast. Thus, additional
examination of this interaction is likely necessary.
Initial published experiments on dysbindin do not reveal characteristics suggestive of a
cytLEK1-interacting protein (Benson et al., 2001). Dysbindin is part of the dystrophin-associated
protein complex in muscle. While it is highly expressed in brain, heart, and skeletal muscle,
similar to cytLEK1, its localization to the sarcolemma of myocytes in vivo does not match the
predominantly cytoplasmic distribution of cytLEK1 within such cells (Benson et al., 2001).
However, our studies with dystrobrevin, the primary binding partner of dysbindin, reveal that
this protein is primarily distributed in the cytoplasm of myocytes in culture (Figure 32). Even in
skeletal muscle of adult mice, certain dystrobrevin isoforms have a partially cytoplasmic
distribution. Additionally, more recent studies have suggested further roles for dysbindin outside
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of the dystrophin complex in muscle. The protein functions in regulation of vesicular trafficking
to organelles as part of the BLOC-1 (biogenesis of lysosome-related organelles) complex (Li et
al., 2003). This is an intriguing role as it shares similarities to the effects of the LIS1 pathway on
movement of organelles, lysosomes, and endosomes (see Introduction). Additionally,
abnormalities in dysbindin are associated with brain dysfunction, including schizophrenia
(Numakawa et al., 2004). LIS1 pathway members are critical for the proper development of this
organ (see Introduction). Thus, relating the function of dysbindin to that of the LIS1 pathway
through cytLEK1 is an intriguing scenario.
Unfortunately, such studies are complicated by various technical challenges. There is
only one known antibody to dysbindin, and we have been unsuccessful in obtaining it from the
relevant laboratory. Without the receipt or generation of such a dysbindin antibody, it is
impossible to conduct any co-IP or colocalization studies of endogenous proteins. Additionally,
transfection of GFP-dysbindin into COS-7 cells results in a pan-cytoplasmic distribution of the
protein with no evident pattern. Co-transfection with myc-SRR does not alter this result. Without
an antibody to dysbindin, it is difficult to tell whether this result is due to improper trafficking of
the transfected GFP-tagged protein or to dysbindin itself not having a distinct cytoplasmic
pattern. This problem is compounded by the lack of published data examining the localization of
dysbindin in cultured cells. Future transfection studies in myocytes may result in a more distinct
distribution of the protein. However, as myc-SRR causes a severe morphological phenotype in
C2C12 myoblasts, colocalization experiments are necessarily limited. Nonetheless, the potential
interaction between cytLEK1 and dysbindin is intriguing enough to warrant future investigation.
Our initial result that the entire SRR is required for binding to dysbindin suggests that this
interaction may interfere with or facilitate the cytLEK1-NudE association occurring at the C
domain within the SRR. Perhaps binding to dysbindin is important for the role of cytLEK1 at the
cell periphery. Further yeast two-hybrid screens utilizing different regions of cytLEK1 as bait
have revealed putative interactions with proteins related to vesicular transport, a dysbindin
function (Pooley et al. unpublished data). Additional experiments in the future will hopefully
reveal the exact nature of any cytLEK1-dysbindin association.
In summary, the results in this chapter reveal and characterize a novel interaction
between cytLEK1 and NudE. This association with NudE marks the first time any cytLEK1
binding partner has been identified. It thus places cytLEK1 within the LIS1 pathway and
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provides a context for understanding its distribution and function. In chapter II, we describe the
expression pattern of cytLEK1 in various tissues and cells. The results in this chapter here now
reveal a purpose for such a cytLEK1 localization in the context of being a member of the LIS1
pathway. CytLEK1 appears to associate with proteins of this pathway predominantly near the
nucleus, including at the centrosome. Thus, it is situated in the primary location of LIS1 pathway
function, and its colocalization with dynein, LIS1, and NudE implies that it has the ability to
widely regulate multiple components of the pathway. Notably, the overlap of the cytLEK1- and
dynein-binding domains within NudE suggests the potential for a complex regulation of multiple
protein-protein interactions, perhaps directed by cytLEK1 itself. Clearly, functional analyses are
the next step in determining the importance of the cytLEK1-NudE association. Isolation of the
critical C domain within cytLEK1 provides a powerful tool for conducting such studies. This
region of cytLEK1 is able to specifically direct localization to a perinuclear region, including the
centrosome, and an interaction with NudE. At the same time, the myc-C protein isolates any
other functional domains in the full length cytLEK1 from the NudE-binding region. Thus, it
serves as a powerful tool for examining, in a dominant negative fashion, the role of cytLEK1
within the LIS1 pathway in chapter IV.
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CHAPTER IV
ANALYSIS OF CYTLEK1 FUNCTION
AND REGULATION OF THE LIS1 PATHWAY
Introduction
Data presented in chapter III reveal an important interaction between cytLEK1 and
NudE. Additionally, cytLEK1 protein is shown to be present in many developing tissues and key
subcellular locations in chapter II. Thus, cytLEK1, through its interaction with NudE, has the
potential to be a significant regulator of the LIS1 pathway in multiple cell types. The LIS1
pathway is critical for many important cellular functions, as described in the Introduction.
Briefly, members of the pathway play a role in dynein-related processes occurring with the
microtubule network. Thus, events such as organelle positioning, cytoskeletal organization, cell
shape, migration, and mitosis are directly regulated by the LIS1 pathway (Hirotsune et al., 1998;
Faulkner et al., 2000; Sasaki et al., 2000; Smith et al., 2000; Dujardin et al., 2003; Liang et al.,
2004; Shu et al., 2004). Disrupting the function of pathway members results in perturbation of
these processes. As cytLEK1 interacts with NudE and colocalizes with other key components of
the LIS1 pathway, we wished to examine whether cytLEK1 is critical for pathway actions. More
specifically, we focused on the C domain of cytLEK1 that binds NudE. We postulated that
isolation of the C domain from any other functional domains in the intact cytLEK1 molecule
would produce a dominant negative effect.
In this chapter, we present data characterizing the role of cytLEK1 on LIS1 pathway
functions. We primarily use the dominant negative myc-C protein to examine the effects of
disrupting cytLEK1 activity in various murine cells lines. Expression of the NudE-binding
domain alone produces severe effects on cell morphology and the microtubule network in a
proposed dominant negative fashion. These cells quickly adopt a dramatically rounded shape.
Interestingly, microtubules are tightly focused around the nucleus, consistent with previous
studies disrupting LIS1 function (Smith et al., 2000). Importantly, these cells expressing the
dominant negative cytLEK1 protein are strongly inhibited in microtubule repolymerization after
treatment with the depolymerizing agent nocodazole. Additional experiments examining the
effects of LEK1 knockdown in cells reveal a similar alteration of the microtubule network. Our
data also show that the C domain confers resistance to detergent extraction, suggesting that it
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mediates interaction with cytoskeletal components. We expand on this by examining the unique
subcellular localization of the myc-C protein in cells. Finally, overexpression of full-length
cytLEK1 causes a tight clustering of the Golgi apparatus near the nucleus, consistent with the
role of other LIS1 pathway members (Sasaki et al., 2000; Smith et al., 2000; Liang et al., 2004).
Examination of additional results of cytLEK1 overexpression is also presented here. In summary,
the experiments in this chapter characterize the effects of cytLEK1 dysfunction on key cellular
events. The severity of the defects in microtubule organization and repolymerization imply a
critical and novel role for cytLEK1 in the LIS1 pathway, which regulates microtubule function in
important cellular processes.
Materials and Methods
Cell culture
NIH 3T3 cells (ATCC) were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM; Cellgro) supplemented with 10% fetal bovine serum, 100 mg/mL
penicillin/streptomycin, and L-glutamine. C2C12 cells (ATCC) were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 20% fetal bovine serum, 100 mg/mL
penicillin/streptomycin, and L-glutamine. All cell lines were maintained in a 95% air-5% CO2
humidified atmosphere at 37˚C.
Transfections
3T3 and C2C12 cells were grown to 40-60% confluency and transfected using FuGENE6
(Roche) per manufacturer’s instructions. Briefly, FuGENE was added to a tube containing
OptiMEM medium (Cellgro) and gently mixed. DNA was then added and gently mixed. After a
15 min incubation, the FuGENE-DNA mixture was pipetted into wells containing cells and fresh
medium. For each well of a 4-well slide, 0.25 mg of total DNA was utilized for transfection.
Cells were generally grown for 24-48 h prior to collection for further examination.
Immunocytochemistry and microscopy
Cells grown on glass chamber slides (Nalge Nunc) were gently washed with PBS and
fixed with Histochoice (Amresco) or 70% ethanol (for Spec1) for 20 min. For pre-extraction to
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visualize microtubules (Toomre et al., 1999; Bennin et al., 2002; Giodini et al., 2002), cells were
additionally washed with PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 3 mM
MgCl2 pH 6.8) and treated with 0.5% Triton X-100 in PHEM for 1 min prior to fixation. Cells
were then washed briefly in PBS, permeabilized with 0.25% Triton X-100 in PBS for 10 min,
and blocked in 2% BSA in PBS for a minimum of 1 h. Primary antibodies in 1% BSA in PBS
were applied overnight at 4˚C. After three PBS washes, secondary antibodies were applied for 1
h at room temperature. The slides were washed three times with PBS and twice with water
before cover slips were attached with Aqua Poly/Mount (PolySciences). Cells were visualized by
fluorescence microscopy on an AX70 (Olympus) or, for confocal analysis, an LSM510 (Zeiss)
microscope. Digital images were captured and processed using Magnafire (Optronics),
Metamorph (Universal Imaging), and Photoshop (Adobe) software.
Nocodazole treatment
Cells were transfected with the appropriate plasmid using FuGENE. Six hours post-
transfection, they were exposed to nocodazole (Sigma), a microtubule depolymerizing agent, at a
final concentration of 5 mg/mL for 3 h in the appropriate medium for the cell type. After washing
out the drug three times with medium, the cells were grown for an additional 0, 10, or 20 min
before pre-extraction and fixation as described above.
Morpholino antisense oligomer treatment
Morpholino oligomers (MO; GeneTools) are composed of a nucleic acid base, a
morpholine ring, and a non-ionic intersubunit linkage. This structure prevents them from being
degraded inside cells by nucleases. They also have minimal interactions with proteins, thus
avoiding non-specific effects associated with other antisense technologies. Morpholinos inhibit
translation of a target RNA through a steric block of the translational machinery. Morpholinos
specific to the 5’ untranslated region of the LEK1 mRNA had previously been constructed and
tested for specificity (Ashe et al., 2004). The L50 morpholino was most effective at knocking
down LEK1 protein expression and was used in all studies. Its sequence was as follows: 5’-
AGCTCCTCACAGAACCTGGCTCCG-3’. A standard control morpholino with no detectable
biological target or activity was provided by the manufacturer and utilized in experiments. Its
sequence was as follows: 5’-CCTCTTACCTCAGTTACAATTTATA-3’. Non-confluent cells
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were treated with morpholinos per manufacturer’s Special Delivery instructions. Briefly, 0.5 mM
Special Delivery morpholino/DNA stock solution was added to H2O and gently mixed. EPEI
Special Delivery solution was pipetted into this mixture and vortexed immediately. This was
followed by a 20 min incubation during which time cells were rinsed three times with PBS.
Serum-free medium (Cellgro) was then added to the Morpholino/EPEI solution and immediately
vortexed. This final delivery medium was added to the cells. After 3 h incubation, the delivery
medium was removed and replaced with fresh medium. Cells were then assayed 72 hours post-
treatment. When confirming cytLEK1 knockdown, special attention was taken to ensure that all
antibody concentrations, camera exposure times, and Photoshop preparations were identical and
conducted in parallel.
WGA endosomal assay
TRITC-labeled wheat germ agglutinin (WGA) was obtained from Sigma for use in an
assay to test trafficking of endosomes containing WGA-binding sites. Cells were transfected
with the appropriate plasmid using FuGENE. Six to eight hours after transfection, cells were
incubated in the dark with 10 mg/mL TRITC-WGA in PBS for 30 min at 4˚C. Cells were then
either immediately washed two times with PBS before fixation (0 min) or incubated with the
appropriate medium for 1 h (60 min) at 37˚C before fixation. Cells were fixed and processed as
described above. No primary or secondary antibody was needed to visualize the WGA since it
was TRITC-labeled.
Antibodies
The monoclonal anti-myc and GM130 antibodies were from BD Biosciences. A
polyclonal anti-myc antibody was acquired from Novus. The antibodies against b-tubulin and
FLAG were manufactured by Sigma. Polyclonal antibody Spec1 to a cytLEK1 peptide (aa 1826-
45) was generated in rabbits (Biosynthesis) and affinity purified using the injected peptide
(Backstrom and Sanders-Bush, 1997). Alexa 488 and Alexa 568 conjugated secondary
antibodies, as well as Phalloidin-488, were obtained from Molecular Probes. DAPI was used to
visualize nuclei (Boehringer Mannheim).
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Results
Disrupting cytLEK1 function alters cell shape and microtubule network organization
Since cytLEK1 interacts with NudE and colocalizes with key components of the LIS1
pathway, we postulated that alteration of cytLEK1 function would disrupt cellular processes
regulated by these proteins. Alterations in LIS1 pathway function have previously been
demonstrated to cause abrupt changes in cell morphology and the microtubule network (Feng et
al., 2000; Smith et al., 2000; Cahana et al., 2001). We tested the ability of the myc-C protein to
act in a dominant negative fashion on the LIS1 pathway by uncoupling the NudE-binding site in
cytLEK1 from other functions in the intact molecule.
Expression of myc-C in 3T3 fibroblasts results in a severe alteration of cell shape (Figure
33 A), a phenotype that previously has been reported with a dominant negative LIS1 protein
(Cahana et al., 2001). Transfected cells round up, and their microtubule networks become tightly
focused around the nucleus and lose their regular broad cytoplasmic distribution (Figure 33 C),
which has also been observed in LIS1-heterozygous fibroblasts (Smith et al., 2000). This change
in morphology of 3T3 cells is visible as soon as 8 hours after transfection. Notably, the cells do
not detach from the plate even 72 hours post-transfection, and thus this effect is not likely to be a
simple cell death response. Similar changes in morphology and the cytoskeleton were observed
in C2C12 myoblasts. Although the myoblasts were initially more resistant to the expression of
myc-C, extending the time of post-transfection incubation resulted in similar changes in
morphology as seen in 3T3 cells. Examination of the rounded myc-C-expressing cells suggests
that endogenous LIS1 and dynein are tightly packed around the nucleus. Expression of myc-SRR
causes similar rounding of cells, but transfection of full-length cytLEK1 does not reveal any such
phenotype (Figure 33 D). The myc-N+R construct, which lacks the NudE-binding domain, was
transfected into 3T3 cells to examine possible changes in phenotype. Importantly, expression of
myc-N+R in these cells results in no change in morphology or cytoskeletal organization (Figure
33 A), suggesting that this phenotype is specific to the presence of the cytLEK1-NudE
interaction domain. Cell counts determined that 88 ± 3% of the myc-C-transfected cells have
rounded up after 24 hours, whereas only 7.7 ± 2% of the myc-N+R-transfected cells are similarly
affected (Figure 33 B, p<0.0001). Examining the small number of cells that are initially resistant
to disruption by myc-C allowed us to analyze the subcellular distribution of the SRR constructs
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Figure 33. Disrupting cytLEK1 function alters cell shape and microtubule network organization. A) 
3T3 cells were transfected with either myc-C or myc-N+R and examined for changes in cell morphology. 
Fluorescence of transfected cells here and in (D) was converted to grayscale and thus appears white. The 
majority of cells expressing myc-C round up within 24 h post-transfection, unlike myc-N+R-expressing 
cells, where morphology is unchanged from non-transfected cells. B) When quantified, 88% of myc-C-
expressing cells round up versus 7.7% of myc-N+R-expressing cells, a statistically significant difference 
(p<0.0001 by Mann-Whitney U-test, Prism 3.0, Graphpad Software). C) 3T3 cells were transfected with 
myc-C and examined 24 h post-transfection. myc-C is visualized in green while tubulin is in red. 
Transfected cells (marked by asterisks) adopt a rounded morphology and have an altered microtubule 
network. The microtubule network becomes tightly focused around the nucleus and loses its regular broad 
cytoplasmic distribution pattern. D) C2C12 cells were transfected with a construct of intact cytLEK1 and 
examined 24 h post-transfection. Transfected cells do not show any abnormalities in cell morphology. 
DAPI (blue) was used to visualize nuclei. Bars: (A) 20 µm; (C-D) 10 µm.
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prior to severe changes in morphology. In this minority population of cells, a differential
distribution of myc-C and myc-N+R is observed. Whereas myc-C, similar to LIS1 (Smith et al.,
2000), is distributed more tightly around the nucleus, myc-N+R is uniformly expressed diffusely
throughout the cytoplasm (Figure 34). By 72 hours post-transfection, nearly all cells transfected
with myc-C have adopted the rounded morphology and perinuclear microtubule network.
To determine whether detergent resistance is conferred by the C domain, we utilized a
detergent pre-extraction protocol, which allows for examination of proteins associated with the
cytoskeleton (Sapir et al., 1997; Toomre et al., 1999; Giodini et al., 2002). Interestingly, pre-
extraction of cells before fixation results in the washing out of myc-N+R, while myc-C is
resistant to detergent treatment and remains in the insoluble cytoskeletal pool (Figure 35).
Considering the role of the LIS1 pathway in microtubule function, the presence of the C domain
of cytLEK1 with detergent-resistant subcellular structures, along with the morphologic changes
observed, provides further evidence of a role for cytLEK1 in microtubule function.
Disrupting cytLEK1 function inhibits microtubule repolymerization
The present data demonstrate that the myc-C protein has a strong effect on the
organization of pre-existing, intact microtubule networks. Additionally, LIS1 overexpression has
been shown to cause altered microtubule polymerization and localization after nocodazole
treatment (Smith et al., 2000). Thus, we next wished to determine whether myc-C inhibits
nascent microtubule polymerization. Cells were transfected with the myc-C construct, cultured
for 6 hours in order to minimize the severe rounding of cells observed with prolonged exposure
to the protein, and then treated for 3 hours with nocodazole. After a 10 min washout of
nocodazole, cells were pre-extracted and the microtubule network analyzed. Remarkably, both
C2C12 and 3T3 cells transfected with myc-C show a nearly complete inability to repolymerize
their microtubule networks after nocodazole washout (Figure 36). While surrounding non-
transfected cells have long microtubule networks emanating from their organizing centers, the
transfected cells lack microtubule segment formation. Even after a 20 min washout, the
microtubule network remains unformed in these cells, suggesting that the defect is both severe
and long-lasting (Figure 37 A). The myc-N+R protein was used as a control since it is unable to
bind NudE and thus would not be expected to affect microtubule repolymerization. For this
experiment, pre-extraction was impossible because it washes out the transfected protein (Figure
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Figure 34. Myc-C exhibits a distinct subcellular localization in murine cells. Disrupting cytLEK1 
function alters cell shape and microtubule network organization. 3T3 cells were transfected with 
myc-C or myc-N+R and any non-rounded cells, which were a small minority of the total myc-C 
population, were examined. Myc proteins are in red (arrows) while a cytoplasmic label (phalloidin) is 
in green. The myc-C protein is distributed in a perinuclear fashion in these cells while the myc-N+R 
protein shows no such specific localization and is instead found throughout the cytoplasm. DAPI 
(blue) was used to visualize nuclei. Bar, 10 µm.
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Figure 35. The C domain of cytLEK1 confers resistance to detergent pre-extraction. C2C12 
cells were transfected with myc-C or myc-N+R (both white) and then fixed before or after Triton 
extraction. The myc-C protein is resistant to pre-extraction and thus likely attached to the 
detergent-resistant cytoskeletal network. The myc-N+R protein is washed out, however, so it is not 
bound to the cytoskeletal network.  DAPI (blue) was used to visualize nuclei. Bars, 20 µm.
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35). As expected, expression of myc-N+R does not lead to any changes in microtubule
repolymerization after nocodazole treatment (Figure 37 B), and both transfected and surrounding
cells have microtubule networks attached to organizing centers. Taken together, these
experiments demonstrate that the presence of the NudE-binding domain of cytLEK1 causes
nearly complete inhibition of microtubule repolymerization and may explain the intense effects
on cell morphology and the cytoskeleton that occur with expression of the myc-C protein.
LEK1 knockdown alters microtubule network organization
To further confirm the role of cytLEK1 in the LIS1 pathway, we examined the effects of
knockdown of the LEK1 protein using morpholino antisense oligomers. These LEK1
morpholinos had previously been utilized by our laboratory and confirmed to effectively and
specifically knock down LEK1 protein expression (Ashe et al., 2004). We verified that cytLEK1
protein expression is indeed knocked down by LEK1 morpholino versus standard control
morpholino treatment in 3T3 fibroblasts (Figure 38 A). As previously reported (Ashe et al.,
2004), LEK1 knockdown induces apoptosis in cells after several days and this was observed here
also. Not surprisingly, LEK1-knockdown cells are very susceptible to environmental stress and
experiments to examine their response to nocodazole treatment resulted in massive cell death and
detachment from the slide surface. While a severe change in morphology to a rounded phenotype
was not observed in LEK1-knockdown cells, their microtubule networks are significantly
altered. Notably, there is a substantial accumulation of microtubules around the nucleus (Figure
38 B-C). Whereas control-treated cells display a uniform distribution of microtubules throughout
the cytoplasm, LEK1-knockdown cells exhibit a tight perinuclear focusing of microtubules,
similar to that observed with expression of the myc-C dominant negative protein and consistent
with inhibition of microtubule transport to the cell periphery. Since the LIS1 pathway is critical
for this transport process, inhibition of the function of any member of the LIS1 pathway has
consistently resulted in accumulation of microtubules around the nucleus (Ahmad et al., 1998;
Smith et al., 2000; Shu et al., 2004). This result thus provides additional evidence that cytLEK1
expression is critical for LIS1 pathway function.
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Figure 36. Disrupting cytLEK1 function inhibits microtubule repolymerization after nocodazole 
challenge in murine cells. Cells were treated with 5 mg/mL nocodazole for 3 h followed by 10 min 
washout before pre-extraction and fixation. Myc-tagged proteins are in green (arrows) and tubulin is in red. 
A) Myc-C expressed in C2C12 myoblasts causes a severe inhibition in microtubule repolymerization after 
nocodazole washout. While surrounding untransfected cells have clearly visible microtubule networks, 
such networks are almost completely absent in transfected cells. Very small, disorganized networks may be 
forming in some cells (arrowhead). B) Myc-C expression in 3T3 fibroblasts causes severe inhibition of 
polymerization in these cells also. Microtubules are seen associated with the organizing center in 
untransfected cells while no such organized repolymerization is visible in transfected cells. DAPI (blue) 
was used to visualize nuclei. Bars, 10 µm.
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Figure 37. Disruption of microtubule repolymerization caused by cytLEK1 dysfunction is long-
lasting and specific. Disrupting cytLEK1 function inhibits microtubule repolymerization after 
nocodazole challenge in murine cells. Cells were treated with 5 mg/mL nocodazole for 3 h followed by 
10 (B) or 20 (A) min washout before pre-extraction and fixation. Myc-tagged proteins are in green 
(arrows) and tubulin is in red. A) Even after 20 min of nocodazole washout, 3T3 cells transfected with 
myc-C have not reformed their microtubule networks. B) 3T3 cells transfected with myc-N+R were 
visualized without pre-extraction to prevent washing out of the myc-N+R protein. Cells that express this 
protein do not show any noticeable inhibition in microtubule repolymerization. DAPI (blue) was used to 
visualize nuclei. Bars, 10 µm.
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Figure 38. LEK1 knockdown alters microtubule network organization. 3T3 cells were treated with 
either LEK1-specific morpholinos (MO) or standard control morpholinos (SC) and examined 72 hours 
post-treatment. A) MO-treated cells show a substantial, but not complete, knockdown of cytLEK1 protein 
(green) compared to controls. B) The microtubule networks (red) of MO-treated cells are tightly focused 
around the nucleus when compared to control cells. C) Despite not exhibiting a rounded morphology, 
knockdown of LEK1 clearly results in a perinuclear accumulation of microtubules (red). DAPI (blue) was 
used to visualize nuclei. Bars: (A) 20 µm; (B-C) 10 µm.
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Examination of endosome positioning after cytLEK1 disruption
Since the LIS1 pathway has been shown to be involved in the process of membrane
trafficking (Liang et al., 2004), experiments were conducted to examine whether expression of
the dominant negative myc-C protein disrupts endosomal movement. The approach utilized
TRITC-labeled wheat germ agglutinin (WGA) that marks endosomes containing WGA-binding
sites. After transfection with the myc-C construct, cells were first incubated at 4˚C to block
endocytosis and to leave WGA at the plasma membrane. They were then either immediately
fixed or switched to 37˚C for 60 min to examine endosomal transport. The 4˚C incubation
successfully blocks endocytosis of WGA, as shown by the immediate (0 min) fixation data
(Figure 39 A). However, there is substantial variation among the cell population at 60 min, even
in non-transfected samples, such that no clear difference in WGA distribution can be observed
between cells expressing myc-C and those expressing myc-N+R (Figure 39 B). Thus, this assay
is not very useful for detecting potential changes in endosomal movement resulting from
expression of myc-C.
Distribution of the Golgi apparatus is altered after cytLEK1 overexpression
Proper positioning of the Golgi apparatus near the nucleus has been shown to dependent
on dynein movement along microtubule tracks (Allan and Vale, 1991; Corthesy-Theulaz et al.,
1992). Further experiments have revealed the involvement of additional LIS1 pathway members
in this process, although the exact details of this regulation are under dispute (Faulkner et al.,
2000; Sasaki et al., 2000; Smith et al., 2000; Tai et al., 2002; Liang et al., 2004). Thus, we first
wished to examine whether disruption of cytLEK1 function using the myc-C protein results in an
alteration of Golgi localization in 3T3 fibroblasts. An antibody to GM130, a marker of the Golgi
apparatus, was used to visualize this organelle. The analysis was made difficult by the severe
rounding of cells induced by expression of myc-C and myc-SRR. Therefore, the small number of
cells (~10%) that do not exhibit a change in cell shape had to be examined instead. Within this
minority population, no significant changes in Golgi positioning are visible. However, additional
studies were conducted to examine any effects of expressing full-length cytLEK1 in 3T3 cells.
Analysis was more effective in these cytLEK1-transfected cells due to their unaltered fibroblastic
shape. Notably, cells overexpressing cytLEK1 at moderate to high levels generally exhibited a
tighter clustering of the Golgi apparatus near the nucleus than non-transfected cells (Figure 40
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Figure 39. Examination of endosome positioning in murine cells expressing myc-C. TRITC-
WGA (red) was used to visualize endosomes. A) Immediately after the 4˚C block of endocytosis,
few labeled endosomes are detected in the cytoplasm of 3T3 fibroblasts. B) After a 60 min post-
block incubation, labeled endosomes have been internalized. Due to substantial variation among
the cell population, no clear differences between cells expressing myc-C and myc-N+R (both red)
are observed. DAPI (blue) was used to visualize nuclei.
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A). Cells transfected with GFP as a control do not exhibit such a dramatic phenotype (Figure 40
B). Thus, these preliminary data suggest that overexpression of cytLEK1 enhances the
movement of the Golgi towards the nucleus. This result is consistent with the putative role of the
LIS1 pathway in moving such organelles in this direction (Allan and Vale, 1991; Corthesy-
Theulaz et al., 1992; Sasaki et al., 2000; Smith et al., 2000; Liang et al., 2004). Further
experiments of a more quantitative nature should be conducted to more precisely determine the
effect of cytLEK1 on Golgi positioning.
Examination of effects of cytLEK1 overexpression on myocyte differentiation
Since depletion of LEK1 has been shown to induce premature differentiation in C2C12
myoblasts (Ashe et al. unpublished data), we examined whether overexpression of cytLEK1 in
these cells also has an effect on this process. As a marker for differentiation after serum
deprivation, expression of sMHC was observed. However, these experiments were inconclusive
due to an interesting consequence of cytLEK1 expression. During the period required for
differentiation to occur, the number of cells expressing the cytLEK1 construct appears to
decrease dramatically. This decrease occurs days 2 and 3 post-transfection, whereas sMHC
expression is not detected in high numbers until day 4. Thus, there remain too few transfected
cells to obtain a significant result regarding cytLEK1 effects on differentiation, as determined by
a chi-square analysis. However, further experiments were conducted to better determine the
cause of the disappearance of these cytLEK1-expressing cells.
Overexpression of cytLEK1 results in disappearance of cells
In order to examine the effects of cytLEK1 overexpression on a cell line with high
transfection efficiency, 3T3 fibroblasts were utilized. Preliminary experiments confirmed a
decrease in cytLEK1-transfected cells as initially observed with C2C12 myoblasts, so a more
comprehensive analysis was undertaken. These data revealed that these cells undergo a dramatic
and significant decline in number between days 2 and 3 post-transfection. In order to confirm
that this change cannot be attributed to simply the burden of overexpressing any protein or the
shock of the transfection procedure, cells were also transfected with a lacZ construct as a control.
Indeed, this decline in transfected cell number is specific to cytLEK1-transfected cells, as it is
significantly greater than for lacZ-transfected control cells. Whereas there is a 62.6% decrease in
cytLEK1 GFP
A B
Figure 40. Overexpression of cytLEK1 in murine cells results in alteration of the distribution
of the Golgi apparatus. The Golgi apparatus of 3T3 fibroblasts was visualized with an antibody
to GM130 (red). A) 3T3 cells were transfected with a FLAG-tagged cytLEK1 construct (green)
and examined for changes in Golgi localization. Transfected cells appear to have a tighter
clustering of the Golgi apparatus near the nucleus than non-transfected cells. B) 3T3 cells were
transfected with a GFP construct (green) as a control. No significant effect on Golgi localization
was observed. DAPI (blue) was used to visualize nuclei.
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Figure 41. Overexpression of cytLEK1 in murine cells results in a decrease in transfected cell
number. Cells were transfected with either a FLAG-tagged cytLEK1 construct (red) or a lacZ
construct (blue). The number of transfected cells per field was determined at days 2 and 3 post-
transfection. The values were averaged based on day 2 numbers and are presented here. A) There is
a 62.6% decrease in the number of cytLEK1-transfected 3T3 fibroblasts between days 2 and 3,
whereas only 6.8% of the lacZ-transfected cells are absent (p<0.0001 by Student’s t-test, Microsoft
Excel). B) C2C12 myoblasts exhibit a similar decline. Between days 2 and 3 post-transfection, there
is an 82.3% decrease in the number of cytLEK1-transfected cells compared to a 45.2% decline for
lacZ-transfected cells (p<0.0001 by Student’s t-test, Microsoft Excel).
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the number of cytLEK1-transfected cells between days 2 and 3, only 6.8% of the lacZ-
transfected cells are absent (Figure 41 A, p<0.0001). This effect does not seem to be cell type-
specific, as confirmed by quantitative experiments with C2C12 myoblasts. Although the absolute
number of transfected cells is lower, thus increasing the standard deviation, cytLEK1-transfected
myoblasts are more affected than control cells. Between days 2 and 3 post-transfection, there is
an 82.3% decrease in the number of cytLEK1-transfected cells compared to a 45.2% decline for
lacZ-transfected cells (Figure 41 B, p<0.0001). The overall higher percentage decline compared
to fibroblasts is likely a result of the lower resistance of myoblasts to cellular and environmental
perturbations. However, the results clearly indicate that cells overexpressing cytLEK1 decrease
significantly in number between 48 and 72 h after transfection. Notably, overexpression of
nucLEK1 is associated with a similar phenotype in various cell lines (Ashe et al. unpublished
data).
Since overexpression of cytLEK1 results in a dramatic decline in the absolute number of
transfected cells, experiments were undertaken to determine if this situation was the result of an
increased rate of apoptosis. As a measure of apoptosis, an antibody specific to cleaved caspase 3
was utilized. Immunofluorescence control experiments on UV-treated C2C12 myoblasts reveal
an increase in the number of cleaved caspase 3-positive cells, thus confirming the sensitivity of
the assay. However, there is no apparent correlation between cytLEK1-transfected cells and the
apoptotic marker 2 days post-transfection. While many apoptotic cells are observed, they are
distributed equally among the non-transfected and cytLEK1-transfected population. Additional
experiments with 3T3 fibroblasts confirm that there is no detectable increase in apoptosis as a
result of cytLEK1 overexpression. Thus, the decrease in cytLEK1 appears to be caused by an
event other than apoptosis. Two additional possibilities, which are both difficult to test, are that
the transfected cells are undergoing necrosis or that the cells are somehow becoming detached
from the glass slide. Regardless of cause, the short time span available for observing cytLEK1-
transfected cells limits the range of possible experimental analyses.
Discussion
In chapters II and III, we present data characterizing the expression pattern of cytLEK1
and examining its interaction with NudE. These experiments reveal an association with NudE
through distinct binding domains and a colocalization of cytLEK1 with key proteins of the LIS1
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pathway. The results suggest that cytLEK1 has the potential to interact with and regulate LIS1
pathway members in a wide range of developing tissues and cells. Thus, examination of
cytLEK1 function is a logical next step and the focus of this chapter. Experiments were designed
to study processes previously shown to be regulated by the LIS1 pathway. Such events include
microtubule organization, organelle positioning, spindle formation, and migration (see
Introduction). CytLEK1 is well-suited to affect LIS1 pathway functions due to its perinuclear
localization, including at the centrosome, and interaction with NudE (chapters II and III). As
determination of the role of LIS1 pathway members has generally consisted of conducting loss-
of-function or dysfunction studies (see Introduction), the experiments in this chapter are similar
in design. In order to examine the specific effects of disrupting the cytLEK1-NudE interaction, a
dominant negative approach was utilized for many studies. While we do present some
experiments using LEK1 knockdown, this method is not the best approach for our purposes for
several reasons. First, LEK1 knockdown results, as confirmed here, in massive cell death several
days after treatment with LEK1-specific morpholinos, presumably due to a requirement of LEK1
for cell survival (Ashe et al., 2004). This response both limits the potential assays that can be
conducted and also introduces an additional variable into experiments. Also, LEK1 is a relatively
unique protein in that it is post-translationally cleaved to yield two peptide products: cytLEK1
and nucLEK1. Any technique that inhibits translation of the LEK1 protein will result in
depletion of both peptide products. Thus, it is difficult to ascertain whether the effects seen are
predominantly due to cytLEK1 or nucLEK1 depletion, or both. This is the case with previous
studies showing an inhibition of proliferation with LEK1 knockdown (Ashe et al., 2004).
However, knockdown experiments can serve to confirm results obtained through other
techniques, such as dominant negative protein expression, and that is their primary use here.
The dominant negative approach utilized in this chapter allows us to specifically examine
the role of the cytLEK1-NudE interaction. By localizing the region of NudE-binding to the small
C domain within cytLEK1 (chapter III), we were able to create a protein, myc-C, that isolates
this domain from any other functional regions within cytLEK1. Thus, myc-C would be expected
to have a dominant negative effect on LIS1 pathway functions. Indeed, the experiments reveal
several disruptions resulting from expression of the myc-C protein in murine cells. Our extensive
characterization of the cytLEK1-NudE interaction allows us to utilize the myc-N+R protein,
which contains the entire SRR except the C domain, as a negative control in these studies. Thus,
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the effects we observe are consistently the result of expressing the isolated C domain specifically
and examining dysfunction of the LIS1 pathway. Our analysis is somewhat complicated by the
lack of knowledge of the direct mechanism of action of most LIS1 pathway members, in addition
to the conflicting functional data in the literature (see Introduction). However, the phenotypes we
observe are generally consistent with the majority of published studies and the emerging model
of LIS1 pathway function.
The most obvious effect of myc-C expression in cells is a dramatic change in cell shape
(Figure 33). The cells lose their fibroblast or myoblast morphology and rapidly adopt a rounded
shape. This effect is clearly specific to the myc-C protein with its isolated C domain, as
expression of myc-N+R does not result in any noticeable change in morphology. Additionally,
overexpression of full-length cytLEK1 does not result in any significant alteration of cell shape,
although these cells do disappear after several days as has been noted (Figures 33, 41). This
result confirms our model for dominant negative function, since it reveals that expression of the
C domain with other cytLEK1 regions does not have as severe an effect as expression of the C
domain alone. It is also important to note that this rounded phenotype is not an artifact of cell
death caused by myc-C expression, as the number of transfected cells does not significantly
decline over a 72 hour period. Thus, this effect is specifically a modification of cell shape.
Alterations in morphology have previously been noted with a LIS dominant negative protein
(Cahana et al., 2001), supporting a role for cytLEK1 in LIS1 pathway function.
As microtubule organization is another key function of the LIS1 pathway (see
Introduction), the cells expressing myc-C were also examined for alterations of the microtubule
network. Notably, there is a dramatic change in microtubule localization in these cells. Instead of
being broadly distributed throughout the cell, the microtubule network becomes tightly focused
around the nucleus. Thus, it appears that there is an inhibition of microtubule transport to the
periphery. This tight perinuclear distribution of microtubules, observed here with cytLEK1
dysfunction, has previously been detected in fibroblasts from LIS1-heterozygous mice, as well as
in dynein and Nudel dysfunction studies, and attributed to the role of the LIS1 pathway in
dynein-directed outward movement of microtubules in cells (Ahmad et al., 1998; Smith et al.,
2000; Shu et al., 2004). Our dominant negative myc-C protein appears to be capable of strongly
disrupting this process, indicating the importance of cytLEK1 function in the LIS1 pathway. It is
worthwhile to note that it is unclear from these experiments whether the cell shape change
123
precedes the microtubule network collapse. Clearly, cells that are severely rounded will have
microtubules that are tightly focused around the nucleus. Conversely, cells that have a collapsed
microtubule network near the nucleus will exhibit an altered morphology. However,
distinguishing between these two scenarios is not critical for our purposes here. The microtubule
network is partly responsible for determining cell shape, and changes in morphology require
cytoskeletal rearrangements. Thus, since the myc-C-expressing cells are rounded, there must
have been a change in microtubule organization at some point. If these cells had normal
regulation of microtubules, then they would likely be unable to exhibit such a defective cell
shape in the first place. Considering the multiple studies noted above that have revealed an
important function for LIS1 pathway members in microtubule regulation, as well as our related
experiments in this chapter, it is likely that an initial disruption of microtubule transport results in
the change in cell shape due to myc-C expression. Indeed, LEK1 knockdown experiments appear
to confirm this proposal, as will be discussed shortly.
The speed with which the cells expressing myc-C undergo this alteration of morphology
and microtubule network organization is impressive. As soon as 8 hours after transfection, most
cells exhibit a rounded phenotype. This suggests that cytLEK1 function is continually required in
order for cells to maintain their microtubule network. Presumably, cytLEK1 participates in the
LIS1-directed continuous movement of microtubules to the periphery using dynein motors
(Ahmad et al., 1998; Smith et al., 2000; Shu et al., 2004). When this transport is disrupted by
myc-C, microtubules begin to accumulate around the nucleus and a change in cell shape results.
Additionally, since cytLEK1 has been shown to be at the centrosome (chapters II and III), it may
be important in stabilizing the microtubule network at this key organizing center. Any disruption
of this structure will naturally alter the arrangement of microtubules within cells. As expression
of myc-C results in a phenotype in such a rapid fashion, the protein is presumably able to quickly
and efficiently replace endogenous cytLEK1 at important subcellular locations. Thus, there is
likely a process of cytLEK1 exchange normally occurring at these sites. If instead cytLEK1 were
tightly attached to these structures for long periods of time, the ability of myc-C to disrupt its
function would be limited and delayed. It seems reasonable to postulate that endogenous
cytLEK1 is constantly recruited to newly-created LIS1-related complexes involved in, for
example, movement of microtubules to the periphery. Alternatively, myc-C may bypass any
regulatory mechanisms that prevent cytLEK1 from interacting with various potential binding
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partners in certain locations. An intriguing question is whether cytLEK1 is required for proper
localization of LIS1 pathway members to their functional positions in cells. It may be that
cytLEK1 serves a structural role in bringing together key proteins, and that myc-C disrupts this
complex formation. The overlap of the cytLEK1- and putative dynein-binding domains within
NudE suggests a potentially complex regulation of protein-protein interactions. Unfortunately,
the severe effect on morphology resulting from myc-C expression limits potential analysis.
While endogenous dynein and LIS1 are abnormally tightly packed around the nucleus in these
cells, this result may be inevitable due to the shape of the cell. Thus, LIS1 pathway member
localization is disrupted in myc-C-expressing cells, but it is impossible to discern whether this
effect is the cause of or, instead, result of microtubule network disorganization. Examination of
the small subset of cells that express myc-C but do not initially round up does not yield any
useful information. The localization of LIS1 pathway members in these cells is unaltered, but
they are also unaffected by any cytoskeletal or morphological changes. Thus, there may be no
significant change in distribution of pathway members simply due to the fact that the myc-C
protein, for whatever reason, is not yet having a dominant negative effect in these cells.
Nonetheless, our results clearly show that expression of myc-C causes dramatic
alterations in morphology and microtubule network organization, consistent with disruption of
LIS1 pathway function. It is interesting to note that the localization of the myc-C protein
supports its cellular effects. In both rounded and non-rounded cells, myc-C exhibits a
predominantly perinuclear distribution, thus placing it in the ideal location for interaction with
endogenous LIS1 pathway members (see Introduction and chapter III). Additionally, the myc-C
protein is resistant to detergent extraction and remains in the insoluble cytoskeletal pool. Thus,
the C domain alone is likely capable of interacting with cytoskeletal structures, consistent with
its role in directing the cytLEK1-NudE association. Endogenous cytLEK1 is also partially
resistant to detergent pre-extraction, especially around the nucleus (Figure 12). The results in this
chapter suggest that the C domain is at least partially responsible for conferring this resistance to
cytLEK1. Additional experiments are required to determine whether other regions of cytLEK1
may also have such a function. Notably, the N+R region of the SRR does not have such an
effect. In fact, this myc-N+R protein lacking the C domain does not exhibit any noticeable
localization within cells but instead is distributed throughout the cytoplasm (chapters III and IV).
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Thus, the dominant negative myc-C protein causes disruption of cytLEK1 function within the
LIS1 pathway through a likely association with cytoskeletal structures.
As the myc-C protein has been shown to have an effect on the organization of pre-
existing microtubule networks, we wished to also study its role in nascent microtubule
polymerization. To conduct such experiments, nocodazole was first utilized to depolymerize the
microtubule network in murine cells, and reformation of the network after drug washout was
consequently examined. These studies were conducted with strict time guidelines to minimize
the severe rounding of cells observed with prolonged exposure to myc-C. Very interestingly,
cells expressing myc-C show a nearly complete inability to repolymerize their microtubule
networks after nocodazole challenge. This severe effect is long-lasting and not observed in non-
transfected or myc-N+R-expressing cells. In most cells transfected with myc-C, there is no
visible formation of microtubules from the organizing center. Conversely, control cells exhibit
long microtubule networks emanating from the centrosome. It is interesting to note that, in the
few myc-C-expressing cells where there is rudimentary formation of a nascent microtubule
network from the organizing center, there is no myc-C protein present near this structure.
Although the sample size is not large enough to make a definitive conclusion, this is an
intriguing observation suggesting that myc-C may be required at the centrosome in order to have
a disruptive effect.
Our repolymerization results here are consistent with previous studies on other LIS1
pathway members. Notably, LIS1 overexpression alters microtubule polymerization and
localization after nocodazole challenge (Smith et al., 2000). Overexpression of GFP-mNudE
results in the formation of additional microtubule-organizing centers throughout the cell and
disrupts normal microtubule organization (Feng et al., 2000). Finally, Nudel knockdown results
in an accumulation of microtubules near the nucleus after a combination nocodazole/vinblastine
treatment (Shu et al., 2004). In general, the effects we observe here appear to be more severe
than those resulting from disruption of other LIS1 family members, such as Nudel. Instead of
observing only an inhibition in microtubule transport, we are unable to detect even
polymerization of microtubules at the centrosome. Thus, our results suggest that cytLEK1 has an
especially critical role in microtubule network formation at the organizing center of cells. This is
consistent with the presence of myc-C at this structure (chapter III). Because of its large size, it is
possible that cytLEK1 serves as a scaffold at the centrosome, bringing together important
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proteins. Proper reformation of centrosomal structures and attachments after nocodazole
challenge may require the presence of cytLEK1. Alternative incorporation of myc-C disrupts
these normal associations and thus does not allow the centrosome to be effectively used as an
organizing center for microtubule repolymerization. It is currently unclear whether cytLEK1
directly binds microtubules or simply associates with other cytoskeletal-binding proteins. An
alternative, but related, explanation focuses on the pre-extraction technique used in these
experiments to better visualize microtubules. It is possible that microtubule networks are, in fact,
partially reformed in transfected cells but are deficient in attachment to a defective myc-C-
containing centrosome. Thus, these microtubules easily detach from this structure and are
washed out during pre-extraction, whereas normal networks remain strongly bound to the
organizing center. This scenario implies, yet again, that cytLEK1 at the centrosome is required
for proper formation and function of protein complexes at this structure.
In order to corroborate the dominant negative studies on cytLEK1 function, experiments
were conducted to examine the effect of LEK1 knockdown on the microtubule network. As has
previously been noted, the primary disadvantages of such studies consist of the resulting cell
death and the inability to distinguish cytLEK1- versus nucLEK1-specific actions. Additionally,
results are complicated by the fact that the knockdown of LEK1 is incomplete, as evidenced by
immunofluorescence labeling of cytLEK1, so some endogenous cytLEK1 remains in these cells.
Consistent with this situation, we observe defects in microtubule network organization that are
similar, but less severe, than our previous data, confirming our dominant negative studies.
Notably, there is yet again a substantial accumulation of microtubules around the nucleus in cells
treated with LEK1 morpholinos. However, the cells exhibit a normal morphology, unlike cells
expressing myc-C. These data suggest that a change in microtubule organization is the primary
event occurring and consequently resulting in alteration of cell shape. Thus, cytLEK1 is critical
for movement of microtubules to the periphery of cells, as evidenced by two separate assays.
LIS1 pathway members have been shown to be crucial for this transport process, and inhibiting
the function of any member consistently results in a perinuclear accumulation of microtubules, as
we also observe here (Ahmad et al., 1998; Smith et al., 2000; Shu et al., 2004). Thus, the role of
cytLEK1 is similar to those of other LIS1 pathway members.
While LEK1 knockdown does not result in a rounded morphology, this finding is not
surprising, as a dominant negative construct specifically examining the NudE-binding domain of
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cytLEK1 would likely not have identical effects to knockdown of full-length LEK1 and its
resulting cytLEK1 and nucLEK1 cleavage products. In addition, some endogenous cytLEK1
remains even after morpholino treatment, which may be enough to prevent severe changes to the
cytoskeleton and cell morphology. Nonetheless, the critical role of cytLEK1 in microtubule
network organization is evident in both dominant negative and knockdown experimental models.
We also wished to examine whether cytLEK1 knockdown affects microtubule repolymerization
after nocodazole challenge. However, such studies were impractical due to the massive cell death
response resulting from the apparent sensitivity of LEK1-knockdown cells to environmental
stresses. Consistent with previous work (Ashe et al., 2004), it appears that LEK1 expression is
required for cell survival and that even incomplete knockdown has highly negative effects on
cells. Similarly, Nudel depletion causes rapid apoptosis of cells (Liang et al., 2004), while loss of
LIS1 produces proliferation defects (Faulkner et al., 2000; Liu et al., 2000). Additionally,
overexpression of cytLEK1 or nucLEK1 results in the eventual disappearance of transfected cells
(Ashe et al. unpublished data; Figure 41). These knockdown and overexpression data are not
surprising considering the putative role of cytLEK1 and nucLEK1 in key cellular processes,
including proliferation. The results we present here reveal the role of cytLEK1 in microtubule
transport and organization, including at the centrosome, and imply that cytLEK1 dysfunction
disrupts a vast array of cellular processes. However, as cells partially depleted of full-length
LEK1 die much faster than cells expressing myc-C, it appears that other regions within LEK1, in
addition to the C domain, have important functional roles. This is consistent with our hypothesis
that cytLEK1 may bring together key proteins through several independent domains.
As cytLEK1 has been shown to be essential for LIS1 pathway functions related to the
microtubule network, experiments were also conducted to examine its role in other processes of
this pathway. Our studies focus on examining organelles and endosomes whose movement is
dependent on the LIS1 pathway. Experiments are complicated by the fact that the literature is not
clear on the exact effects of the LIS1 pathway on such entities (Faulkner et al., 2000; Sasaki et
al., 2000; Smith et al., 2000; Tai et al., 2002; Liang et al., 2004) and that results can be highly
subjective. These studies innately contain a high degree of variability, as the localization of
endosomes, for example, is highly variable among even “identical” cells of a control population.
This is likely part of the cause of the inconsistent results often reported in the literature.
However, dramatic changes are more easily evident and can be quantified, if necessary. Our
128
experiments examining the effects of myc-C expression on endosome trafficking are
inconclusive due to the caveats listed above. The amount of variation seen in control populations
makes it very difficult to detect or quantify any changes due to cytLEK1 dysfunction.
Additionally, the rounding of cells expressing myc-C complicates examination of cytoplasmic
structures.
Studies were thus conducted instead to look at the localization of the Golgi apparatus in
cells transfected with full-length cytLEK1. As these cells do not exhibit a change in morphology,
it is far easier to visualize Golgi positioning. Interestingly, cells overexpressing cytLEK1 exhibit
a tight clustering of the Golgi apparatus near the nucleus. This effect appears to be significant
when compared to non- or GFP-transfected control cells. However, as there is variability among
even control cells in this assay, future quantitative analysis is needed to confirm this phenotype.
An additional concern based on these preliminary data, which will have to be addressed in the
future, is whether the expression level of cytLEK1 affects the phenotype and what the
significance of such a result may be. Our current results, though, do suggest that cytLEK1 plays
a role in enhancing movement of the Golgi apparatus towards the nucleus. These data are
consistent with the putative but disputed role of the LIS1 pathway in moving organelles in this
direction (Allan and Vale, 1991; Corthesy-Theulaz et al., 1992; Sasaki et al., 2000; Smith et al.,
2000; Liang et al., 2004). While disrupting cytLEK1 function results in inhibition of LIS1
pathway actions, overexpression of cytLEK1 enhances these processes. Thus, our results clearly
show that cytLEK1 is a positive regulator of LIS1 pathway functions. Its role appears to extend
beyond just microtubule organization into movement of organelles. This is consistent with the
significant colocalization of cytLEK1 with several LIS1 pathway members at key subcellular
locations (chapter III). It will be interesting to study in future experiments whether cytLEK1
plays a role in additional processes of the LIS1 pathway. Examination of the role of cytLEK1
during mitosis is especially critical, due to the role of pathway members in dividing cells and the
localization of cytLEK1 to key mitotic structures (chapter II). Also, no mitotic cells expressing
myc-C have ever been detected, suggesting a potential defect in cell division processes due to
cytLEK1 dysfunction.
In summary, the data in this chapter reveal a function for cytLEK1 in regulation of the
LIS1 pathway. These results are especially exciting as they utilize characterization of a novel
cytLEK1-NudE interaction to define, for the first time, a role for cytLEK1. Consistent with its
129
presence at key subcellular structures (chapter II) and co-IP/colocalization with numerous LIS1
pathway members (chapter III), cytLEK1 has an important function in processes controlled by
this pathway. Notably, cytLEK1 dysfunction results in alteration of cell shape and microtubule
organization. Our results suggest that cytLEK1 plays a role in a wide range of LIS1 pathway
activities, including organelle movement. Additionally, the dominant negative myc-C protein
severely inhibits microtubule repolymerization after nocodazole challenge, consistent with the
presence of this protein at the centrosome. These data suggest that proper cytLEK1 activity
requires the presence of multiple domains within the molecule that bind to several partner
proteins. LEK1 is essential for basic cellular functions, as knockdown of the protein results in
microtubule disorganization and eventual cell death. Future studies will reveal the exact nature of
the role of cytLEK1 within the LIS1 pathway and reveal whether cytLEK1, similar to LIS1, is
necessary for correct regulation of the LIS1 pathway during embryonic development.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS
Conclusions
The studies presented in this document examine for the first time the expression,
localization, interaction, and function of cytLEK1. These novel results provide an understanding
of the important role of cytLEK1 in key cellular processes through regulation of the LIS1
pathway. In chapter II, we reveal that cytLEK1 is present in the mouse predominantly at
embryonic stages, consistent with its putative role in murine development. Its wide pattern of
expression suggests that it has the potential to function in several tissues, including the heart and
brain where it is highly expressed. In fact, the pattern observed for cytLEK1 is very similar to
that of its binding partner, NudE(L) (Feng et al., 2000; Niethammer et al., 2000; Sasaki et al.,
2000; Yan et al., 2003). Thus, these two proteins are likely intimately associated in a wide range
of settings during development. Additionally, the subcellular distribution of cytLEK1 is revealed
to be similar to that of other LIS1 pathway members (see Introduction), suggesting a common
function in cells. The protein is detected in the cytoplasm with a perinuclear predominance, and
it is found on both the spindle and spindle poles of mitotic cells.
In chapter III, these expression studies are placed in the context of the cytLEK1-NudE
interaction discovered through a yeast two-hybrid screen. The association of these two proteins is
determined to be dependent on the C domain within the spectrin repeat region of cytLEK1.
Conversely, cytLEK1 binds to a region in NudE that overlaps with the putative dynein-binding
domain, suggesting a possibly complex regulation of protein-protein interactions. Examination of
the small myc-C protein reveals that it distributes to areas of high NudE concentration, especially
at the centrosome. Studies of endogenous proteins confirm that cytLEK1 colocalizes with NudE
in murine cells. Additional experiments reveal a similar result with cytLEK1 and the two known
binding partners of NudE: dynein and LIS1. The codistribution is most evident around the
nucleus, consistent with the cellular region where cytLEK1 is detergent resistant and likely
associates with the cytoskeleton. The less apparent colocalization near the cell periphery
suggests the existence of additional binding partners and functions for cytLEK1 at this
subcellular location.
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In chapter IV, experiments are conducted to test the function of cytLEK1 with regard to
its association with the LIS1 pathway. Several approaches are utilized, including dominant
negative protein expression, LEK1 knockdown, and cytLEK1 overexpression. These data reveal
that cytLEK1 is essential for proper regulation of microtubule organization and function through
the LIS1 pathway. These effects extend to repolymerization of microtubule networks after
nocodazole challenge and, thus, suggest a broad role for cytLEK1 in cytoskeletal processes.
Knockdown studies confirm the importance of LEK1 for microtubule networks and the
requirement of proper LEK1 levels for cell viability. Experiments were initiated to examine the
role of cytLEK1 within additional processes controlled by the LIS1 pathway. Organelle
movement appears to be regulated by cytLEK1, suggesting a wide function for the protein in the
LIS1 pathway.
By incorporating the results and discussion presented in this document, it is possible to
begin to form a broad model for cytLEK1 function in cells (Figure 42). Clearly, the details of
this model are incomplete, as the exact roles of even the established LIS1 pathway members are
currently unknown (see Introduction). Based on its expression pattern, cytLEK1 appears to
function predominantly in processes occurring during murine embryonic development. It likely
plays a fundamental role in a wide variety of tissues and cells, consistent with other LIS1
pathway members (Hirotsune et al., 1998; Feng et al., 2000; Niethammer et al., 2000; Sasaki et
al., 2000; Smith et al., 2000; Dujardin et al., 2003; Yan et al., 2003; Liang et al., 2004; Shu et al.,
2004). However, the existence of some tissue-specific differences in expression pattern suggests
that cytLEK1 is either more important in certain tissues and/or has additional functions in them.
The importance of LIS1 pathway members during embryonic development is not surprising
given the role of the pathway in controlling the processes of proliferation, migration, and
differentiation (see Introduction). Such events occur at a very high rate in the developing
organism with little room for error.
An interesting unanswered question remains, however, about the general developmental
role of cytLEK1. Is cytLEK1 truly not expressed and thus not required in the adult mouse? If this
is the case, then there are two possible explanations: Either the function of cytLEK1 is specific to
cells in the embryo, or another protein takes over the role of cytLEK1 in the adult animal.
Neither of these scenarios is especially convincing. CytLEK1 regulates basic cellular processes
that occur, to some degree, in nearly all cells. Thus, it is difficult to imagine that its role is no
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Figure 42. Model of cytLEK1 function. See text for details.
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longer essential in adult cells. While no other Mitosin/CENP-F-like molecule has been detected
in the mouse, the existence of such a protein would help explain this LEK1 expression issue.
However, the severe effects caused by LEK1 depletion in cells suggest that other proteins are
incapable of compensating for LEK1 knockdown, at least in a cell culture environment. Thus, a
final possible explanation is that cytLEK1 is indeed present in adult tissues but at a low
expression level, similar to NudE, that cannot be consistently detected (Feng et al., 2000). This
scenario reinforces the proposal that cytLEK1 and other similar proteins are especially critical
during development due to the unprecedented amount of proliferation, migration, and
differentiation occurring at this time. In fact, immunofluorescence studies of adult tissues reveal
that while cytLEK1 and nucLEK1 levels appear to be substantially reduced compared to
embryonic stages, the proteins are not completely absent in adult organisms. Determination of
whether cytLEK1 is then present in unique environments with embryonic characteristics, such as
stem cell niches and tumors, is an intriguing avenue of future study. Notably, examination of
stem cell microchip arrays reveals that LEK1 expression is upregulated in all tested cell lines
(Abeyta et al., 2004).
Regarding the cellular function of cytLEK1 within our model, there are several important
results to consider. Depletion of LEK1 has previously been shown to affect proliferation and
differentiation of cells (Ashe et al., 2004), although the exact role of cytLEK1 versus nucLEK1
is unclear. It is likely that the interaction of nucLEK1 with Rb family members (Ashe et al.,
2004) is important for control of cell division. However, cytLEK1 specifically has a greater
potential for regulation of key cellular processes through its widespread cytoplasmic distribution
and association with LIS1 family members. Our data here suggest that the cytLEK1-NudE
interaction is most critical around the nucleus, including at the centrosome. As discussed in
chapter IV, cytLEK1 likely forms a complex with NudE and other LIS1 pathway-related proteins
at these locations. CytLEK1 may, in fact, function as a key scaffolding element of the
centrosomal structure, such that disruption of cytLEK1 activity results in the inability to properly
attach and reform microtubule networks from this organizing center and couple it to the nucleus.
The effects of cytLEK1 dysfunction on the existing microtubule network may be partly related to
this centrosomal role, as well as association of cytLEK1 with LIS1-containing complexes that
transport microtubules to the periphery through the action of dynein motors. Based on this
function of cytLEK1 and the presence of endogenous protein on the spindle, it is likely that
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cytLEK1 is similarly required for proper mitotic progression, a process highly dependent on the
LIS1 pathway.
The design of our dominant negative protein reveals that dissociating the NudE-binding
domain from other regions of cytLEK1 disrupts functions of the LIS1 pathway. Any roles of
additional domains of cytLEK1, however, are currently unknown. Interestingly, the overlap
between the cytLEK1- and putative dynein-binding domain of NudE reveals that cytLEK1 may
in fact control the dynein-NudE interaction, perhaps even through cytLEK1-dynein binding.
Such regulation of protein associations may extend to additional LIS1 pathway members through
other cytLEK1 regions. Our data here clearly reveal that the role of cytLEK1 is not simply to
bind NudE, as the myc-C protein is able to perform this function and yet causes extensive
disruption of cellular processes. Thus, cytLEK1, which is much larger in size than LIS1 or
NudE(L), likely interacts with multiple LIS1 pathway members to bring them together into a
functional complex at the correct subcellular location. LIS1 alone associates with NudE(L),
dynactin, dynein, and microtubules, while NudE(L) binds to LIS1, cytLEK1, and dynein (see
Introduction and chapter III). Thus, even the smaller protein members of this pathway exhibit
multiple associations suggestive of a complex set of interactions. Our results imply that each
cytLEK1 molecule, through a currently unknown mechanism, likely associates with only a
subset of all potential interacting partners. This selectivity is based on the cellular position and
function at hand, and it is consistent with published data on the incomplete colocalization of all
LIS1 pathway members (see Introduction and chapter III).
Based on the speed with which expression of the myc-C protein results in cellular
changes, cytLEK1 likely exists as a protein population that is constantly in flux with continuous
formation/disruption of such interactions. Considering the dynamic nature of processes such as
microtubule movement to the periphery, it is not surprising that cytLEK1 would first be recruited
to a certain cellular location and then later be needed in a different position. It remains unclear
whether cytLEK1 at the centrosome has a more permanent role. At the present time, the
association with NudE, which itself binds to dynein and LIS1, is currently the only known piece
of this potentially intricate regulation of cytLEK1-containing complexes. Future direct binding
assays will elaborate on the dysbindin results and also likely reveal an interaction between
cytLEK1 and Nudel. Importantly, recent studies in our laboratory suggest that other regions of
cytLEK1 may associate with additional proteins related to the LIS1 pathway (Pooley et al.
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unpublished data). These putative interactions with dynactin and certain vesicular trafficking
proteins may represent the other molecules cytLEK1 brings together and may help better explain
the role of cytLEK1 at the periphery of cells.
In summary, this model envisions cytLEK1 as a positive regulator of the LIS1 pathway
during development (Figure 42). A certain subset of cytLEK1 protein near the nucleus interacts
with NudE and other pathway members. By bringing together a specific set of proteins at the
centrosome and other perinuclear regions, cytLEK1 enables components to be in place for LIS1-
related processes utilizing dynein motors. Such events, which are especially key during
embryonic development, include microtubule transport, cytoskeletal organization, cell
morphology, migration, and organelle movement. This same population of cytoskeletal cytLEK1
also functions similarly at the spindle poles and spindle of mitotic cells, although future
experiments are required to confirm this. CytLEK1 present at the periphery of cells likely plays a
different role, which may be less related to LIS1 pathway functions. Preliminary data suggest it
possibly acts in leading edge processes and vesicular trafficking, consistent with its peripheral
localization. Future elaboration on this model is especially dependent on the discovery and
confirmation of additional cytLEK1 binding partners. However, it is apparent from the studies in
this document that cytLEK1 is a key regulator of the LIS1 pathway.
Future Directions
Additional examination of LEK1 expression and distribution pattern
Our data here present, for the first time, the expression pattern of cytLEK1 in tissues and
cells. Additional studies examining the distribution of cytLEK1, however, are required. While
current in vivo work has focused primarily on the heart, the association of cytLEK1 with LIS1
pathway members necessitates experiments in the developing brain. Although we show that
cytLEK1 is expressed in this organ, detailed localization studies with tissue sections are needed
to determine the exact distribution of cytLEK1. It will be interesting to reveal whether cytLEK1
is present only in a certain cell type, such as neurons, or in many different cells. Additionally, the
presence of cytLEK1 in brain structures where neuroblast proliferation occurs would suggest a
key role in mitotic processes during brain development, similar to other LIS1 pathway members
(Hirotsune et al., 1998; Feng and Walsh, 2004; Shu et al., 2004). A comprehensive analysis of
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protein expression via Western blot in this tissue will assist in determining the exact period of
cytLEK1 expression and also whether oligomerization is truly occurring (chapter II). In addition
to the brain, localization of cytLEK1 in the postnatal heart should be examined to discern the
precise nature of the change in subcellular distribution that occurs at this stage (chapter II).
Distinguishing between perinuclear and true nuclear localization of cytLEK1 is important for
revealing the role of the protein in this tissue. In cell culture, additional studies utilizing confocal
deconvolution analysis are required to examine cytLEK1 localization in mitotic cells.
Conducting parallel experiments for nucLEK1 in all these cells and tissues will assist in
delineating the individual functions of the LEK1 peptide products. Finally, a careful analysis of
adult tissues using quantitative RT-PCR and multiple LEK1 antibodies is required in order to
conclusively confirm that LEK1 is absent in the adult mouse.
The creation of additional LEK1 antibodies will assist these expression studies.
Monoclonal antibodies specific for both cytLEK1 and nucLEK1 using the Spec1 and 863
epitopes are currently under development. In addition to confirming our existing data, these
antibodies will allow, for the first time, colocalization studies between cytLEK1 and nucLEK1.
Thus, it will be possible to determine, for example, whether the apparent nuclear distribution of
cytLEK1 in the postnatal heart is instead uncleaved LEK1. The monoclonal antibodies may also
have different reactivity with fixation/extraction conditions as compared to our current
polyclonal reagents, thus enabling studies that have been difficult. Detailed examination of a
codistribution of endogenous cytLEK1 and microtubules may then be possible.
Future experiments will not be limited to normal tissues and cells in culture. The
increased expression of Mitosin/CENP-F in tumors (de la Guardia et al., 2001; Esguerra et al.,
2004) and the putative role of LEK1 in proliferation processes make worthwhile the examination
of LEK1 expression in murine cancers. Studies should investigate both cytLEK1 and nucLEK1
in various tumor tissues to see if there is upregulation of these proteins, consistent with a positive
role in regulating proliferation. Additionally, adult stem cells are emerging as an exciting field of
research in various organs (Sadiq and Gerber, 2004). As these cells may share characteristics
with embryonic cells, they may also express cytLEK1 and nucLEK1. Existing microchip array
data already reveal that LEK1 is expressed in certain stem cell lines (Abeyta et al., 2004).
However, additional colocalization studies of cytLEK1 and stem cell markers in tissues are
needed. Immunofluorescence cytLEK1 experiments on available stem cell lines may also yield
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interesting data. It would not be surprising for cytLEK1 and other LIS1 pathway members to
play a role in the recrutiment of stem cells, as processes such as proliferation, migration, and
differentiation are involved.
For further examination of cytLEK1 localization and regulation, the LIS1 +/- and NudE -
/- mice generated by other laboratories (Hirotsune et al., 1998; Cahana et al., 2001; Feng and
Walsh, 2004) can serve as useful reagents. Investigating the distribution of cytLEK1 in primary
cells derived from these mice will reveal the function of LIS1 pathway members in directing
cytLEK1 to its proper subcellular location. Our current model focuses on the role of cytLEK1 in
bringing together proteins at critical cellular areas. However, it is also possible that cytLEK1
localization itself is dependent on LIS1 pathway members. If, for example, cytLEK1 distribution
is altered in NudE -/- cells, then this would imply that cytLEK1 position is dictated by the NudE
protein, likely through an interaction with the C domain. Such experiments are also feasible with
an RNAi approach, although the often inconsistent efficacy of RNAi-induced knockdown would
then be a complicating factor during analysis.
Finally, the lack of precise data on the cleavage event of LEK1 complicates LEK1
studies. Experiments utilizing protein sequencing and mass spectrometry techniques have been
wholly unsuccessful at determining the exact cleavage site (Price et al. unpublished data).
Generation of a full-length LEK1 mammalian expression construct may alleviate certain
technical issues and allow examination of the cleavage event. However, our efforts to combine
the available cytLEK1 and nucLEK1 constructs into a full-length product have been
unsuccessful. The necessary triple ligation event appears to occur at a very low rate and is
complicated by the incorporation of bacterial DNA into the vector product, perhaps due to a
similarity of LEK1 sequence with part of the bacterial genome. As these experiments have been
repeated multiple times with no success, this strategy does not appear to be feasible. A long-
range RT-PCR approach may be possible, although a 10 kb product is extremely difficult to
amplify and will likely contain multiple polymerase errors. Generation of full-length LEK1 is
important not only for examining the cleavage event but also for conducting true overexpression
and rescue studies. The current cytLEK1 and nucLEK1 constructs have serious detrimental
effects on transfected cells, and it is unclear whether this is simply an artifact of incorrect protein
size and resultant misfolding. The ability to overexpress full-length LEK1 in cells will help
reveal the function of this protein and its cleavage. Experiments to rescue cells treated with
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LEK1 morpholino will also be possible, thus serving as an additional control of knockdown
specificity. In summary, the studies proposed in this section will reveal the distribution of
cytLEK1 in key tissues and cells that have not previously been examined in detail.
Discovery of novel cytLEK1 binding partners
The function of cytLEK1 likely involves multiple associations with important cellular
proteins, including members of the LIS1 pathway (see Conclusions). Discovering additional
binding partners of cytLEK1 is thus key to better understanding its role in cells. For this reason,
additional yeast two-hybrid screens utilizing unexamined parts of the protein as bait are of great
importance. Already, such a screen has been performed with an N-terminal region of cytLEK1
and has yielded intriguing results related to dynactin and vesicle trafficking (Pooley et al.
unpublished data). Confirmation of these interactions through co-IP and colocalization studies is
the necessary next step. Remaining unexamined regions of cytLEK1 will require further yeast
two-hybrid screens. Additionally, the putative interaction of the SRR with dysbindin must be
confirmed, as discussed in chapter III. Direct yeast two-hybrid matings will examine whether
cytLEK1, as predicted, is able to bind to Nudel. Mapping multiple binding partners of cytLEK1
to distinct domains enables discovery of its potential functions, especially with regard to forming
protein complexes. Thus, revealing any interactions of cytLEK1 with additional LIS1 pathway
members, such as LIS and dynein, is of great importance.
Once these binding partners of cytLEK1 are known, it will be interesting to examine how
these proteins associate using a biochemical approach. Such studies will answer the question of
whether cytLEK1 is essential for bringing together LIS1 pathway members into a functional
complex. For example, it has been reported that RNAi-mediated knockdown of Nudel results in a
decreased association of dynein and LIS1, suggesting that Nudel plays a key role in directing this
interaction through its binding to both proteins (Shu et al., 2004). Similar experiments need to be
conducted for cytLEK1. Morpholinos may be used for LEK1 knockdown in murine cells, and
co-IPs can then be performed between various LIS1 pathway members from these lysates, as
allowed by available reagents. For example, if cytLEK1 does indeed play a role in regulating the
interaction of dynein with NudE, the morpholino-treated samples may have an altered amount of
dynein that co-immunoprecipitates with NudE. If cytLEK1 enhances this association, then there
may be a lower level of co-immunoprecipitated protein in the knockdown cells. A complicating
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factor for these experiments is the cell death resulting from LEK1 knockdown. Thus,
examination of such interactions in primary cells derived from a LEK1 +/- mouse may be a more
feasible alternative approach. Inducible expression of a dominant negative protein in cells may
also provide a uniform population for conducting these studies. For example, expression of myc-
C may disrupt the co-immunoprecipitation of two LIS1 pathway members, thus specifying the
nature of the dominant negative effect. As additional binding partners of cytLEK1 are
discovered, new dominant negative deletion constructs can be created to examine further protein
interactions. Colocalization studies will also be conducted in parallel to examine changes in the
distribution of the examined proteins. In summary, these experiments studying the interactions of
cytLEK1 and LIS1 pathway members will provide critical biochemical information on the role
of cytLEK1 in cells.
Characterization of additional functions of cytLEK1 in the LIS1 pathway
Multiple experiments have already been presented in chapter IV that examine the
function of cytLEK1 in the LIS1 pathway. However, additional roles of this pathway remain that
have not yet been studied in relation to cytLEK1. One such process is cell migration, which is
regulated by the LIS1 pathway and is important during many stages of development (Hirotsune
et al., 1998; Dujardin et al., 2003; Shu et al., 2004). Our data on the role of cytLEK1 in
microtubule regulation suggest that cytLEK1 dysfunction likely also affects migration. However,
direct experiments testing this hypothesis have not been conducted. We are thus in the process of
examining the movement of cells expressing myc-C using a real-time light microscopy system.
Additional actions of the LIS1 pathway suggest conducting a detailed analysis of organelle
positioning in cells where cytLEK1 function is enhanced or disrupted. Our initial results with the
Golgi apparatus in chapter IV require further quantification and confirmation. Additionally, it is
possible to observe the movement of structures, such as lysosomes, using a real-time
fluorescence microscopy system to examine the distinct motions that are regulated by cytLEK1,
as has been previously done for Nudel (Liang et al., 2004). The role of both the LIS1 pathway
and dysbindin in such lysosome-related processes (Li et al., 2003; Liang et al., 2004) makes the
potential existence of a cytLEK1/NudE/dysbindin complex especially intriguing.
Examination of the function of cytLEK1 during mitosis is an important avenue of future
research. Localization of the protein to key mitotic structures (chapter II) suggests that it may
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play a role in regulation of cell division by the LIS1 pathway (Faulkner et al., 2000; Tai et al.,
2002; Yan et al., 2003; Feng and Walsh, 2004). Although there have been some technical
difficulties, synchronizing cells with disruptions in cytLEK1 function and examining their
progression through the cell cycle is important. Attention should be paid to the formation of the
spindle apparatus, as this process is regulated by NudE (Feng and Walsh, 2004), and also to the
dynein-directed movement of chromosomes towards the spindle poles. Flow cytometry analysis
can help reveal the exact disruptions in cell cycle progression due to cytLEK1 dysfunction.
Notably, LEK1 knockdown has previously been shown to cause cell cycle arrest at multiple
stages (Ashe et al., 2004). Finally, any ability of cytLEK1 to compensate for deficiencies of LIS1
pathway members is currently unknown. It would be interesting to overexpress cytLEK1, or full-
length LEK1 when available, in cells heterozygous or homozygous null for a distinct LIS1
pathway member and then examine if cytLEK1 is able to rescue any of the known defects. The
resulting phenotype will thus reveal the specific processes affected by cytLEK1. Conversely, a
dominant negative protein may instead be expressed in these cells in order to determine whether
cytLEK1 dysfunction has any additional effect in a cell already deficient for NudE, for example.
All these experiments examining the function of cytLEK1 on LIS1 pathway processes
may be conducted with several reagents. The dominant negative myc-C protein remains the most
appealing tool due to its specific examination of the cytLEK1-NudE interaction. However,
morpholino knockdown of LEK1 has also been used successfully for several of our studies.
Overexpression of full-length cytLEK1 is an option as well. The availability of LEK1 +/- or -/-
mice in the near future will create important primary cell reagents. Finally, the discovery of
additional binding partners of cytLEK1 and characterization of the relevant binding domains will
allow the generation of new dominant negative constructs examining the specific roles of
different regions of cytLEK1. In addition to the C2C12 and 3T3 cell lines we primarily use,
cardiomyocyte and neuronal cells may be utilized to examine the effects of cytLEK1 in specific
tissues where it is believed to play an important role. The use of cardiomyocytes, especially, will
enable examination of the function of the LIS1 pathway in the heart for the first time. In
summary, these studies will reveal important additional roles of cytLEK1 in multiple cellular
processes of the LIS1 pathway.
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Examination of LEK1 function in vivo
For the functional studies that we present here, cultured cells are exclusively utilized.
This approach was chosen due to the feasibility of such experiments and the extensive literature
on LIS1 pathway members in vitro (see Introduction). As cytLEK1 function has now been
shown to be important in regulating several key processes of the LIS1 pathway, in vivo
experiments can be conducted in parallel with the proposed in vitro experiments described
above. This approach will allow us to examine the role of cytLEK1 within the LIS1 pathway
during murine development. Currently, a LEK1 -/- conditional allele is being generated to
examine LEK1 function in the heart (Pooley et al. unpublished data). It will be of interest to also
study such an ablated allele in the developing brain, as it is an important site of LEK1 expression
and LIS1 pathway function (see Introduction). The brain is ideally suited for examination of cell
movement, and the heart is a useful model organ for proliferation studies due to the relatively
abrupt termination of cell division at postnatal stages. If examination of the cytLEK1-NudE
interaction specifically during embryogenesis is desired, then we can generate a transgenic
mouse that expresses the myc-C protein in different tissues during key developmental periods.
Based on the in vitro data on cytLEK1 function, disruption of cytLEK1 during murine
development is hypothesized to affect the LIS1 pathway processes of proliferation, migration,
and differentiation. BrdU and immunofluorescence analyses will reveal any defects in
proliferation and spindle function. Migration of cells may be significantly inhibited in the mice,
and it will be interesting to examine whether the important nucleus-centrosome distance is
different, as observed with Nudel (Shu et al., 2004). Experiments will also examine any altered
localization of LIS1 pathway members in tissues. Many additional experiments can be conducted
with both tissues and primary cells from these mice, and it is impractical to list all potential
studies here. However, the overall focus will be on initially examining processes previously
shown in our in vitro studies to be regulated by cytLEK1 and then performing further
experiments related to the published functions of known cytLEK1 binding partners, including
NudE. The generation of these mice disrupted in LEK1 activity will reveal whether the function
of cytLEK1, like that of LIS1, is required for correct regulation of the LIS1 pathway during
embryonic development.
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